var title_f4_31_4592="Pigmented nails in Addisons";
var content_f4_31_4592=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F57205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F57205&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hyperpigmentation of nails in primary adrenal insufficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 232px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fingers of a 28-year-old white woman with Addison's disease (underneath) compared to those of a normal woman (top). There is hyperpigmentation of the skin and increased pigmentation of the distal half of the nails that occurred during the period of adrenal insufficiency. The proximal half of the nails are hypopigmented, a reflection of the reduction in ACTH secretion after the institution of glucocorticoid therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David N Orth, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_31_4592=[""].join("\n");
var outline_f4_31_4592=null;
var title_f4_31_4593="Calculator: Body Surface Area (Du Bois Method)";
var content_f4_31_4593=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"BodySurfaceArea_form\" name=\"BodySurfaceArea_form\" onkeydown=\"clrResults();\" onkeyup=\"BodySurfaceArea_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Body Surface Area (Du Bois Method)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"10\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" bgcolor=\"#6c9a9c\">",
"        <span class=\"medCalcFontFormuli\">",
"         BSA = 0.007184 * Height",
"         <sup>",
"          0.725",
"         </sup>",
"         * Weight",
"         <sup>",
"          0.425",
"         </sup>",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"      <tr>",
"       <td align=\"right\" width=\"50%\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Input:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Height",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Height_param\" onblur=\"BodySurfaceArea_fx(); minMaxCheck();\" onchange=\"BodySurfaceArea_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Height_unit\" onchange=\"BodySurfaceArea_fx();\" style=\"width:105px;\">",
"             <option selected=\"selected\" value=\"1|0|cm\">",
"              cm",
"             </option>",
"             <option value=\"30.48|0|ft\">",
"              ft",
"             </option>",
"             <option value=\"2.54|0|in\">",
"              in",
"             </option>",
"             <option value=\"1e-04|0|micm\">",
"              micm",
"             </option>",
"             <option value=\"0.1|0|mm\">",
"              mm",
"             </option>",
"             <option value=\"100|0|m\">",
"              m",
"             </option>",
"             <option value=\"1e-07|0|nm\">",
"              nm",
"             </option>",
"             <option value=\"91.44|0|yd\">",
"              yd",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"right\" width=\"42%\">",
"            <span class=\"medCalcFontOneBold\">",
"             Weight",
"            </span>",
"           </td>",
"           <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"            &nbsp;",
"            <input name=\"Weight_param\" onblur=\"BodySurfaceArea_fx(); minMaxCheck();\" onchange=\"BodySurfaceArea_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"           </td>",
"           <td align=\"left\" valign=\"top\" width=\"115\">",
"            <select class=\"medCalcFontSelect\" name=\"Weight_unit\" onchange=\"BodySurfaceArea_fx();\" style=\"width:105px;\">",
"             <option value=\"0.001|0|gm\">",
"              gm",
"             </option>",
"             <option selected=\"selected\" value=\"1|0|kg\">",
"              kg",
"             </option>",
"             <option value=\"0.45359237|0|lb\">",
"              lb",
"             </option>",
"             <option value=\"1e-06|0|mg\">",
"              mg",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <center>",
"         <span class=\"medCalcFontIO\">",
"          Result:",
"         </span>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"          <tr>",
"           <td align=\"right\">",
"            <span class=\"medCalcFontOneBold\">",
"             BSA",
"            </span>",
"           </td>",
"           <td nowrap=\"nowrap\" valign=\"top\">",
"            &nbsp;",
"            <input name=\"BSA_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"           </td>",
"           <td valign=\"top\">",
"            <span class=\"medCalcFontOne\">",
"             <select class=\"medCalcFontSelect\" name=\"BSA_unit\" onchange=\"BodySurfaceArea_fx();\" style=\"width:105px;\">",
"              <option value=\"0.0001|0|cm^2\">",
"               cm^2",
"              </option>",
"              <option value=\"0.0001|0|sqcm\">",
"               sqcm",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|sqm\">",
"               sqm",
"              </option>",
"              <option value=\"0.0001|0|sqrcm\">",
"               sqrcm",
"              </option>",
"              <option value=\"1|0|sqrm\">",
"               sqrm",
"              </option>",
"             </select>",
"            </span>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"3\">",
"            &nbsp;",
"            <br/>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td align=\"center\" colspan=\"3\">",
"            <span class=\"medCalcFontOneBold\">",
"             Decimal Precision:",
"            </span>",
"            <select class=\"medCalcFontSelect\" name=\"decpts\" onchange=\"BodySurfaceArea_fx();\">",
"             <option>",
"              0",
"             </option>",
"             <option>",
"              1",
"             </option>",
"             <option selected=\"selected\">",
"              2",
"             </option>",
"             <option>",
"              3",
"             </option>",
"            </select>",
"           </td>",
"          </tr>",
"         </table>",
"        </center>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontOneBold\">",
"     Notes",
"    </span>",
"    <ul class=\"medCalcFontOne\">",
"     <li>",
"      <font color=\"#aa0000\">",
"       The default unit of measure for weight is kilograms.  Please verify that the correct unit of measure has been selected.",
"      </font>",
"     </li>",
"    </ul>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontRef\">",
"     <b>",
"      References",
"     </b>",
"    </span>",
"    <ol>",
"     <li>",
"      <span class=\"medCalcFontRef\">",
"       Dubois D, Dubois EF. A formula to estimate the approximate surface area if height and weight be known.",
"       <i>",
"        Arch Intern Med",
"       </i>",
"       . 1916; 17:863-871.",
"      </span>",
"     </li>",
"    </ol>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_31_4593=[" /* <![CDATA[ */",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function BodySurfaceArea_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.BodySurfaceArea_form){",
"",
"",
"doCalc = true;",
"if (Height_param.value.indexOf(',') >= 0){ Height_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Height_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Height_unit.options[Height_unit.selectedIndex].value.split('|');",
"Height = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Weight_param.value.indexOf(',') >= 0){ Weight_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Weight_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Weight_unit.options[Weight_unit.selectedIndex].value.split('|');",
"Weight = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = decpts.options[decpts.selectedIndex].text;",
"BSA =  0.007184 * power(Height, 0.725) * power(Weight, 0.425);",
"",
"unit_parts = BSA_unit.options[BSA_unit.selectedIndex].value.split('|');",
"if (doCalc) BSA_param.value = fixDP((BSA - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.BodySurfaceArea_form){",
"",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.BodySurfaceArea_form){",
"",
"BSA_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"/* ]]> */"].join("\n");
var outline_f4_31_4593=null;
var title_f4_31_4594="Digitalis effect tutorial";
var content_f4_31_4594=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56737&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Digitalis effect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 115px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCABzAY4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3WRP9f/o95/r4xzP0+5wfn6+/uORjgkT/AF/+j3n+vjHM/T7nB+fr7+45GOMiTU7z9/8A8Uv4g/18Y5u7bj7nB/0jr7+45GOCTU7z9/8A8Uv4g/18Y5u7bj7nB/0jr7+45GOJT/r7vI9qN9Ne3X/D/e/r800ZP+Jn4o/0e8/5CsPWfp/o1rwfn6+/uORjjYkT/X/6Pef6+Mcz9PucH5+vv7jkY45PStQu11HxIV8N66xbVISQLq3yh+z2w2tm45Y9QRkYYcgggasmp3n7/wD4pfxB/r4xzd23H3OD/pHX39xyMcRDb+u/oU73Wvbr/h/vf1+aeLU/4lf/AB73n/IV08cz9P8ASbfg/P19/ccjHGxIn+v/ANHvP9fGOZ+n3OD8/X39xyMccn4p1C7fTiG8N67EBqlgcvdW5GRcQELxcH5j0B6AkZIAyNWTU7z9/wD8Uv4g/wBfGObu24+5wf8ASOvv7jkY4F8X3f1sCvyrX8f8P97+vz15E/1/+j3n+vjHM/T7nB+fr7+45GOMfRk/4mfij/R7z/kKw9Z+n+jWvB+fr7+45GOFk1O8/f8A/FL+IP8AXxjm7tuPucH/AEjr7+45GOMrStQu11HxIV8N66xbVISQLq3yh+z2w2tm45Y9QRkYYcgggD3X9dPQIXtv26/4f739fn1kif6//R7z/Xxjmfp9zg/P19/ccjHGP4tT/iV/8e95/wAhXTxzP0/0m34Pz9ff3HIxwsmp3n7/AP4pfxB/r4xzd23H3OD/AKR19/ccjHGV4p1C7fTiG8N67EBqlgcvdW5GRcQELxcH5j0B6AkZIAyCfwv+v0Clfmjr26/4f739fn1kif6//R7z/Xxjmfp9zg/P19/ccjHBIn+v/wBHvP8AXxjmfp9zg/P19/ccjHGRJqd5+/8A+KX8Qf6+Mc3dtx9zg/6R19/ccjHBJqd5+/8A+KX8Qf6+Mc3dtx9zg/6R19/ccjHFp/193kTG+mvbr/h/vf1+aaMn/Ez8Uf6Pef8AIVh6z9P9GteD8/X39xyMcbEif6//AEe8/wBfGOZ+n3OD8/X39xyMccnpWoXa6j4kK+G9dYtqkJIF1b5Q/Z7YbWzccseoIyMMOQQQNWTU7z9//wAUv4g/18Y5u7bj7nB/0jr7+45GOIht/Xf0Kd7rXt1/w/3v6/NPFqf8Sv8A497z/kK6eOZ+n+k2/B+fr7+45GONiRP9f/o95/r4xzP0+5wfn6+/uORjjk/FOoXb6cQ3hvXYgNUsDl7q3IyLiAheLg/MegPQEjJAGRqyanefv/8Ail/EH+vjHN3bcfc4P+kdff3HIxwL4vu/rYFflWv4/wCH+9/X568if6//AEe8/wBfGOZ+n3OD8/X39xyMcY+jJ/xM/FH+j3n/ACFYes/T/RrXg/P19/ccjHCyanefv/8Ail/EH+vjHN3bcfc4P+kdff3HIxxlaVqF2uo+JCvhvXWLapCSBdW+UP2e2G1s3HLHqCMjDDkEEAe6/rp6BC9t+3X/AA/3v6/PrJE/1/8Ao95/r4xzP0+5wfn6+/uORjjH8Wp/xK/+Pe8/5Cunjmfp/pNvwfn6+/uORjhZNTvP3/8AxS/iD/Xxjm7tuPucH/SOvv7jkY4yvFOoXb6cQ3hvXYgNUsDl7q3IyLiAheLg/MegPQEjJAGQT+F/1+gUr80de3X/AA/3v6/PrJE/1/8Ao95/r4xzP0+5wfn6+/uORjgkT/X/AOj3n+vjHM/T7nB+fr7+45GOMiTU7z9//wAUv4g/18Y5u7bj7nB/0jr7+45GOCTU7z9//wAUv4g/18Y5u7bj7nB/0jr7+45GOLT/AK+7yJjfTXt1/wAP97+vzTRk/wCJn4o/0e8/5CsPWfp/o1rwfn6+/uORjjYkT/X/AOj3n+vjHM/T7nB+fr7+45GOOT0rULtdR8SFfDeusW1SEkC6t8ofs9sNrZuOWPUEZGGHIIIGrJqd5+//AOKX8Qf6+Mc3dtx9zg/6R19/ccjHEQ2/rv6FO91r26/4f739fmni1P8AiV/8e95/yFdPHM/T/Sbfg/P19/ccjHGxIn+v/wBHvP8AXxjmfp9zg/P19/ccjHHJ+KdQu304hvDeuxAapYHL3VuRkXEBC8XB+Y9AegJGSAMjVk1O8/f/APFL+IP9fGObu24+5wf9I6+/uORjgXxfd/WwK/Ktfx/w/wB7+vz15E/1/wDo95/r4xzP0+5wfn6+/uORjjH0ZP8AiZ+KP9HvP+QrD1n6f6Na8H5+vv7jkY4WTU7z9/8A8Uv4g/18Y5u7bj7nB/0jr7+45GOMrStQu11HxIV8N66xbVISQLq3yh+z2w2tm45Y9QRkYYcgggD3X9dPQIXtv26/4f739fn1kif6/wD0e8/18Y5n6fc4Pz9ff3HIxxj+LU/4lf8Ax73n/IV08cz9P9Jt+D8/X39xyMcLJqd5+/8A+KX8Qf6+Mc3dtx9zg/6R19/ccjHGV4p1C7fTiG8N67EBqlgcvdW5GRcQELxcH5j0B6AkZIAyCfwv+v0Clfmjr26/4f739fn1kif6/wD0e8/18Y5n6fc4Pz9ff3HIxwSJ/r/9HvP9fGOZ+n3OD8/X39xyMcZEmp3n7/8A4pfxB/r4xzd23H3OD/pHX39xyMcEmp3n7/8A4pfxB/r4xzd23H3OD/pHX39xyMcWn/X3eRMb6a9uv+H+9/X5poyf8TPxR/o95/yFYes/T/RrXg/P19/ccjHGxIn+v/0e8/18Y5n6fc4Pz9ff3HIxxyelahdrqPiQr4b11i2qQkgXVvlD9nthtbNxyx6gjIww5BBA1ZNTvP3/APxS/iD/AF8Y5u7bj7nB/wBI6+/uORjiIbf139Cne617df8AD/e/r808Wp/xK/8Aj3vP+Qrp45n6f6Tb8H5+vv7jkY42JE/1/wDo95/r4xzP0+5wfn6+/uORjjk/FOoXb6cQ3hvXYgNUsDl7q3IyLiAheLg/MegPQEjJAGRqyanefv8A/il/EH+vjHN3bcfc4P8ApHX39xyMcC+L7v62BX5Vr+P+H+9/X568if6//R7z/Xxjmfp9zg/P19/ccjHGPoyf8TPxR/o95/yFYes/T/RrXg/P19/ccjHCyanefv8A/il/EH+vjHN3bcfc4P8ApHX39xyMcZWlahdrqPiQr4b11i2qQkgXVvlD9nthtbNxyx6gjIww5BBAHuv66egQvbft1/w/3v6/PrJE/wBf/o95/r4xzP0+5wfn6+/uORjjH8Wp/wASv/j3vP8AkK6eOZ+n+k2/B+fr7+45GOFk1O8/f/8AFL+IP9fGObu24+5wf9I6+/uORjjK8U6hdvpxDeG9diA1SwOXurcjIuICF4uD8x6A9ASMkAZBP4X/AF+gUr80de3X/D/e/r8+skT/AF/+j3n+vjHM/T7nB+fr7+45GOCRP9f/AKPef6+Mcz9PucH5+vv7jkY4yJNTvP3/APxS/iD/AF8Y5u7bj7nB/wBI6+/uORjgk1O8/f8A/FL+IP8AXxjm7tuPucH/AEjr7+45GOLT/r7vImN9Ne3X/D/e/r800ZP+Jn4o/wBHvP8AkKw9Z+n+jWvB+fr7+45GONiRP9f/AKPef6+Mcz9PucH5+vv7jkY45PStQu11HxIV8N66xbVISQLq3yh+z2w2tm45Y9QRkYYcgggasmp3n7//AIpfxB/r4xzd23H3OD/pHX39xyMcRDb+u/oU73Wvbr/h/vf1+aeLU/4lf/Hvef8AIV08cz9P9Jt+D8/X39xyMcbEif6//R7z/Xxjmfp9zg/P19/ccjHHJ+KdQu304hvDeuxAapYHL3VuRkXEBC8XB+Y9AegJGSAMjVk1O8/f/wDFL+IP9fGObu24+5wf9I6+/uORjgXxfd/WwK/Ktfx/w/3v6/PXkT/X/wCj3n+vjHM/T7nB+fr7+45GOMfRk/4mfij/AEe8/wCQrD1n6f6Na8H5+vv7jkY4WTU7z9//AMUv4g/18Y5u7bj7nB/0jr7+45GOMrStQu11HxIV8N66xbVISQLq3yh+z2w2tm45Y9QRkYYcgggD3X9dPQIXtv26/wCH+9/X59ZIn+v/ANHvP9fGOZ+n3OD8/X39xyMcTQR/vbj/AEa+P7wdLjGPlXr8/J/+tWFJqd5+/wD+KX8Qf6+Mc3dtx9zg/wCkdff3HIxxNBqV4Zbj/ilvEJxIOl5bDHyr1/0nmqe39f5Gcr8u/wCPp/eNGRP9f/o95/r4xzP0+5wfn6+/uORjgkT/AF/+j3n+vjHM/T7nB+fr7+45GOCRP9f/AKPef6+Mcz9PucH5+vv7jkY4JE/1/wDo95/r4xzP0+5wfn6+/uORjikv6+7yCMtte3X/AA/3v6/PH0ZP+Jn4o/0e8/5CsPWfp/o1rwfn6+/uORjjYkT/AF/+j3n+vjHM/T7nB+fr7+45GOMfRk/4mfij/R7z/kKw9Z+n+jWvB+fr7+45GONiRP8AX/6Pef6+Mcz9PucH5+vv7jkY4iC0/rv6FOWq17df8P8Ae/r88fxan/Er/wCPe8/5Cunjmfp/pNvwfn6+/uORjjw/4r3upab8e/Dmi2Gq+ILbS9Sms3urNdWuAHMlwVbB8z5cgADaQBgYxXuHi1P+JX/x73n/ACFdPHM/T/Sbfg/P19/ccjHHg/xnXH7S/gkeXMP3mn/Iz5f/AI+m/iz1/GnH4n6Ixru9Jf1/L5s+jIrZbeBoUhvykcsSAyXRdsAIPmZnJZj/AHiSeRz6ZejJ/wATPxR/o95/yFYes/T/AEa14Pz9ff3HIxxsSJ/r/wDR7z/Xxjmfp9zg/P19/ccjHGPoyf8AEz8Uf6Pef8hWHrP0/wBGteD8/X39xyMcJrVf109DanLTft1/w/3v6/PYkT/X/wCj3n+vjHM/T7nB+fr7+45GOMfxan/Er/497z/kK6eOZ+n+k2/B+fr7+45GONiRP9f/AKPef6+Mcz9PucH5+vv7jkY4x/Fqf8Sv/j3vP+Qrp45n6f6Tb8H5+vv7jkY4Jr3X/X6BSl70de3X/D/e/r89iRP9f/o95/r4xzP0+5wfn6+/uORjgkT/AF/+j3n+vjHM/T7nB+fr7+45GOCRP9f/AKPef6+Mcz9PucH5+vv7jkY4JE/1/wDo95/r4xzP0+5wfn6+/uORji0v6+7yJjLbXt1/w/3v6/PH0ZP+Jn4o/wBHvP8AkKw9Z+n+jWvB+fr7+45GONiRP9f/AKPef6+Mcz9PucH5+vv7jkY4x9GT/iZ+KP8AR7z/AJCsPWfp/o1rwfn6+/uORjjYkT/X/wCj3n+vjHM/T7nB+fr7+45GOIgtP67+hTlqte3X/D/e/r88fxan/Er/AOPe8/5Cunjmfp/pNvwfn6+/uORjjYkT/X/6Pef6+Mcz9PucH5+vv7jkY4x/Fqf8Sv8A497z/kK6eOZ+n+k2/B+fr7+45GONiRP9f/o95/r4xzP0+5wfn6+/uORjgS977v62BS91a/j/AIf739fmSJ/r/wDR7z/Xxjmfp9zg/P19/ccjHGPoyf8AEz8Uf6Pef8hWHrP0/wBGteD8/X39xyMcbEif6/8A0e8/18Y5n6fc4Pz9ff3HIxxj6Mn/ABM/FH+j3n/IVh6z9P8ARrXg/P19/ccjHA1qv66egU5ab9uv+H+9/X5+Z/tO3V9onhK31TR73WtNvW1OK2aSHUZUUp5Lvgosm0tuUHdjOABnjFN8UJNF+zedVW61v+0ja2Go/bH1SdmE5WAlsmQnGTuC42g4IAI4j/a1XHw7tf3Vwn/E6i5kk3Af6PLwfmPPv6d+1T+LV/4xZz5Vx/yCNP8AmMnyj5LfqN3Ptx3HTHDl8LOelZ1tfL9PMT9ma6vtb8F6hq2s3utalfjUzbCWfUZZECBYGC7Gk27sk4bbnnrivZJE/wBf/o95/r4xzP0+5wfn6+/uORjjxX9k5c/DHUT5Vw3/ABOmG5Jdq/6uDjG4c++PTmvapE/1/wDo95/r4xzP0+5wfn6+/uORjih4d2gtf6uvMx9GT/iZ+KP9HvP+QrD1n6f6Na8H5+vv7jkY42JE/wBf/o95/r4xzP0+5wfn6+/uORjjH0ZP+Jn4o/0e8/5CsPWfp/o1rwfn6+/uORjjYkT/AF/+j3n+vjHM/T7nB+fr7+45GOIgtP67+hu5arXt1/w/3v6/PH8Wp/xK/wDj3vP+Qrp45n6f6Tb8H5+vv7jkY42JE/1/+j3n+vjHM/T7nB+fr7+45GOMfxan/Er/AOPe8/5Cunjmfp/pNvwfn6+/uORjjYkT/X/6Pef6+Mcz9PucH5+vv7jkY4Eve+7+tgUvdWv4/wCH+9/X5kif6/8A0e8/18Y5n6fc4Pz9ff3HIxxj6Mn/ABM/FH+j3n/IVh6z9P8ARrXg/P19/ccjHGxIn+v/ANHvP9fGOZ+n3OD8/X39xyMcY+jJ/wATPxR/o95/yFYes/T/AEa14Pz9ff3HIxwNar+unoFOWm/br/h/vf1+exIn+v8A9HvP9fGOZ+n3OD8/X39xyMcY/i1P+JX/AMe95/yFdPHM/T/Sbfg/P19/ccjHGxIn+v8A9HvP9fGOZ+n3OD8/X39xyMcY/i1P+JX/AMe95/yFdPHM/T/Sbfg/P19/ccjHBNe6/wCv0ClL3o69uv8Ah/vf1+exIn+v/wBHvP8AXxjmfp9zg/P19/ccjHHO/EXR73WPCGtW2jvrFpqy4kspLXUDAwnCrsVmD4IY4BzkYIOQQCOikT/X/wCj3n+vjHM/T7nB+fr7+45GOCRP9f8A6Pef6+Mcz9PucH5+vv7jkY4tf1+HkRdSVm/x/wAP97+vz8Q/Zn1YeI/CHiCPU7zWL7WDfR/a5Xv5t3lOqrGwYuNrHY6hl+YbVyRhcd38K7SRvDE2rTPr041W8+12632pNOYbV5AbdADI2D5RQk5Jy3LcDb41cWM2m/tB+KvCNkbo2PilfLuEmusFFlCzSvgAqzhDOse7IBcEk/Nn6ZkT/X/6Pef6+Mcz9PucH5+vv7jkY4FtoZUb6c26/wCB59jH8Wp/xK/+Pe8/5Cunjmfp/pNvwfn6+/uORjjYkT/X/wCj3n+vjHM/T7nB+fr7+45GOMfxan/Er/497z/kK6eOZ+n+k2/B+fr7+45GONiRP9f/AKPef6+Mcz9PucH5+vv7jkY4hL3vu/rY6FL3Vr+P+H+9/X5kif6//R7z/Xxjmfp9zg/P19/ccjHGPoyf8TPxR/o95/yFYes/T/RrXg/P19/ccjHGxIn+v/0e8/18Y5n6fc4Pz9ff3HIxxj6Mn/Ez8Uf6Pef8hWHrP0/0a14Pz9ff3HIxwNar+unoFOWm/br/AIf739fnsSJ/r/8AR7z/AF8Y5n6fc4Pz9ff3HIxxj+LU/wCJX/x73n/IV08cz9P9Jt+D8/X39xyMcbEif6//AEe8/wBfGOZ+n3OD8/X39xyMcY/i1P8AiV/8e95/yFdPHM/T/Sbfg/P19/ccjHBNe6/6/QKUvejr26/4f739fnsSJ/r/APR7z/Xxjmfp9zg/P19/ccjHBIn+v/0e8/18Y5n6fc4Pz9ff3HIxwSJ/r/8AR7z/AF8Y5n6fc4Pz9ff3HIxwSJ/r/wDR7z/Xxjmfp9zg/P19/ccjHFpf193kTGW2vbr/AIf739fnzR0waoPGNkx1e087UoUE9peGKWI/ZrXBVg/3s4IzkdAeMivLf2d9fvbjV/EXh7xXc6zd+J7C4yzT6pNMvlrIkcibC/lhkdVAcZJ8zggKTXr+jJ/xM/FH+j3n/IVh6z9P9GteD8/X39xyMceKfFK01Xwl8e9G17Qdxn8QkWKW91dMFacJHEBIU5MQLwPjJJKnBXAxNPYzraSjO+1vyj5na6bp+7+39Ujk8SPZnxFZ2FnBe6q88caQ3VvHKwVpWO5pllAZiSAFxtBOfTpE/wBf/o95/r4xzP0+5wfn6+/uORjjmdR0mHRfCOn6XaxX7W9je6XaxtJON21J7ZRuwwG4gdQMcjpjjppE/wBf/o95/r4xzP0+5wfn6+/uORjgXxP5f1saU0owik/x/wAP94JE/wBf/o95/r4xzP0+5wfn6+/uORjjH0ZP+Jn4o/0e8/5CsPWfp/o1rwfn6+/uORjjYkT/AF/+j3n+vjHM/T7nB+fr7+45GOMfRk/4mfij/R7z/kKw9Z+n+jWvB+fr7+45GOE1qv66ehVOWm/br/h/vf1+exIn+v8A9HvP9fGOZ+n3OD8/X39xyMcTQR/vbj/Rr4/vB0uMY+Vevz8n/wCtUMif6/8A0e8/18Y5n6fc4Pz9ff3HIxxNBH+9uP8ARr4/vB0uMY+Vevz8n/61U1p/Xl5Gcpe7v+Pp/eMKTw3Z/v8AjxB/r4+utXPH3OD+/wCvofccjHBJ4bs/3/HiD/Xx9dauePucH9/19D7jkY415E/1/wDo95/r4xzP0+5wfn6+/uORjgkT/X/6Pef6+Mcz9PucH5+vv7jkY4FFdv608jSNWWnvduv+H+9/X58npXh+0fUfEisuugR6pCgxrFwDj7PbHDETfM3PBOSBgZAAxqyeG7P9/wAeIP8AXx9dauePucH9/wBfQ+45GOE0ZP8AiZ+KP9HvP+QrD1n6f6Na8H5+vv7jkY42JE/1/wDo95/r4xzP0+5wfn6+/uORjiIRVtv6v6FOpK697t1/w/3v6/Pk/FHh+0i04sq67n+1LBPn1i4YAG4gBGDMfm54PUHBBBHEWpfDLwtqGrf2pfaTqtxqVvPEIbqXV7lpYcFWAVjPkHJJGOhPbts+LU/4lf8Ax73n/IV08cz9P9Jt+D8/X39xyMcbEif6/wD0e8/18Y5n6fc4Pz9ff3HIxw4q0tPL+tiG1OKUtf6j/e/r88dvDVkqzKB4gwJ4xzrdycfc4P7/AJPvz1HPpl6V4ftH1HxIrLroEeqQoMaxcA4+z2xwxE3zNzwTkgYGQAMdZIn+v/0e8/18Y5n6fc4Pz9ff3HIxxj6Mn/Ez8Uf6Pef8hWHrP0/0a14Pz9ff3HIxwnFXWn9W9C6dR237df8AD/e/r81k8N2f7/jxB/r4+utXPH3OD+/6+h9xyMcZXijw/aRacWVddz/algnz6xcMADcQAjBmPzc8HqDgggjjrJE/1/8Ao95/r4xzP0+5wfn6+/uORjjH8Wp/xK/+Pe8/5Cunjmfp/pNvwfn6+/uORjgnFcr0/r7gpVJc0fe7df8AD/e/r81k8N2f7/jxB/r4+utXPH3OD+/6+h9xyMcEnhuz/f8AHiD/AF8fXWrnj7nB/f8AX0PuORjjXkT/AF/+j3n+vjHM/T7nB+fr7+45GOCRP9f/AKPef6+Mcz9PucH5+vv7jkY4tRXb+tPImNWWnvduv+H+9/X58npXh+0fUfEisuugR6pCgxrFwDj7PbHDETfM3PBOSBgZAAxqyeG7P9/x4g/18fXWrnj7nB/f9fQ+45GOE0ZP+Jn4o/0e8/5CsPWfp/o1rwfn6+/uORjjYkT/AF/+j3n+vjHM/T7nB+fr7+45GOIhFW2/q/oU6krr3u3X/D/e/r8+T8UeH7SLTiyrruf7UsE+fWLhgAbiAEYMx+bng9QcEEEcasnhuz/f8eIP9fH11q54+5wf3/X0PuORjhPFqf8AEr/497z/AJCunjmfp/pNvwfn6+/uORjjYkT/AF/+j3n+vjHM/T7nB+fr7+45GOBRXNt2/rYFUlyr3vx/w/3v6/PIk8N2f7/jxB/r4+utXPH3OD+/6+h9xyMcZWleH7R9R8SKy66BHqkKDGsXAOPs9scMRN8zc8E5IGBkADHWSJ/r/wDR7z/Xxjmfp9zg/P19/ccjHGPoyf8AEz8Uf6Pef8hWHrP0/wBGteD8/X39xyMcDirrT+regQqSt8Xbr/h/vf1+ebr/AMPfD2vQSQa1p+sX0CXMbLFc6vcyIrYUZ2mfG7DMM+jYyO2b4o8D6JF4XOmLZ6z/AGd9vsLb7K+sXLRCIzQIY9pmIxtOAOg4xjHHeSJ/r/8AR7z/AF8Y5n6fc4Pz9ff3HIxxj+LU/wCJX/x73n/IV08cz9P9Jt+D8/X39xyMcVLSL/r9DOmouab62/8Abf739fnm6N8PfD2gW1xb6Jp+safbm5RjDb6vcom4+XklRPjccD5vpyMcacnhuz/f8eIP9fH11q54+5wf3/X0PuORjjXkT/X/AOj3n+vjHM/T7nB+fr7+45GOCRP9f/o95/r4xzP0+5wfn6+/uORjh2T3/rbyCnLkSUXZev8Ah/vf1+fJ6V4ftH1HxIrLroEeqQoMaxcA4+z2xwxE3zNzwTkgYGQAMasnhuz/AH/HiD/Xx9dauePucH9/19D7jkY4TRk/4mfij/R7z/kKw9Z+n+jWvB+fr7+45GONiRP9f/o95/r4xzP0+5wfn6+/uORjiIRVtv6v6GjqSuve7df8P97+vz5PxR4ftItOLKuu5/tSwT59YuGABuIARgzH5ueD1BwQQRxqyeG7P9/x4g/18fXWrnj7nB/f9fQ+45GOE8Wp/wASv/j3vP8AkK6eOZ+n+k2/B+fr7+45GONiRP8AX/6Pef6+Mcz9PucH5+vv7jkY4FFc23b+tgVSXKve/H/D/e/r88iTw3Z/v+PEH+vj661c8fc4P7/r6H3HIxxlaV4ftH1HxIrLroEeqQoMaxcA4+z2xwxE3zNzwTkgYGQAMdZIn+v/ANHvP9fGOZ+n3OD8/X39xyMcY+jJ/wATPxR/o95/yFYes/T/AEa14Pz9ff3HIxwOKutP6t6BCpK3xduv+H+9/X5rJ4bs/wB/x4g/18fXWrnj7nB/f9fQ+45GOMrxR4ftItOLKuu5/tSwT59YuGABuIARgzH5ueD1BwQQRx1kif6//R7z/Xxjmfp9zg/P19/ccjHGP4tT/iV/8e95/wAhXTxzP0/0m34Pz9ff3HIxwTiuV6f19wUqkuaPvduv+H+9/X5rJ4bs/wB/x4g/18fXWrnj7nB/f9fQ+45GOKt3pmjW19HZXF1q8N5dzj7PBJr86yTbQhYKpnyxAOcjOARkjt0Mif6//R7z/Xxjmfp9zg/P19/ccjHHmnj9cfGf4aDyrhf3+oja0uWP+jRcA7jz757jnji1Fdv6+4hVZK2vbr/h/vGzpnhbTZtd1+5kt9Z+0W2oJBFL/a04dUeC0ZlLCbJJKryc9EGQFGOQ8QWF9afE6KHU08c2XhyW6t4rS6sdalltpJP3P7u5XLuhd3KB965+QADDOPSdGT/iZ+KP9HvP+QrD1n6f6Na8H5+vv7jkY4qzeEoZNTu7m5u/ENxaNfw3aafNqG6CKZWiZWB3eYeVyELmME5CjA2zTWn9f5E1XKVkn26+UfMq+KPD9pFpxZV13P8Aalgnz6xcMADcQAjBmPzc8HqDgggjjVk8N2f7/jxB/r4+utXPH3OD+/6+h9xyMcJ4tT/iV/8AHvef8hXTxzP0/wBJt+D8/X39xyMcbEif6/8A0e8/18Y5n6fc4Pz9ff3HIxwlFc23b+tjVVJcq978f8P97+vzyJPDdn+/48Qf6+PrrVzx9zg/v+vofccjHGVpXh+0fUfEisuugR6pCgxrFwDj7PbHDETfM3PBOSBgZAAx1kif6/8A0e8/18Y5n6fc4Pz9ff3HIxxj6Mn/ABM/FH+j3n/IVh6z9P8ARrXg/P19/ccjHA4q60/q3oEKkrfF26/4f739fmsnhuz/AH/HiD/Xx9dauePucH9/19D7jkY4yvFHh+0i04sq67n+1LBPn1i4YAG4gBGDMfm54PUHBBBHHWSJ/r/9HvP9fGOZ+n3OD8/X39xyMcY/i1P+JX/x73n/ACFdPHM/T/Sbfg/P19/ccjHBOK5Xp/X3BSqS5o+926/4f739fmsnhuz/AH/HiD/Xx9dauePucH9/19D7jkY4JPDdn+/48Qf6+PrrVzx9zg/v+vofccjHGvIn+v8A9HvP9fGOZ+n3OD8/X39xyMcEif6//R7z/Xxjmfp9zg/P19/ccjHFqK7f1p5Exqy097t1/wAP97+vz5PSvD9o+o+JFZddAj1SFBjWLgHH2e2OGIm+ZueCckDAyABi/d+EdMnlWSeDXHktrtJIWfWbkmJyoTI/ffeKuwz6N1HaXRk/4mfij/R7z/kKw9Z+n+jWvB+fr7+45GONiRP9f/o95/r4xzP0+5wfn6+/uORjiYRVtv6+4p1Hda9uv+H+8eC/EDUTbeOtVt3fxJb+FPDrafLqrpqsrHzZp4WUvumLlBGGKmIBw+M8AY9jk8N2f7/jxB/r4+utXPH3OD+/6+h9xyMcYHjvwnp93JPfta3ifa9R06DULcNG0V+i3EIRZw2SxXe2CpGcgMSAAO2kT/X/AOj3n+vjHM/T7nB+fr7+45GOBJXtb+vuM6c5rVy/H0/vf1r88iTw3Z/v+PEH+vj661c8fc4P7/r6H3HIxxlaV4ftH1HxIrLroEeqQoMaxcA4+z2xwxE3zNzwTkgYGQAMdZIn+v8A9HvP9fGOZ+n3OD8/X39xyMcY+jJ/xM/FH+j3n/IVh6z9P9GteD8/X39xyMcJxV1p/VvQ0hUlb4u3X/D/AHv6/NZPDdn+/wCPEH+vj661c8fc4P7/AK+h9xyMcTQeG7Pzbj5PER/eDga3cgj5V6/v+a0ZE/1/+j3n+vjHM/T7nB+fr7+45GOJoI/3tx/o18f3g6XGMfKvX5+T/wDWqnFW2/r7jOVWXL8X4+n94wpNTvP3/wDxS/iD/Xxjm7tuPucH/SOvv7jkY4JNTvP3/wDxS/iD/Xxjm7tuPucH/SOvv7jkY415E/1/+j3n+vjHM/T7nB+fr7+45GOCRP8AX/6Pef6+Mcz9PucH5+vv7jkY4aX9fd5FRqLT5df8P97+vz5PStQu11HxIV8N66xbVISQLq3yh+z2w2tm45Y9QRkYYcgggasmp3n7/wD4pfxB/r4xzd23H3OD/pHX39xyMcJoyf8AEz8Uf6Pef8hWHrP0/wBGteD8/X39xyMcbEif6/8A0e8/18Y5n6fc4Pz9ff3HIxxEFp/Xf0Kc1dfLr/h/vf1+fJ+KdQu304hvDeuxAapYHL3VuRkXEBC8XB+Y9AegJGSAMjVk1O8/f/8AFL+IP9fGObu24+5wf9I6+/uORjhPFqf8Sv8A497z/kK6eOZ+n+k2/B+fr7+45GONiRP9f/o95/r4xzP0+5wfn6+/uORjgS977v62BTXKv8/8P97+vzyJNTvP3/8AxS/iD/Xxjm7tuPucH/SOvv7jkY4ytK1C7XUfEhXw3rrFtUhJAurfKH7PbDa2bjlj1BGRhhyCCB1kif6//R7z/Xxjmfp9zg/P19/ccjHGPoyf8TPxR/o95/yFYes/T/RrXg/P19/ccjHA1qv66egQmrfd1/w/3v6/NZNTvP3/APxS/iD/AF8Y5u7bj7nB/wBI6+/uORjjK8U6hdvpxDeG9diA1SwOXurcjIuICF4uD8x6A9ASMkAZHWSJ/r/9HvP9fGOZ+n3OD8/X39xyMcY/i1P+JX/x73n/ACFdPHM/T/Sbfg/P19/ccjHBNe6/6/QKU1zR+XX/AA/3v6/NZNTvP3//ABS/iD/Xxjm7tuPucH/SOvv7jkY4JNTvP3//ABS/iD/Xxjm7tuPucH/SOvv7jkY415E/1/8Ao95/r4xzP0+5wfn6+/uORjgkT/X/AOj3n+vjHM/T7nB+fr7+45GOLS/r7vImNRafLr/h/vf1+fJ6VqF2uo+JCvhvXWLapCSBdW+UP2e2G1s3HLHqCMjDDkEEDVk1O8/f/wDFL+IP9fGObu24+5wf9I6+/uORjhNGT/iZ+KP9HvP+QrD1n6f6Na8H5+vv7jkY42JE/wBf/o95/r4xzP0+5wfn6+/uORjiILT+u/oU5q6+XX/D/e/r8+T8U6hdvpxDeG9diA1SwOXurcjIuICF4uD8x6A9ASMkAZGrJqd5+/8A+KX8Qf6+Mc3dtx9zg/6R19/ccjHCeLU/4lf/AB73n/IV08cz9P8ASbfg/P19/ccjHGxIn+v/ANHvP9fGOZ+n3OD8/X39xyMcCXvfd/WwKa5V/n/h/vf1+eRJqd5+/wD+KX8Qf6+Mc3dtx9zg/wCkdff3HIxxlaVqF2uo+JCvhvXWLapCSBdW+UP2e2G1s3HLHqCMjDDkEEDrJE/1/wDo95/r4xzP0+5wfn6+/uORjjH0ZP8AiZ+KP9HvP+QrD1n6f6Na8H5+vv7jkY4GtV/XT0CE1b7uv+H+9/X5rJqd5+//AOKX8Qf6+Mc3dtx9zg/6R19/ccjHGV4p1C7fTiG8N67EBqlgcvdW5GRcQELxcH5j0B6AkZIAyOskT/X/AOj3n+vjHM/T7nB+fr7+45GOMfxan/Er/wCPe8/5Cunjmfp/pNvwfn6+/uORjgmvdf8AX6BSmuaPy6/4f739fmsmp3n7/wD4pfxB/r4xzd23H3OD/pHX39xyMcEmp3n7/wD4pfxB/r4xzd23H3OD/pHX39xyMca8if6//R7z/Xxjmfp9zg/P19/ccjHBIn+v/wBHvP8AXxjmfp9zg/P19/ccjHFpf193kTGotPl1/wAP97+vz5PStQu11HxIV8N66xbVISQLq3yh+z2w2tm45Y9QRkYYcgggasmp3n7/AP4pfxB/r4xzd23H3OD/AKR19/ccjHCaMn/Ez8Uf6Pef8hWHrP0/0a14Pz9ff3HIxxsSJ/r/APR7z/Xxjmfp9zg/P19/ccjHEQWn9d/QpzV18uv+H+9/X58n4p1C7fTiG8N67EBqlgcvdW5GRcQELxcH5j0B6AkZIAyNWTU7z9//AMUv4g/18Y5u7bj7nB/0jr7+45GOE8Wp/wASv/j3vP8AkK6eOZ+n+k2/B+fr7+45GONiRP8AX/6Pef6+Mcz9PucH5+vv7jkY4Eve+7+tgU1yr/P/AA/3v6/PIk1O8/f/APFL+IP9fGObu24+5wf9I6+/uORjjK0rULtdR8SFfDeusW1SEkC6t8ofs9sNrZuOWPUEZGGHIIIHWSJ/r/8AR7z/AF8Y5n6fc4Pz9ff3HIxxj6Mn/Ez8Uf6Pef8AIVh6z9P9GteD8/X39xyMcDWq/rp6BCat93X/AA/3v6/NZNTvP3//ABS/iD/Xxjm7tuPucH/SOvv7jkY4yvFOoXb6cQ3hvXYgNUsDl7q3IyLiAheLg/MegPQEjJAGR1kif6//AEe8/wBfGOZ+n3OD8/X39xyMcY/i1P8AiV/8e95/yFdPHM/T/Sbfg/P19/ccjHBNe6/6/QKU1zR+XX/D/e/r81k1O8/f/wDFL+IP9fGObu24+5wf9I6+/uORjjwj4t67qh+P3giAWuqWcdvNbPFZvNF5zGWYJJh1kI+dUVcM4HHOAa+jpE/1/wDo95/r4xzP0+5wfn6+/uORjj5v+M64/aX8Ejy5h+80/wCRny//AB9N/Fnr+NWl/X9I560/c08uv+H+8z2TStQu11HxIV8N66xbVISQLq3yh+z2w2tm45Y9QRkYYcgggasmp3n7/wD4pfxB/r4xzd23H3OD/pHX39xyMcJoyf8AEz8Uf6Pef8hWHrP0/wBGteD8/X39xyMcbEif6/8A0e8/18Y5n6fc4Pz9ff3HIxxEFp/Xf0OhzV18uv8Ah/vf1+fJ+KdQu304hvDeuxAapYHL3VuRkXEBC8XB+Y9AegJGSAMjVk1O8/f/APFL+IP9fGObu24+5wf9I6+/uORjhPFqf8Sv/j3vP+Qrp45n6f6Tb8H5+vv7jkY42JE/1/8Ao95/r4xzP0+5wfn6+/uORjgS977v62BTXKv8/wDD/e/r88iTU7z9/wD8Uv4g/wBfGObu24+5wf8ASOvv7jkY4ytK1C7XUfEhXw3rrFtUhJAurfKH7PbDa2bjlj1BGRhhyCCB1kif6/8A0e8/18Y5n6fc4Pz9ff3HIxxj6Mn/ABM/FH+j3n/IVh6z9P8ARrXg/P19/ccjHA1qv66egQmrfd1/w/3v6/NZNTvP3/8AxS/iD/Xxjm7tuPucH/SOvv7jkY4yvFOoXb6cQ3hvXYgNUsDl7q3IyLiAheLg/MegPQEjJAGR1kif6/8A0e8/18Y5n6fc4Pz9ff3HIxxj+LU/4lf/AB73n/IV08cz9P8ASbfg/P19/ccjHBNe6/6/QKU1zR+XX/D/AHv6/NZNTvP3/wDxS/iD/Xxjm7tuPucH/SOvv7jkY4JNTvP3/wDxS/iD/Xxjm7tuPucH/SOvv7jkY415E/1/+j3n+vjHM/T7nB+fr7+45GOCRP8AX/6Pef6+Mcz9PucH5+vv7jkY4tL+vu8iY1Fp8uv+H+9/X58npWoXa6j4kK+G9dYtqkJIF1b5Q/Z7YbWzccseoIyMMOQQQNWTU7z9/wD8Uv4g/wBfGObu24+5wf8ASOvv7jkY4TRk/wCJn4o/0e8/5CsPWfp/o1rwfn6+/uORjiOTxHY/8JtP4W+zal/af2WPUsmUeWIvMSPBPmZL7unHQjkY4mEdP67+hTqJNfLq/wC7/e/r88/xTqF2+nEN4b12IDVLA5e6tyMi4gIXi4PzHoD0BIyQBkasmp3n7/8A4pfxB/r4xzd23H3OD/pHX39xyMcJ4tT/AIlf/Hvef8hXTxzP0/0m34Pz9ff3HIxxsSJ/r/8AR7z/AF8Y5n6fc4Pz9ff3HIxwkve+7+tgU1yr/P8Aw/3v6/PIk1O8/f8A/FL+IP8AXxjm7tuPucH/AEjr7+45GOMrStQu11HxIV8N66xbVISQLq3yh+z2w2tm45Y9QRkYYcgggdZIn+v/ANHvP9fGOZ+n3OD8/X39xyMcY+jJ/wATPxR/o95/yFYes/T/AEa14Pz9ff3HIxwNar+unoEJq33df8P97+vzWTU7z9//AMUv4g/18Y5u7bj7nB/0jr7+45GOJoNSvDLcf8Ut4hOJB0vLYY+Vev8ApPNaMif6/wD0e8/18Y5n6fc4Pz9ff3HIxxNBH+9uP9Gvj+8HS4xj5V6/Pyf/AK1U1p/X+RnKouX/AIPp/eIZE/1/+j3n+vjHM/T7nB+fr7+45GOCRP8AX/6Pef6+Mcz9PucH5+vv7jkY4yJPDdn+/wCPEH+vj661c8fc4P7/AK+h9xyMcEnhuz/f8eIP9fH11q54+5wf3/X0PuORjhq/b+tPIqLjpr2/9t/vCaMn/Ez8Uf6Pef8AIVh6z9P9GteD8/X39xyMcbEif6//AEe8/wBfGOZ+n3OD8/X39xyMccnpXh+0fUfEisuugR6pCgxrFwDj7PbHDETfM3PBOSBgZAAxqyeG7P8Af8eIP9fH11q54+5wf3/X0PuORjiIXtt/V/QpuN1r2/8Abf739fmni1P+JX/x73n/ACFdPHM/T/Sbfg/P19/ccjHEmp63pun65YaReG8j1HVJ2+xwl2bzPKVGcEhiAQpBBJ7jB44x/FHh+0i04sq67n+1LBPn1i4YAG4gBGDMfm54PUHBBBHHkfxelSz+OHgPR7MatCy3cMskr6rPJKyTypEyKS5KHbG2WVhkOAcbRTinzP5f1sROooU07/17v94+iJE/1/8Ao95/r4xzP0+5wfn6+/uORjjH0ZP+Jn4o/wBHvP8AkKw9Z+n+jWvB+fr7+45GOFk8N2f7/jxB/r4+utXPH3OD+/6+h9xyMcZWleH7R9R8SKy66BHqkKDGsXAOPs9scMRN8zc8E5IGBkADCd7rT+rehcHG2/b/ANt/vf1+fWSJ/r/9HvP9fGOZ+n3OD8/X39xyMcY/i1P+JX/x73n/ACFdPHM/T/Sbfg/P19/ccjHCyeG7P9/x4g/18fXWrnj7nB/f9fQ+45GOMrxR4ftItOLKuu5/tSwT59YuGABuIARgzH5ueD1BwQQRwTvyvT+vuCk480de3/tv97+vz6yRP9f/AKPef6+Mcz9PucH5+vv7jkY4JE/1/wDo95/r4xzP0+5wfn6+/uORjjIk8N2f7/jxB/r4+utXPH3OD+/6+h9xyMcEnhuz/f8AHiD/AF8fXWrnj7nB/f8AX0PuORji1ft/WnkTFx017f8Atv8AeE0ZP+Jn4o/0e8/5CsPWfp/o1rwfn6+/uORjjYkT/X/6Pef6+Mcz9PucH5+vv7jkY45PSvD9o+o+JFZddAj1SFBjWLgHH2e2OGIm+ZueCckDAyABjVk8N2f7/jxB/r4+utXPH3OD+/6+h9xyMcRC9tv6v6FNxute3/tv97+vzTxan/Er/wCPe8/5Cunjmfp/pNvwfn6+/uORjjYkT/X/AOj3n+vjHM/T7nB+fr7+45GOOT8UeH7SLTiyrruf7UsE+fWLhgAbiAEYMx+bng9QcEEEcasnhuz/AH/HiD/Xx9dauePucH9/19D7jkY4Ffm27f1sCceVa/17v97+vz15E/1/+j3n+vjHM/T7nB+fr7+45GOMfRk/4mfij/R7z/kKw9Z+n+jWvB+fr7+45GOFk8N2f7/jxB/r4+utXPH3OD+/6+h9xyMcZWleH7R9R8SKy66BHqkKDGsXAOPs9scMRN8zc8E5IGBkADA73Wn9W9Ag4237f+2/3v6/PrJE/wBf/o95/r4xzP0+5wfn6+/uORjjH8Wp/wASv/j3vP8AkK6eOZ+n+k2/B+fr7+45GOFk8N2f7/jxB/r4+utXPH3OD+/6+h9xyMcZXijw/aRacWVddz/algnz6xcMADcQAjBmPzc8HqDgggjgnflen9fcFJx5o69v/bf739fn1kif6/8A0e8/18Y5n6fc4Pz9ff3HIxwSJ/r/APR7z/Xxjmfp9zg/P19/ccjHGRJ4bs/3/HiD/Xx9dauePucH9/19D7jkY4JPDdn+/wCPEH+vj661c8fc4P7/AK+h9xyMcWr9v608iYuOmvb/ANt/vCaMn/Ez8Uf6Pef8hWHrP0/0a14Pz9ff3HIxxsSJ/r/9HvP9fGOZ+n3OD8/X39xyMccnpXh+0fUfEisuugR6pCgxrFwDj7PbHDETfM3PBOSBgZAAxqyeG7P9/wAeIP8AXx9dauePucH9/wBfQ+45GOIhe239X9Cm43Wvb/23+9/X5p4tT/iV/wDHvef8hXTxzP0/0m34Pz9ff3HIxxsSJ/r/APR7z/Xxjmfp9zg/P19/ccjHHJ+KPD9pFpxZV13P9qWCfPrFwwANxACMGY/NzweoOCCCONWTw3Z/v+PEH+vj661c8fc4P7/r6H3HIxwK/Nt2/rYE48q1/r3f739fnryJ/r/9HvP9fGOZ+n3OD8/X39xyMcY+jJ/xM/FH+j3n/IVh6z9P9GteD8/X39xyMcLJ4bs/3/HiD/Xx9dauePucH9/19D7jkY4ytK8P2j6j4kVl10CPVIUGNYuAcfZ7Y4Yib5m54JyQMDIAGB3utP6t6BBxtv2/9t/vf1+fWSJ/r/8AR7z/AF8Y5n6fc4Pz9ff3HIxxj+LU/wCJX/x73n/IV08cz9P9Jt+D8/X39xyMcLJ4bs/3/HiD/Xx9dauePucH9/19D7jkY4yvFHh+0i04sq67n+1LBPn1i4YAG4gBGDMfm54PUHBBBHBO/K9P6+4KTjzR17f+2/3v6/PrJE/1/wDo95/r4xzP0+5wfn6+/uORjj5o+L0kj/HJPEE9tPDo3hW80qG/k3NLIiSMZhIducDqvXrtA5bA+gJPDdn+/wCPEH+vj661c8fc4P7/AK+h9xyMceA/E7TYYP8AhdWxdSH2b+xNnm30smN2zPmZkPme27dt7Yq1f+vl5HLXkuRWf9WX95/1+PvujJ/xM/FH+j3n/IVh6z9P9GteD8/X39xyMcbEif6//R7z/Xxjmfp9zg/P19/ccjHHJ6V4ftH1HxIrLroEeqQoMaxcA4+z2xwxE3zNzwTkgYGQAMasnhuz/f8AHiD/AF8fXWrnj7nB/f8AX0PuORjiIXtt/V/Q6m43Wvb/ANt/vf1+aeLU/wCJX/x73n/IV08cz9P9Jt+D8/X39xyMcbEif6//AEe8/wBfGOZ+n3OD8/X39xyMccn4o8P2kWnFlXXc/wBqWCfPrFwwANxACMGY/NzweoOCCCONWTw3Z/v+PEH+vj661c8fc4P7/r6H3HIxwK/Nt2/rYE48q1/r3f739fnryJ/r/wDR7z/Xxjmfp9zg/P19/ccjHGPoyf8AEz8Uf6Pef8hWHrP0/wBGteD8/X39xyMcLJ4bs/3/AB4g/wBfH11q54+5wf3/AF9D7jkY4ytK8P2j6j4kVl10CPVIUGNYuAcfZ7Y4Yib5m54JyQMDIAGB3utP6t6BBxtv2/8Abf739fn1kif6/wD0e8/18Y5n6fc4Pz9ff3HIxxj+LU/4lf8Ax73n/IV08cz9P9Jt+D8/X39xyMcLJ4bs/wB/x4g/18fXWrnj7nB/f9fQ+45GOMrxR4ftItOLKuu5/tSwT59YuGABuIARgzH5ueD1BwQQRwTvyvT+vuCk480de3/tv97+vz6yRP8AX/6Pef6+Mcz9PucH5+vv7jkY4JE/1/8Ao95/r4xzP0+5wfn6+/uORjjIk8N2f7/jxB/r4+utXPH3OD+/6+h9xyMcEnhuz/f8eIP9fH11q54+5wf3/X0PuORji1ft/WnkTFx017f+2/3hNGT/AImfij/R7z/kKw9Z+n+jWvB+fr7+45GOPJ9O1SOD9rHX7S9ku909hFaWcLyszBtlvMUB3EAYWVuuMn1NeiaV4ftH1HxIrLroEeqQoMaxcA4+z2xwxE3zNzwTkgYGQAMeH6DpcF38atPnuf7RkupfE2s2LztfS+e0MEEQhj8zfuBUMRnPIIBJA4mnt/X+RnWkuaFn1X5L+8z6E8Wp/wASv/j3vP8AkK6eOZ+n+k2/B+fr7+45GONiRP8AX/6Pef6+Mcz9PucH5+vv7jkY45PxR4ftItOLKuu5/tSwT59YuGABuIARgzH5ueD1BwQQRxqyeG7P9/x4g/18fXWrnj7nB/f9fQ+45GOEr823b+tjZOPKtf693+9/X568if6//R7z/Xxjmfp9zg/P19/ccjHGPoyf8TPxR/o95/yFYes/T/RrXg/P19/ccjHCyeG7P9/x4g/18fXWrnj7nB/f9fQ+45GOMrSvD9o+o+JFZddAj1SFBjWLgHH2e2OGIm+ZueCckDAyABgd7rT+regQcbb9v/bf739fn1kif6//AEe8/wBfGOZ+n3OD8/X39xyMcTQR/vbj/Rr4/vB0uMY+Vevz8n/61YUnhuz/AH/HiD/Xx9dauePucH9/19D7jkY4mg8N2fm3HyeIj+8HA1u5BHyr1/f81Tvbb+vuM5Sjy7/1p/eNGRP9f/o95/r4xzP0+5wfn6+/uORjgkT/AF/+j3n+vjHM/T7nB+fr7+45GOMiTU7z9/8A8Uv4g/18Y5u7bj7nB/0jr7+45GOIdQ1XU47S+ez8Ja5NcrIpiikvrZFd8LhWbzzjJ/iwcZHpTX9fh5FK+mvbr/h/vf1+cujJ/wATPxR/o95/yFYes/T/AEa14Pz9ff3HIxxsSJ/r/wDR7z/Xxjmfp9zg/P19/ccjHHlGm+IvHiX+vNF8NppHfUYmlX/hJIh5L+RbgJn+IlQrbu2/H8NUdf1H403120ukeF7HSrSK6ik8iTUUuJJMKv7t3MgBViQcqFYcAMMZpRVkZ+2Tatfp37R7v+vz9N8Wp/xK/wDj3vP+Qrp45n6f6Tb8H5+vv7jkY4+f/wBoOGDUfGHjKdLOaYaToFnDJLIhb7LcPewsoLnI3NE7YwTwWHZseheIvEfjySxK3Hw2mgQajZtu/wCEkif5xPCUTA7swVd38O7P8NU7HQvFGo3XxGudc8K6hpp8Sw21nElvf2939nKwmIsxaVN/31IH1GRjNCVpfcRKftYqEevf0Xd/1+frsEsN3am5tFuJ7eaSKSKWO5Do6sEIIIfDZByCM9Rz6ZmjJ/xM/FH+j3n/ACFYes/T/RrXg/P19/ccjHHlHw3+KmmaVocHhTxJb3Fr4g0YizuV+1wwQAQOsQAeSdVZsKM4PUEjCjjoNN+JXh2G/wBekaUYn1GKVP8AidWI+UQW6nrdYY5Q/MMgdMgggKW6/r9DelNON79uv+H+8enyJ/r/APR7z/Xxjmfp9zg/P19/ccjHGP4tT/iV/wDHvef8hXTxzP0/0m34Pz9ff3HIxx59p/xebxVdzQfD3wlrGuGJkluXub5bNIQSioNxLBmYhupBAGRnB2v8ReI/HkliVuPhtNAg1Gzbd/wkkT/OJ4SiYHdmCru/h3Z/hpyV4szhXipLV9O7/l7P+vz9WkT/AF/+j3n+vjHM/T7nB+fr7+45GOCRP9f/AKPef6+Mcz9PucH5+vv7jkY4wrbVdTe033nhLXILkyRGWJL62kWNyEyobzxu5yA2B26dppNTvP3/APxS/iD/AF8Y5u7bj7nB/wBI6+/uORjh/wBfl5Gkbu2vbr/h/vCaMn/Ez8Uf6Pef8hWHrP0/0a14Pz9ff3HIxxsSJ/r/APR7z/Xxjmfp9zg/P19/ccjHHJ6VqF2uo+JCvhvXWLapCSBdW+UP2e2G1s3HLHqCMjDDkEEDVk1O8/f/APFL+IP9fGObu24+5wf9I6+/uORjiIbf139Cne617df8P97+vzTxan/Er/497z/kK6eOZ+n+k2/B+fr7+45GONiRP9f/AKPef6+Mcz9PucH5+vv7jkY45PxTqF2+nEN4b12IDVLA5e6tyMi4gIXi4PzHoD0BIyQBkc54o1P4q/23e/8ACMeF9P8A7H82IRf2jd/vw21Mhtlxt+90I7Y5BHAn733f1sK7UVr+P+H+9/X5+lX0sFna3lzdrcQW8MiySyy3IVI1AQksS+Bxzk9OORjjg/hp468PeMNU8Trok148p1GO4SKWQo7wiOCLzApfJBZCM9VymduRXG6no3xN8XahY2fjnQ44/C8d0r6hZ6RfKr3fClEcyTHI3bejDqTnKqVPGXh3UE1K88S+DvDOo2mu+Hr+MW8IW2kja3+yW6m2cJLv4XJQR5wHIGGOUbtdaf19xClNJu+it13+H+993c9zkT/X/wCj3n+vjHM/T7nB+fr7+45GOPO9F8ZWvjvwtf6lp9ldpZ2/iS0s4ZPtLN5yLc2xWQhipUsGHBBxxzxxieMPirY3vwl1rX/D9pq0Udw32O2upb6GJop2CrjaJjJ5ijLgBScAHIHzDlvgsbjRvAutaDcabez6jp/ii2W5FtdQ7YmFxbKFKmVTlmjZVbbtJ/i4JBP4X/X6EwqP2sIp9uvp/ePoiRP9f/o95/r4xzP0+5wfn6+/uORjgkT/AF/+j3n+vjHM/T7nB+fr7+45GOMiTU7z9/8A8Uv4g/18Y5u7bj7nB/0jr7+45GOMHxb4/s/CwhXWNB8Qxz3t4kFrbxTQTTTvhCVWNJyzHkc44LKMgkCqT/r7vIu/Krt/j/h/vf1+e7oyf8TPxR/o95/yFYes/T/RrXg/P19/ccjHGxIn+v8A9HvP9fGOZ+n3OD8/X39xyMceIWmu/Fe+vtYvNB8HWFpa3F3DJJbajfO80Mht4MKx81Oq+WeVBXdg4K8d54T1Pxj/AGVc/wDCY+F7j+0vtihf7Ku4vJEeI8A+ZcZ353c9Pu8jHEx00/r8gU+azT7df8P942/Fqf8AEr/497z/AJCunjmfp/pNvwfn6+/uORjjYkT/AF/+j3n+vjHM/T7nB+fr7+45GOOT8U6hdvpxDeG9diA1SwOXurcjIuICF4uD8x6A9ASMkAZGrJqd5+//AOKX8Qf6+Mc3dtx9zg/6R19/ccjHCXxfd/WxavyrX8f8P97+vz15E/1/+j3n+vjHM/T7nB+fr7+45GOMfRk/4mfij/R7z/kKw9Z+n+jWvB+fr7+45GOFk1O8/f8A/FL+IP8AXxjm7tuPucH/AEjr7+45GOOA034kRxX+vP8A8IP8QX8/UYpNq6c5MeILddrjzOHO3I9mQ9+Ha7X9foR7RQWr7ef8vaR6tIn+v/0e8/18Y5n6fc4Pz9ff3HIxxj+LU/4lf/Hvef8AIV08cz9P9Jt+D8/X39xyMcck/wAT4/33/FBfEb/XIedMfj7vB/edfT6iuO8RXfxT1lJNZj0u40WwW4sGs9FlkhmW4lMsZUXErSJLGSxj4CjHQ7MFi5r3X/X6EUq65la/T9P7x7tIn+v/ANHvP9fGOZ+n3OD8/X39xyMcfOPxALajoHxv1mC1u49Pe+07TkkllBPnW0kaShgHJIyVIJzww6cgeiW/xQd7Xdd/D/4hRXLPE0iR6fJIiNhNyhi4Lc5wSATxwOg4d7S8vfhF8TxqHhvxJZQX2rXeqRPcBIDEn7qVPMjkkDHlBkhWzzgk9KtYwnL2toxf9WXme1aMn/Ez8Uf6Pef8hWHrP0/0a14Pz9ff3HIxxsSJ/r/9HvP9fGOZ+n3OD8/X39xyMcec/DTW9SvfD0t9daLrN9dXUllNNPFcQKGdrO0JJBmXlvvDA4DL0IIXptV8RHTLK7vNS0LWLO0inj8ye4v7REQEoBuY3OMkkAH3HPpnDb+u/odl9nft18o/3v6/Ox4tT/iV/wDHvef8hXTxzP0/0m34Pz9ff3HIxxsSJ/r/APR7z/Xxjmfp9zg/P19/ccjHHh2veM/FXjzTFuPA+h3Vh4Xk1G3i/ti7mV7gyCaAIYoWkCkiTjLFlPQsm04vtoXxSHmZ8VeIOJVU50nTeSduCf8ASuvIx9ByOz2l939bEQqc0Vb8/wDD3l/Vz2KRP9f/AKPef6+Mcz9PucH5+vv7jkY4x9GT/iZ+KP8AR7z/AJCsPWfp/o1rwfn6+/uORjjkPCdn440vUrmbxHeeINdtPljFsbWwttshaMhyyXJJO3KgdPmByMcbelahdrqPiQr4b11i2qQkgXVvlD9nthtbNxyx6gjIww5BBATeq/r9DSne2/br5x/vHWSJ/r/9HvP9fGOZ+n3OD8/X39xyMcY/i1P+JX/x73n/ACFdPHM/T/Sbfg/P19/ccjHCyanefv8A/il/EH+vjHN3bcfc4P8ApHX39xyMcZXinULt9OIbw3rsQGqWBy91bkZFxAQvFwfmPQHoCRkgDIJ/C/6/QKV+aOvbr/h/vf1+fWSJ/r/9HvP9fGOZ+n3OD8/X39xyMcEif6//AEe8/wBfGOZ+n3OD8/X39xyMcc/qviI6ZZXd5qWhaxZ2kU8fmT3F/aIiAlANzG5xkkgA+459OAvv2gfBVreXFs8Guuy3ABeJkkQbSoPzLMQ2cHDLkdCDjFWn/X9Iz5uW1326+n949H0ZP+Jn4o/0e8/5CsPWfp/o1rwfn6+/uORjj5++GSPPrfwu1a5kuLi+1jU9avrpywG+UoiHaBjbnYD9T1xwPU4PGUcOh+MvEOm6NqOoWMN19qEsOo27Rfu7WDKs6Ttk/IeVD4yO4IHmGnWFxpvw3+FC3uhXbXUXiO0mguklhxJHOzTCOM+ZuVmBjJyFGVGSMCpp7E1ns77JPf8Aw+Z774tT/iV/8e95/wAhXTxzP0/0m34Pz9ff3HIxxsSJ/r/9HvP9fGOZ+n3OD8/X39xyMccn4p1C7fTiG8N67EBqlgcvdW5GRcQELxcH5j0B6AkZIAyNWTU7z9//AMUv4g/18Y5u7bj7nB/0jr7+45GOEvi+7+tjZX5Vr+P+H+9/X568if6//R7z/Xxjmfp9zg/P19/ccjHGPoyf8TPxR/o95/yFYes/T/RrXg/P19/ccjHHBL8XI9bv7nT/AAP4V1zXr6K7RJibpYraIYPLXCu6ZJjIUng9QxwAW6b4i8eJf680Xw2mkd9RiaVf+EkiHkv5FuAmf4iVCtu7b8fw1TV2mYxrxV1d9O7/AJez/r8/V5E/1/8Ao95/r4xzP0+5wfn6+/uORjiaCP8Ae3H+jXx/eDpcYx8q9fn5P/1q4vRNc8T3Ivf7d8B6np5WeHy/s+s29zuztyGzImD93B5+9221uwaleGW4/wCKW8QnEg6XlsMfKvX/AEnmh9v66eQc3NC6f427f3v6/PRkT/X/AOj3n+vjHM/T7nB+fr7+45GOCRP9f/o95/r4xzP0+5wfn6+/uORjgkT/AF/+j3n+vjHM/T7nB+fr7+45GOCRP9f/AKPef6+Mcz9PucH5+vv7jkY4pL+vu8ioy217df8AD/e/r88fRk/4mfij/R7z/kKw9Z+n+jWvB+fr7+45GONiRP8AX/6Pef6+Mcz9PucH5+vv7jkY4x9GT/iZ+KP9HvP+QrD1n6f6Na8H5+vv7jkY42JE/wBf/o95/r4xzP0+5wfn6+/uORjiILT+u/oU5arXt1/w/wB7+vzx/Fqf8Sv/AI97z/kK6eOZ+n+k2/B+fr7+45GONiRP9f8A6Pef6+Mcz9PucH5+vv7jkY4x/Fqf8Sv/AI97z/kK6eOZ+n+k2/B+fr7+45GONiRP9f8A6Pef6+Mcz9PucH5+vv7jkY4Eve+7+tgUvdWv4/4f739fnma54c0bXCTrWgx6gYJlEX2xUm8sN5e4DcxwTgcj25445fSfAXhJ9R8RK/g/TWWHUooow1tCRGpt7YlBz3LMeO7V3cif6/8A0e8/18Y5n6fc4Pz9ff3HIxxj6Mn/ABM/FH+j3n/IVh6z9P8ARrXg/P19/ccjHA1qv66egoNNb9uv+H+9/X56cFpBZ2ptrSyngt4ZIoooo5QqRqAgCABsDjgY6cdMcZni1P8AiV/8e95/yFdPHM/T/Sbfg/P19/ccjHGxIn+v/wBHvP8AXxjmfp9zg/P19/ccjHGP4tT/AIlf/Hvef8hXTxzP0/0m34Pz9ff3HIxwTXuv+v0HSl70de3X/D/e/r89iRP9f/o95/r4xzP0+5wfn6+/uORjgkT/AF/+j3n+vjHM/T7nB+fr7+45GOCRP9f/AKPef6+Mcz9PucH5+vv7jkY4JE/1/wDo95/r4xzP0+5wfn6+/uORji0v6+7yJjLbXt1/w/3v6/PH0ZP+Jn4o/wBHvP8AkKw9Z+n+jWvB+fr7+45GONiRP9f/AKPef6+Mcz9PucH5+vv7jkY4x9GT/iZ+KP8AR7z/AJCsPWfp/o1rwfn6+/uORjjYkT/X/wCj3n+vjHM/T7nB+fr7+45GOIgtP67+hTlqte3X/D/e/r88fxan/Er/AOPe8/5Cunjmfp/pNvwfn6+/uORjjYkT/X/6Pef6+Mcz9PucH5+vv7jkY4x/Fqf8Sv8A497z/kK6eOZ+n+k2/B+fr7+45GONiRP9f/o95/r4xzP0+5wfn6+/uORjgS977v62BS91a/j/AIf739fmSJ/r/wDR7z/Xxjmfp9zg/P19/ccjHGPoyf8AEz8Uf6Pef8hWHrP0/wBGteD8/X39xyMcbEif6/8A0e8/18Y5n6fc4Pz9ff3HIxxj6Mn/ABM/FH+j3n/IVh6z9P8ARrXg/P19/ccjHA1qv66egU5ab9uv+H+9/X549v8ADDwZZ6//AG1aeFUt9Qt7mNonjkKpEQEAxGH2Bu4IHBIOQeRkfEjwLHcz3WuaJe63outz6jYJLNBc+ZDM4lgSIzRM5DmPJKgEDJ5J7ejyJ/r/APR7z/Xxjmfp9zg/P19/ccjHGP4tT/iV/wDHvef8hXTxzP0/0m34Pz9ff3HIxw5aRf8AX6EQhCTSfdf+2/3v6/PiLrwP8Q57e5hk+Jd+EdhG5TSIEbLBRkMsoIbkYIPGByO234Z+GmieH9YuNZeLWNW17z1Uanql4JrhFKxrtBBAzgYDYyA2N2OB2kif6/8A0e8/18Y5n6fc4Pz9ff3HIxwSJ/r/APR7z/Xxjmfp9zg/P19/ccjHFL+vw8iUotpvfTr6f3jH0ZP+Jn4o/wBHvP8AkKw9Z+n+jWvB+fr7+45GONiRP9f/AKPef6+Mcz9PucH5+vv7jkY4x9GT/iZ+KP8AR7z/AJCsPWfp/o1rwfn6+/uORjjYkT/X/wCj3n+vjHM/T7nB+fr7+45GOIgtP67+hq5arXt1/wAP97+vzx/Fqf8AEr/497z/AJCunjmfp/pNvwfn6+/uORjjYkT/AF/+j3n+vjHM/T7nB+fr7+45GOMfxan/ABK/+Pe8/wCQrp45n6f6Tb8H5+vv7jkY42JE/wBf/o95/r4xzP0+5wfn6+/uORjgS977v62BS91a/j/h/vf1+ZIn+v8A9HvP9fGOZ+n3OD8/X39xyMcY+jJ/xM/FH+j3n/IVh6z9P9GteD8/X39xyMcbEif6/wD0e8/18Y5n6fc4Pz9ff3HIxxj6Mn/Ez8Uf6Pef8hWHrP0/0a14Pz9ff3HIxwNar+unoFOWm/br/h/vf1+exIn+v/0e8/18Y5n6fc4Pz9ff3HIxxj+LU/4lf/Hvef8AIV08cz9P9Jt+D8/X39xyMcbEif6//R7z/Xxjmfp9zg/P19/ccjHGP4tT/iV/8e95/wAhXTxzP0/0m34Pz9ff3HIxwTXuv+v0ClL3o69uv+H+9/X57Eif6/8A0e8/18Y5n6fc4Pz9ff3HIxxFfWkN3a3ltd2U89tNIsUsUsodHVggKMC2GyDjnPUfhLIn+v8A9HvP9fGOZ+n3OD8/X39xyMcEif6//R7z/Xxjmfp9zg/P19/ccjHFpf193kTGW2vbr/h/vf1+flGmfCvT4r/xBb6Fq3i/w/p9vqMUcdlpeqiOEEwW7FiGLEuSx5yf4emK0YPg74cbUZb/AMQLr/iW8SWFIpdavxOYlUg7PlKhgdx4bcOnT5s9doyf8TPxR/o95/yFYes/T/RrXg/P19/ccjHGxIn+v/0e8/18Y5n6fc4Pz9ff3HIxxMG2tf6/An2dNNWS6f8Atv8AeMLxHaQWmhQ21pZTwW8OpabFFFHKFSNRc24CABsDjgY6cdMcbsif6/8A0e8/18Y5n6fc4Pz9ff3HIxxj+LU/4lf/AB73n/IV08cz9P8ASbfg/P19/ccjHGxIn+v/ANHvP9fGOZ+n3OD8/X39xyMcJL3vu/rY0UvdWv4/4f739fmSJ/r/APR7z/Xxjmfp9zg/P19/ccjHGPoyf8TPxR/o95/yFYes/T/RrXg/P19/ccjHGxIn+v8A9HvP9fGOZ+n3OD8/X39xyMcY+jJ/xM/FH+j3n/IVh6z9P9GteD8/X39xyMcDWq/rp6BTlpv26/4f739fnsSJ/r/9HvP9fGOZ+n3OD8/X39xyMcY/i1P+JX/x73n/ACFdPHM/T/Sbfg/P19/ccjHGxIn+v/0e8/18Y5n6fc4Pz9ff3HIxxj+LU/4lf/Hvef8AIV08cz9P9Jt+D8/X39xyMcE17r/r9ApS96Ovbr/h/vf1+d/VdNs9Tsruz1LTZLu0lmjEkFw4kRhlCAyliCc4IPOOORjiGLQ9LtdHuNJttGEOlmQRGzTasO19u5Sgbad249v4vyvyJ/r/APR7z/Xxjmfp9zg/P19/ccjHBIn+v/0e8/18Y5n6fc4Pz9ff3HIxxaX9fd5Exltr26/4f739fn5G3wd8Nahq3iU6fFrWhAXv2ORNLu1iWWGWG2donViw27mYhRgfMAeAAvT+J/ACal4P0rRdMvNS06fQ7qzlsLxjHMY3hRUQuhYKxwSeMDO3sCtbujJ/xM/FH+j3n/IVh6z9P9GteD8/X39xyMcbEif6/wD0e8/18Y5n6fc4Pz9ff3HIxxMLta/1+AuSC262/wDbf7x47rNj8WbHTDbXV14c1O3j1K2CXlw00VxKxuYzDvSNgg5MYOM4GcMSM1buvAnjrxULlPG3iiWx02WcRz6VoI2xuhjVcGaRt5yWyVYOvTkcbe/8Wp/xK/8Aj3vP+Qrp45n6f6Tb8H5+vv7jkY42JE/1/wDo95/r4xzP0+5wfn6+/uORjhL4vu/rYdk4q7/H/D/e/r86Oj6NYaFpS6ZpGmzWdhbSxpFDHLhUHyk5+fliSTuOTk5JzVXRk/4mfij/AEe8/wCQrD1n6f6Na8H5+vv7jkY42JE/1/8Ao95/r4xzP0+5wfn6+/uORjjH0ZP+Jn4o/wBHvP8AkKw9Z+n+jWvB+fr7+45GOBrVf109CqctN+3X/D/e/r89iRP9f/o95/r4xzP0+5wfn6+/uORjiaCP97cf6NfH94OlxjHyr1+fk/8A1qhkT/X/AOj3n+vjHM/T7nB+fr7+45GOJoI/3tx/o18f3g6XGMfKvX5+T/8AWqmtP68vIzlL3d/x9P7xkSeFdPH2j/SNa4uYh/yGbzvs/wCmvv1ok8K6ePtH+ka1xcxD/kM3nfZ/019+tFFVyR7Gca1TT3n06/4TL0vwzYPqPiVTPq+ItVgjXGrXYJBt7U8kSfMfmPJyQMDOAMaknhXTx9o/0jWuLmIf8hm877P+mvv1ooqYQjbYr21S6959Ov8AhMvxT4ZsIdOZkn1cn+1bCP59Wu2GGuLcHgydeTg9QcEEEDGpJ4V08faP9I1ri5iH/IZvO+z/AKa+/WiihQjzbdgjWqcsfef3/wCAJPCunj7R/pGtcXMQ/wCQzed9n/TX361l6X4ZsH1HxKpn1fEWqwRrjVrsEg29qeSJPmPzHk5IGBnAGCihwjdaBTrVLfE+nX/CaknhXTx9o/0jWuLmIf8AIZvO+z/pr79ay/FPhmwh05mSfVyf7VsI/n1a7YYa4tweDJ15OD1BwQQQMFFE4R5XoFKtU5o+8+nX/CaknhXTx9o/0jWuLmIf8hm877P+mvv1ok8K6ePtH+ka1xcxD/kM3nfZ/wBNffrRRVckexMa1TT3n06/4TL0vwzYPqPiVTPq+ItVgjXGrXYJBt7U8kSfMfmPJyQMDOAMaknhXTx9o/0jWuLmIf8AIZvO+z/pr79aKKmEI22K9tUuvefTr/hMvxT4ZsIdOZkn1cn+1bCP59Wu2GGuLcHgydeTg9QcEEEDGpJ4V08faP8ASNa4uYh/yGbzvs/6a+/WiihQjzbdgjWqcsfef3/4Ak8K6ePtH+ka1xcxD/kM3nfZ/wBNffrWXpfhmwfUfEqmfV8RarBGuNWuwSDb2p5Ik+Y/MeTkgYGcAYKKHCN1oFOtUt8T6df8JqSeFdPH2j/SNa4uYh/yGbzvs/6a+/WsvxT4ZsIdOZkn1cn+1bCP59Wu2GGuLcHgydeTg9QcEEEDBRROEeV6BSrVOaPvPp1/wmpJ4V08faP9I1ri5iH/ACGbzvs/6a+/WiTwrp4+0f6RrXFzEP8AkM3nfZ/019+tFFVyR7ExrVNPefTr/hMvS/DNg+o+JVM+r4i1WCNcatdgkG3tTyRJ8x+Y8nJAwM4AxqSeFdPH2j/SNa4uYh/yGbzvs/6a+/WiiphCNtivbVLr3n06/wCEy/FPhmwh05mSfVyf7VsI/n1a7YYa4tweDJ15OD1BwQQQMaknhXTx9o/0jWuLmIf8hm877P8Apr79aKKFCPNt2CNapyx95/f/AIAk8K6ePtH+ka1xcxD/AJDN532f9NffrWXpfhmwfUfEqmfV8RarBGuNWuwSDb2p5Ik+Y/MeTkgYGcAYKKHCN1oFOtUt8T6df8JqSeFdPH2j/SNa4uYh/wAhm877P+mvv1rL8U+GbCHTmZJ9XJ/tWwj+fVrthhri3B4MnXk4PUHBBBAwUUThHlegUq1Tmj7z6df8JqSeFdPH2j/SNa4uYh/yGbzvs/6a+/WiTwrp4+0f6RrXFzEP+Qzed9n/AE19+tFFVyR7ExrVNPefTr/hMvS/DNg+o+JVM+r4i1WCNcatdgkG3tTyRJ8x+Y8nJAwM4AxqSeFdPH2j/SNa4uYh/wAhm877P+mvv1ooqYQjbYr21S6959Ov+Ey/FPhmwh05mSfVyf7VsI/n1a7YYa4tweDJ15OD1BwQQQMaknhXTx9o/wBI1ri5iH/IZvO+z/pr79aKKFCPNt2CNapyx95/f/gCTwrp4+0f6RrXFzEP+Qzed9n/AE19+tZel+GbB9R8SqZ9XxFqsEa41a7BINvankiT5j8x5OSBgZwBgoocI3WgU61S3xPp1/wmpJ4V08faP9I1ri5iH/IZvO+z/pr79ay/FPhmwh05mSfVyf7VsI/n1a7YYa4tweDJ15OD1BwQQQMFFE4R5XoFKtU5o+8+nX/CaknhXTx9o/0jWuLmIf8AIZvO+z/pr79aJPCunj7R/pGtcXMQ/wCQzed9n/TX360UVXJHsTGtU0959Ov+Ey9L8M2D6j4lUz6viLVYI1xq12CQbe1PJEnzH5jyckDAzgDGpJ4V08faP9I1ri5iH/IZvO+z/pr79aKKmEI22K9tUuvefTr/AITL8U+GbCHTmZJ9XJ/tWwj+fVrthhri3B4MnXk4PUHBBBAxqSeFdPH2j/SNa4uYh/yGbzvs/wCmvv1oooUI823YI1qnLH3n9/8AgCTwrp4+0f6RrXFzEP8AkM3nfZ/019+tZel+GbB9R8SqZ9XxFqsEa41a7BINvankiT5j8x5OSBgZwBgoocI3WgU61S3xPp1/wmpJ4V08faP9I1ri5iH/ACGbzvs/6a+/Wp7fwnpxmuh9p1viUDjWrz+4v/TWiiq5I22MpV6nJ8T27/4T/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     The ST segment is depressed and concave upward.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_31_4594=[""].join("\n");
var outline_f4_31_4594=null;
var title_f4_31_4595="Patient information: Gallbladder cancer (The Basics)";
var content_f4_31_4595=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83153\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/37/27220\">",
"         Anatomy of the gallbladder",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?1/56/1923\">",
"         Patient information: Gallbladder removal (cholecystectomy) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?8/29/8658\">",
"         Patient information: Gallstones (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/27/17842\">",
"         Patient information: Hair loss from cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/17/34066\">",
"         Patient information: Jaundice in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/40/1667\">",
"         Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/36/579\">",
"         Patient information: Managing pain when you have cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/21/25939\">",
"         Patient information: Medical care during advanced illness (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/57/19346\">",
"         Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/32/40450\">",
"         Patient information: Radiation therapy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/4/29762\">",
"         Patient information: When your cancer treatment makes you tired (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?7/21/7507\">",
"         Patient information: Gallstones (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Gallbladder cancer (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/gallbladder-cancer-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H8182471\">",
"      <span class=\"h1\">",
"       What is gallbladder cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Gallbladder cancer happens when normal cells in the gallbladder change into abnormal cells and grow out of control. The gallbladder is a small, pear-shaped organ that is tucked under the liver (",
"      <a class=\"graphic graphic_figure graphicRef68129 \" href=\"UTD.htm?26/37/27220\">",
"       figure 1",
"      </a>",
"      ). The gallbladder stores bile, a fluid that helps the body break down fat.",
"     </p>",
"     <p>",
"      Most people with gallbladder cancer have or have had another gallbladder condition called &ldquo;gallstones.&rdquo; Gallstones are small stones that form inside the gallbladder.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8182486\">",
"      <span class=\"h1\">",
"       What are the symptoms of gallbladder cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Early on, gallbladder cancer might not cause any symptoms. In many cases, gallbladder cancer is found unexpectedly when:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A doctor does surgery to treat a person&rsquo;s gallstones. Gallstones can cause symptoms similar to those of gallbladder cancer.",
"       </li>",
"       <li>",
"        A doctor does imaging tests of the belly for another reason. Imaging tests create pictures of the inside of the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      When gallbladder cancer causes symptoms, they can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Belly pain, especially in the upper right side or upper middle part of the belly",
"       </li>",
"       <li>",
"        Loss of appetite",
"       </li>",
"       <li>",
"        Nausea or vomiting",
"       </li>",
"       <li>",
"        Weight loss",
"       </li>",
"       <li>",
"        Jaundice, which is when the skin and white part of the eye turn yellow",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      All of these symptoms can also be caused by conditions that are not gallbladder cancer. But if you have these symptoms, tell your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8182501\">",
"      <span class=\"h1\">",
"       Is there a test for gallbladder cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. To check for gallbladder cancer, your doctor will do an imaging test. Imaging tests can include an ultrasound, CT scan, or MRI scan.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8182516\">",
"      <span class=\"h1\">",
"       What is cancer staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cancer staging is a way in which doctors find out if a cancer has spread past the layer of tissue where it began, and, if so, how far.",
"     </p>",
"     <p>",
"      The right treatment for you will depend a lot on the stage of your gallbladder cancer and your other medical problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8182531\">",
"      <span class=\"h1\">",
"       How is gallbladder cancer treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Gallbladder cancer is usually treated with 1 or more of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Surgery",
"       </li>",
"       <li>",
"        Chemotherapy &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells.",
"       </li>",
"       <li>",
"        Radiation therapy &ndash; Radiation kills cancer cells.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Gallbladder cancer can sometimes be cured with treatment. This is most likely when the cancer is found at an early stage. But, often, gallbladder cancer is not found at an early stage. If your gallbladder cancer cannot be cured, your doctor can do other treatments to help with your pain, jaundice, or other symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8182546\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, your doctor will check you every so often to see if the cancer comes back. Follow-up tests usually include imaging tests.",
"     </p>",
"     <p>",
"      You should also watch for the symptoms listed above. Having those symptoms could mean your gallbladder cancer has come back. Tell your doctor or nurse if you have any symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8182561\">",
"      <span class=\"h1\">",
"       What happens if my gallbladder cancer comes back or spreads?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your gallbladder cancer comes back or spreads, you might have more radiation therapy, chemotherapy, or both.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8182576\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to follow all of your doctor&rsquo;s instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for gallbladder cancer involves making many choices, such as what treatment to have. Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H8182591\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/29/8658?source=see_link\">",
"       Patient information: Gallstones (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/56/1923?source=see_link\">",
"       Patient information: Gallbladder removal (cholecystectomy) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/17/34066?source=see_link\">",
"       Patient information: Jaundice in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=see_link\">",
"       Patient information: Radiation therapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=see_link\">",
"       Patient information: Managing pain when you have cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/4/29762?source=see_link\">",
"       Patient information: When your cancer treatment makes you tired (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=see_link\">",
"       Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/57/19346?source=see_link\">",
"       Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/27/17842?source=see_link\">",
"       Patient information: Hair loss from cancer treatment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=see_link\">",
"       Patient information: Medical care during advanced illness (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/21/7507?source=see_link\">",
"       Patient information: Gallstones (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?4/31/4595?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83153 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-AB4CE9AEE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_31_4595=[""].join("\n");
var outline_f4_31_4595=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8182471\">",
"      What is gallbladder cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8182486\">",
"      What are the symptoms of gallbladder cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8182501\">",
"      Is there a test for gallbladder cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8182516\">",
"      What is cancer staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8182531\">",
"      How is gallbladder cancer treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8182546\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8182561\">",
"      What happens if my gallbladder cancer comes back or spreads?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8182576\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8182591\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83153\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/37/27220\">",
"      Anatomy of the gallbladder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/56/1923?source=related_link\">",
"      Patient information: Gallbladder removal (cholecystectomy) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/21/7507?source=related_link\">",
"      Patient information: Gallstones (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/29/8658?source=related_link\">",
"      Patient information: Gallstones (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/27/17842?source=related_link\">",
"      Patient information: Hair loss from cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/17/34066?source=related_link\">",
"      Patient information: Jaundice in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=related_link\">",
"      Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=related_link\">",
"      Patient information: Medical care during advanced illness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/57/19346?source=related_link\">",
"      Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/4/29762?source=related_link\">",
"      Patient information: When your cancer treatment makes you tired (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_31_4596="Dimethyl fumarate: Patient drug information";
var content_f4_31_4596=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dimethyl fumarate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/16/9476?source=see_link\">",
"     see \"Dimethyl fumarate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F16562890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tecfidera&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F16565337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691969",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat MS (multiple sclerosis).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F16565338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4231862",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dimethyl fumarate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4194404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may interact with other drugs or health problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4194405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor and pharmacist about all of your drugs (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F16565339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F16565340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4186184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor if any of these side effects or any other side effects bother you:",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F16565341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s4186185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these side effects:",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2699690",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects at",
"       <a href=\"file://www.fda.gov/medwatch\" target=\"_blank\">",
"        file://www.fda.gov/medwatch",
"       </a>",
"       .",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F16565342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696083",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug as ordered by your doctor. Read and follow the dosing on the label closely.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, open, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F16565343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F16565344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part not used after 3 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4194563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check with your pharmacist about how to throw out unused drugs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F16565345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88900 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-3A23DB03CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_31_4596=[""].join("\n");
var outline_f4_31_4596=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16562890\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16565337\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16565338\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16565339\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16565340\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16565341\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16565342\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16565343\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16565344\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16565345\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/16/9476?source=related_link\">",
"      Dimethyl fumarate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_31_4597="Treatment and prevention of leptospirosis";
var content_f4_31_4597=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prevention of leptospirosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/31/4597/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/31/4597/contributors\">",
"     E Dale Everett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/31/4597/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/31/4597/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/31/4597/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/31/4597/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/31/4597/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/31/4597/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 6, 2009.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leptospirosis is a zoonosis with protean manifestations caused by the spirochete Leptospira interrogans. Synonyms for the disease include Weil's disease, Swineherd's disease, rice-field fever, cane-cutter fever, swamp fever, mud fever, hemorrhagic jaundice, Stuttgart disease, and Canicola fever.",
"   </p>",
"   <p>",
"    The treatment and prevention of leptospirosis will be presented here. The epidemiology, microbiology, clinical manifestations, and diagnosis of this disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43879?source=see_link\">",
"     \"Microbiology, epidemiology, clinical manifestations, and diagnosis of leptospirosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of infections with Leptospira are self-limiting. Although penicillins, tetracyclines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    have antileptospiral activity in vitro and in animal models, it remains controversial whether antimicrobials produce a beneficial effect in mild human leptospirosis since the illness has a variable natural history. Nevertheless, if the illness is severe enough to result in a physician visit and the diagnosis is recognized, antibiotic therapy should be given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two small randomized trials have demonstrated benefit from antimicrobial therapy. In a study of 29 patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg PO twice daily) or placebo, doxycycline shortened the illness by an average of two days and prevented shedding of the organism in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4597/abstract/1\">",
"     1",
"    </a>",
"    ]. In a study of 42 patients with severe leptospirosis treated with penicillin (6 million units daily) or placebo, those who received penicillin had fewer days of fever, more rapid resolution of renal function, and a shorter hospital stay; penicillin therapy also prevented urinary shedding [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4597/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two randomized trials have compared penicillin (6 million units daily) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (1 g every 24 hours),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    (1 g every six hours), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg IV every 12 hours); all regimens were observed to be therapeutically equivalent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4597/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In one randomized trial of 264 patients with severe leptospirosis in northeastern Thailand comparing cefotaxime,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    and doxycycline, all the regimens had similar efficacy for leptospirosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4597/abstract/4\">",
"     4",
"    </a>",
"    ]. Among these patients 132 patients were diagnosed with rickettsial infection; for these patients, treatment with doxycycline was superior to treatment with penicillin G. Therefore, doxycycline or cefotaxime (or ceftriaxone) are appropriate therapies for the treatment of severely ill patients in areas endemic for leptospirosis and rickettsial infection.",
"   </p>",
"   <p>",
"    In vitro studies show that newer macrolides, fluoroquinolones, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/16/41224?source=see_link\">",
"     telithromycin",
"    </a>",
"    have excellent activity against leptospires [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4597/abstract/5\">",
"     5",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    have comparable clinical efficacy; azithromycin is better tolerated than doxycycline but is more expensive and less readily available [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4597/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Adverse reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Jarisch-Herxheimer reaction may occur with penicillin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4597/abstract/7\">",
"     7",
"    </a>",
"    ]. In a case report, reversible cardiomegaly with a suggestion of pulmonary hypertension by echocardiography occurred within six hours of the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    for leptospirosis in a triathlete who had participated in a triathlon swimming in the Liffey River in Ireland [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4597/abstract/8\">",
"     8",
"    </a>",
"    ]. The authors speculate that this was a Jarisch-Herxheimer response.",
"   </p>",
"   <p>",
"    Supportive care with dialysis, ventilatory support, and blood products may be necessary in severe cases of leptospirosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Antimicrobial treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human leptospirosis is often self-limited and requires no antibiotic treatment. Symptomatic patients presenting for medical care should be treated to shorten the illness and decrease shedding of the organism in the urine. We suggest the following approach that varies with the clinical presentation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest treatment with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      for outpatients because it is also effective for rickettsial disease, which can be confused with leptospirosis (100 mg orally twice daily in adults; 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in two equally divided doses in children &ge;8 years of age to a maximum dose of 200 mg daily). The exceptions are children &le;8 years or pregnant women, in whom we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      (25 to 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      in three equally divided doses).",
"     </li>",
"     <li>",
"      For hospitalized adults with severe disease, we suggest intravenous therapy with penicillin (6 million units daily),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (100 mg twice daily),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (1 g every 24 hours), or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      (1 g every six hours).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In children with severe disease, we suggest intravenous therapy with penicillin (250,000 to 400,000",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per day in four to six divided doses; maximum dose 6 million units daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in two equally divided doses; maximum dose 200 mg daily),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (80 to 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    once daily; maximum dose 4 g daily), or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    (150 to 200",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in three to four equally divided doses; maximum dose 12 g daily). Doxycycline should be avoided in children less than eight years of age.",
"   </p>",
"   <p>",
"    For children less than eight years of age with severe penicillin allergy, we suggest therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    on day one; maximum dose 500",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    followed by 5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    once daily on subsequent days; maximum dose 250",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    (15",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    divided in two equal doses; maximum dose 1",
"    <span class=\"nowrap\">",
"     g/day).",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the diagnosis is in doubt in areas endemic for both leptospirosis and rickettsial infection, we suggest a regimen other than penicillin should be used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The duration of treatment is usually five to seven days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of maternal leptospirosis infection on pregnancy is limited to information published in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4597/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Transplacental infection occurs, but the rate of fetal transmission and the type and frequency of fetal complications are unknown.",
"   </p>",
"   <p>",
"    In one review of 14 pregnancies with active maternal infection and known outcome, there were eight spontaneous abortions, four infants with active disease, and two healthy neonates [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4597/abstract/10\">",
"     10",
"    </a>",
"    ]. A risk of abortion or fetal death of over 50 percent was also reported in a series of 11 cases from French Guyana [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4597/abstract/12\">",
"     12",
"    </a>",
"    ]. There is sparse information on sequelae in surviving neonates.",
"   </p>",
"   <p>",
"    Treatment of infected pregnant women is similar to that in other patients with the exception of the choice of drugs. Penicillin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    are safe in pregnancy, but",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    should not be given. Among patients with severe penicillin allergy,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    may be given [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4597/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality rates in hospitalized patients with leptospirosis have ranged from 4 to 52 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4597/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. A retrospective review of 282 cases of leptospirosis during a 2002 outbreak in India identified risk factors for mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4597/abstract/16\">",
"     16",
"    </a>",
"    ]. Significant predictors of death in logistic regression analysis included involvement of the lung (eg, hemoptysis) and central nervous system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccination of domestic animals against leptospirosis provides substantial protection, but is not effective in 100 percent of animals. Some immunized animals become infected and excrete leptospires in their urine.",
"   </p>",
"   <p>",
"    In a field trial of 940 United States soldiers deployed for jungle training in Panama,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    prophylaxis (200 mg PO every week for two to three weeks and at the end of exposure) was effective in preventing cases of leptospirosis compared to placebo (1 versus 20 cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4597/abstract/17\">",
"     17",
"    </a>",
"    ]. Whether doxycycline could be used as prophylaxis following exposure to an infected animal is not known.",
"   </p>",
"   <p>",
"    The major control measure available for humans is to avoid potential sources of infection such as stagnant water, water derived from run off from animal farms, rodent control, and protection of food from animal contamination. No vaccine is available for human immunization in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/40/37505?source=see_link\">",
"       \"Patient information: Leptospirosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The vast majority of infections with leptospira are self-limiting; it remains controversial whether antimicrobials produce a beneficial effect in human leptospirosis since the illness has a variable natural history. The controversy arises primarily because while treatment results in a shorter duration of illness and decreased shedding of the organism in the urine, randomized, controlled trials have not demonstrated a mortality benefit for patients with mild disease (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Standard practice is to treat patients who have even mild disease and we suggest antibiotic therapy for these patients (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Antimicrobial treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no head to head trials of oral antimicrobials for mild disease and both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      and penicillin were effective in placebo controlled trials. We suggest treatment with oral doxycycline for outpatients because it is also effective for rickettsial disease, which can be confused with leptospirosis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The exceptions are children &le;8 years or pregnant women, in whom we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Antimicrobial treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend treatment of hospitalized patients with parenteral antibiotics (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Parenteral penicillin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      , and third generation cephalosporins are all acceptable options, although in areas endemic for both leptospirosis and rickettsial infection, we suggest a regimen other than penicillin (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Antimicrobial treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mortality rates in hospitalized patients with leptospirosis have ranged from 4 to 52 percent, with higher mortality rates occurring in patients requiring intensive care unit admission on presentation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No vaccine is available for human immunization in the United States. The major preventive measure available is to avoid potential sources of infection. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      prophylaxis for individuals who will be exposed to leptospires in highly endemic environments (eg, military deployed in jungles, veterinarians following urine exposure from animals with known leptospirosis) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4597/abstract/1\">",
"      McClain JB, Ballou WR, Harrison SM, Steinweg DL. Doxycycline therapy for leptospirosis. Ann Intern Med 1984; 100:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4597/abstract/2\">",
"      Watt G, Padre LP, Tuazon ML, et al. Placebo-controlled trial of intravenous penicillin for severe and late leptospirosis. Lancet 1988; 1:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4597/abstract/3\">",
"      Panaphut T, Domrongkitchaiporn S, Vibhagool A, et al. Ceftriaxone compared with sodium penicillin g for treatment of severe leptospirosis. Clin Infect Dis 2003; 36:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4597/abstract/4\">",
"      Suputtamongkol Y, Niwattayakul K, Suttinont C, et al. An open, randomized, controlled trial of penicillin, doxycycline, and cefotaxime for patients with severe leptospirosis. Clin Infect Dis 2004; 39:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4597/abstract/5\">",
"      Hospenthal DR, Murray CK. In vitro susceptibilities of seven Leptospira species to traditional and newer antibiotics. Antimicrob Agents Chemother 2003; 47:2646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4597/abstract/6\">",
"      Phimda K, Hoontrakul S, Suttinont C, et al. Doxycycline versus azithromycin for treatment of leptospirosis and scrub typhus. Antimicrob Agents Chemother 2007; 51:3259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4597/abstract/7\">",
"      Emmanouilides CE, Kohn OF, Garibaldi R. Leptospirosis complicated by a Jarisch-Herxheimer reaction and adult respiratory distress syndrome: case report. Clin Infect Dis 1994; 18:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4597/abstract/8\">",
"      Tunbridge AJ, Dockrell DH, Channer KS, McKendrick MW. A breathless triathlete. Lancet 2002; 359:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4597/abstract/9\">",
"      Chedraui PA, San Miguel G. A case of leptospirosis and pregnancy. Arch Gynecol Obstet 2003; 269:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4597/abstract/10\">",
"      Shaked Y, Shpilberg O, Samra D, Samra Y. Leptospirosis in pregnancy and its effect on the fetus: case report and review. Clin Infect Dis 1993; 17:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4597/abstract/11\">",
"      Tramoni G, Cl&eacute;ment HJ, Lopez F, Viale JP. [An unusual case of post partum haemorrhage: leptospirosis infection]. Ann Fr Anesth Reanim 2003; 22:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4597/abstract/12\">",
"      Carles G, Montoya E, Joly F, Peneau C. [Leptospirosis and pregnancy. Eleven cases in French Guyana]. J Gynecol Obstet Biol Reprod (Paris) 1995; 24:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4597/abstract/13\">",
"      Dupont H, Dupont-Perdrizet D, Perie JL, et al. Leptospirosis: prognostic factors associated with mortality. Clin Infect Dis 1997; 25:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4597/abstract/14\">",
"      Chawla V, Trivedi TH, Yeolekar ME. Epidemic of leptospirosis: an ICU experience. J Assoc Physicians India 2004; 52:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4597/abstract/15\">",
"      LaRocque RC, Breiman RF, Ari MD, et al. Leptospirosis during dengue outbreak, Bangladesh. Emerg Infect Dis 2005; 11:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4597/abstract/16\">",
"      Pappachan MJ, Mathew S, Aravindan KP, et al. Risk factors for mortality in patients with leptospirosis during an epidemic in northern Kerala. Natl Med J India 2004; 17:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4597/abstract/17\">",
"      Takafuji ET, Kirkpatrick JW, Miller RN, et al. An efficacy trial of doxycycline chemoprophylaxis against leptospirosis. N Engl J Med 1984; 310:497.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5524 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-F0948400E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_31_4597=[""].join("\n");
var outline_f4_31_4597=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Adverse reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Antimicrobial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43879?source=related_link\">",
"      Microbiology, epidemiology, clinical manifestations, and diagnosis of leptospirosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/40/37505?source=related_link\">",
"      Patient information: Leptospirosis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_31_4598="Acanthosis nigricans - axilla";
var content_f4_31_4598=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F66384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F66384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acanthosis nigricans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperpigmented velvety plaques are present in the axilla.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_31_4598=[""].join("\n");
var outline_f4_31_4598=null;
var title_f4_31_4599="Empyema after liver biopsy PA";
var content_f4_31_4599=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Empyema after liver biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Homogeneous opacification of the right hemithorax with visible pulmonary vessels, the so-called filter effect, typical of a pleural process.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_31_4599=[""].join("\n");
var outline_f4_31_4599=null;
var title_f4_31_4600="First generation (Typical) antipsychotic medication poisoning";
var content_f4_31_4600=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   First generation (Typical) antipsychotic medication poisoning",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/31/4600/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/31/4600/contributors\">",
"     Eric J Lavonas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/31/4600/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/31/4600/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/31/4600/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/31/4600/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/31/4600/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antipsychotic medications are primarily used to treat agitation, hallucinations, and other manifestations of psychosis arising from numerous causes, including psychiatric illnesses (schizophrenia, mania), medical illnesses (alcohol withdrawal), and neurologic disease (Alzheimer disease). When used to treat psychiatric diseases, they also aid in restructuring disordered thinking.",
"   </p>",
"   <p>",
"    Antipsychotic medications are also used to treat a number of nonpsychiatric conditions, including nausea and vomiting (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"     droperidol",
"    </a>",
"    ), vertigo (prochlorperazine, droperidol), itching (promethazine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    ), migraine headache (prochlorperazine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    , droperidol), Tourette's syndrome (haloperidol,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6472?source=see_link\">",
"     pimozide",
"    </a>",
"    ), postherpetic neuralgia (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/10/38055?source=see_link\">",
"     fluphenazine",
"    </a>",
"    ), and hiccups (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Typical antipsychotic medications were first used clinically in 1951. Although their use in psychiatric disorders has been outpaced by that of atypical antipsychotic agents, they remain widely used to treat nausea. Poisoning and overdose from these drugs remains common. In 2010, American poison control centers reported more than 4800 exposures to phenothiazines, resulting in no deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4600/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antipsychotic medications are generally categorized as \"low potency,\" \"high potency,\" or \"atypical\" agents. This topic review will discuss the management of typical, high, and low potency antipsychotic medication poisoning (",
"    <a class=\"graphic graphic_table graphicRef71627 \" href=\"UTD.htm?40/19/41276\">",
"     table 1",
"    </a>",
"    ). A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef64216 \" href=\"UTD.htm?28/24/29068\">",
"     table 2",
"    </a>",
"    ). Poisoning from atypical antipsychotic agents is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43320?source=see_link\">",
"     \"Second generation (atypical) antipsychotic medication poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical antipsychotic agents antagonize dopamine (D) receptors in several areas of the brain, including the cortex, basal ganglia, limbic system, hypothalamus, and chemoreceptor trigger zone. The efficacy and potency of these agents is directly related to D2 receptor binding affinity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4600/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, not all forms of D2 receptor blockade are desirable. D2 antagonism in the mesocortical regions impairs cognition and exacerbates the negative symptoms of schizophrenia, such as avolition, anhedonia, poverty of speech, flattened affect, and social withdrawal.",
"   </p>",
"   <p>",
"    The typical antipsychotic agents also block a variety of other central and peripheral nervous system receptors. Blockade of muscarinic acetylcholine receptors may cause dry mouth, tachycardia, sedation, and constipation, and can provoke episodes of urinary retention and angle-closure glaucoma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4600/abstract/2\">",
"     2",
"    </a>",
"    ]. Alpha-1 adrenergic receptor antagonism can cause orthostatic hypotension and reflex tachycardia. Histamine-1 receptor antagonism contributes to sedation.",
"   </p>",
"   <p>",
"    Antipsychotic agents can also affect cardiac ion channels. Most typical antipsychotics block the human ether-a-go-go-related gene (hERG) channel, reducing the delayed inward potassium rectifier potassium current (IKr) and prolonging cardiac repolarization [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4600/abstract/4\">",
"     4",
"    </a>",
"    ]. This is manifest on the electrocardiogram as QT interval prolongation, and in extreme cases, this can lead to torsades de pointes (TdP) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4600/abstract/5-10\">",
"     5-10",
"    </a>",
"    ]. Although this effect is most pronounced with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"     thioridazine",
"    </a>",
"    , many other antipsychotic agents, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"     droperidol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6472?source=see_link\">",
"     pimozide",
"    </a>",
"    , and sertindole, have been associated with QT prolongation and TdP [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4600/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    QRS prolongation may occur due to antipsychotic medication-induced sodium channel blockade, particularly with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"     thioridazine",
"    </a>",
"    and mesoridazine [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4600/abstract/4,12-14\">",
"     4,12-14",
"    </a>",
"    ]. Several antipsychotic medications, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6472?source=see_link\">",
"     pimozide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    , block L-type calcium channels, but the relevance of this for human exposures is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4600/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute extrapyramidal syndromes (EPS), such as acute dystonic reactions and akathisia, appear to be related to an imbalance between dopamine (presumably D2) receptor antagonism and muscarinic (presumably M1) receptor antagonism in the CNS. Medications such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    , which have a high",
"    <span class=\"nowrap\">",
"     D2/M1",
"    </span>",
"    receptor affinity ratio, are the most likely to cause EPS; M1 receptor antagonists, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/55/3958?source=see_link\">",
"     benztropine",
"    </a>",
"    , and the dopamine agonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    are equally effective remedies for acute EPS [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4600/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the neuroleptic malignant syndrome (NMS) has long been thought to be a centrally mediated phenomenon, some evidence suggests that antipsychotic medications directly affect skeletal muscle mitochondria, possibly uncoupling oxidative phosphorylation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4600/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link\">",
"     \"Neuroleptic malignant syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     KINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typical antipsychotic medications are absorbed quickly and enter the brain rapidly. As an example, the peak clinical effect of orally administered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    occurs within two to four hours after dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4600/abstract/20\">",
"     20",
"    </a>",
"    ]. In overdose, delayed peak serum concentrations can occur, particularly if anticholinergic effects delay gut motility.",
"   </p>",
"   <p>",
"    Once absorbed, antipsychotic medications diffuse into lipophilic tissues; volumes of distribution (VD) are generally in the range of 8 to 10",
"    <span class=\"nowrap\">",
"     L/kg,",
"    </span>",
"    precluding removal by hemodialysis. Elimination half-lives range from 6 to 24 hours; for each agent, the range of half-lives measured varies greatly between individuals (",
"    <a class=\"graphic graphic_table graphicRef51653 \" href=\"UTD.htm?30/38/31339\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4600/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES OF OVERDOSE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Great variability exists in the amount of drug needed to cause signs and symptoms of overdose. In general, the elderly and people who are naive to the medications become symptomatic at lower doses. While conscious patients may give a history of overdose, many patients present obtunded and any history is provided by family, friends, first responders, and pharmacists. Not all patients with antipsychotic medication overdose have a history of psychiatric illness; patients may overdose on medications obtained from family members or others.",
"   </p>",
"   <p>",
"    Acute extrapyramidal syndromes (EPS), such as akathisia and dystonic reactions, can occur with antipsychotic medication at any dose. The time to onset varies widely. In one emergency department case series, 44 percent of patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    for migraine headache developed akathisia within one hour of administration, while an additional 3 percent developed akathisia within 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4600/abstract/22\">",
"     22",
"    </a>",
"    ]. The onset of EPS appears to be more gradual following oral dosing: half of cases occur within 48 hours of initiation of the antipsychotic medication, and 90 percent occur within five days [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4600/abstract/23\">",
"     23",
"    </a>",
"    ]. Extrapyramidal symptoms are rare in overdose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typical antipsychotic poisoning does not cause any pathognomonic signs. Pupils may be miotic, normal size, or mydriatic. Portions of the anticholinergic toxidrome, such as tachycardia, mild hyperthermia, dry skin, and diminished bowel sounds may be present, but this is by no means consistent or reliable. Mild hypotension may result from alpha adrenergic blockade. Profound hyperthermia suggests the neuroleptic malignant syndrome (NMS). Alterations in mental status range from mild somnolence to coma.",
"   </p>",
"   <p>",
"    Akathisia is an acute psychomotor restlessness, characterized by a feeling of unease and inability to sit still. Most patients can suppress these behaviors briefly using voluntary control. Acute dystonic reactions are sustained muscular spasms, most commonly affecting the neck (30 percent), tongue (17 percent), or jaw (15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4600/abstract/23\">",
"     23",
"    </a>",
"    ]. Choreoathetoid movements, opisthotonus, oculogyric crisis, and respiratory dystonia are less common manifestations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have overdosed on antipsychotic medication may be clinically indistinguishable from those who have overdosed on a wide variety of medications with sedative properties, including benzodiazepines, prescription insomnia medications (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"     zolpidem",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/61/15318?source=see_link\">",
"     zaleplon",
"    </a>",
"    ), cyclic antidepressants, skeletal muscle relaxants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    ), centrally acting alpha 2 receptor agonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    ), anticonvulsants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ), and atypical antipsychotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36231?source=see_link\">",
"     \"Tricyclic antidepressant poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43320?source=see_link\">",
"     \"Second generation (atypical) antipsychotic medication poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41863?source=see_link\">",
"     \"Phenytoin poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neither vital signs, physical examination, nor clinical course clearly distinguish cases of typical antipsychotic medication overdose from those of other sedatives. Fortunately, in the absence of cardiovascular effects, the same supportive care measures provide effective treatment for both typical antipsychotic medication overdoses and these mimics.",
"   </p>",
"   <p>",
"    Many nontoxicologic syndromes can produce CNS depression, including hypoglycemia, acute hepatic failure, CNS infections, massive cerebrovascular accidents, severe electrolyte disorders, blunt head trauma, and septic or other forms of shock (",
"    <a class=\"graphic graphic_table graphicRef59893 \" href=\"UTD.htm?3/43/3773\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"     \"Diagnosis of delirium and confusional states\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=see_link\">",
"     \"Stupor and coma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because they cause anxiety and can be temporarily suppressed by reassurance and voluntary control, acute extrapyramidal syndromes are sometimes misdiagnosed as an anxiety reaction or conversion disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LABORATORY EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific laboratory tests are needed to diagnose or treat typical antipsychotic medication overdose. Serum concentrations of specific antipsychotic drugs may be obtained if the diagnosis is in doubt. However, the results have little clinical value because they cannot be obtained readily and levels correlate poorly with clinical manifestations. Antipsychotic medications have been associated with hyponatremia and thus a serum sodium concentration should be measured in patients with an altered mental status or seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4600/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine laboratory evaluation of the poisoned patient includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fingerstick glucose, to rule out hypoglycemia as the cause of any alteration in mental status",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      and salicylate levels, to rule out these common coingestions",
"     </li>",
"     <li>",
"      Electrocardiogram (ECG), to rule out conduction system poisoning by drugs that effect the QRS or QTc intervals",
"     </li>",
"     <li>",
"      Pregnancy test in women of childbearing age",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Airway, breathing, and circulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although pure antipsychotic medication overdoses rarely cause significant respiratory depression, many patients overdose on multiple substances and require airway protection. Oxygen saturation monitoring should be performed and supplemental oxygen administered as necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=see_link\">",
"     \"Rapid sequence intubation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypotension should initially be treated with IV boluses of isotonic fluid, such as normal saline. Hypotension refractory to normal saline should be treated with a direct-acting alpha-adrenergic agonist, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/36/39488?source=see_link\">",
"     phenylephrine",
"    </a>",
"    or norepinephrine.",
"   </p>",
"   <p>",
"    QRS prolongation may contribute to impaired circulation. As with cyclic antidepressants, QRS prolongation from acute antipsychotic intoxication is treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    , 1 to 2",
"    <span class=\"nowrap\">",
"     meq/kg",
"    </span>",
"    IV push. Treatment of QRS prolongation with sodium bicarbonate is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36231?source=see_link\">",
"     \"Tricyclic antidepressant poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A summary table to facilitate emergent management of typical antipsychotic medication poisoning is provided (",
"    <a class=\"graphic graphic_table graphicRef64216 \" href=\"UTD.htm?28/24/29068\">",
"     table 2",
"    </a>",
"    ). The general management of drug poisoning is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=see_link\">",
"     \"General approach to drug poisoning in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     General treatment and antidotal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with antipsychotic medication overdose present with CNS depression and no more than minor vital sign perturbations. These cases are easily managed with supportive care and hospitalization until signs of overdose have resolved.",
"   </p>",
"   <p>",
"    Rarely, patients experience a severely symptomatic overdose. Patients with a profoundly depressed mental status or coma require aggressive intervention, including endotracheal intubation.",
"   </p>",
"   <p>",
"    Seizures that occur in the setting of antipsychotic overdose or toxicity are treated with benzodiazepines. Such seizures are generally self-limited and traditional antiepileptics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    are NOT indicated.",
"   </p>",
"   <p>",
"    Hyperthermia, when mild, may be treated by undressing the patient or with evaporative cooling measures. Severe hyperthermia, particularly if it develops in the setting of muscular rigidity, altered mental status, and autonomic instability, raises the specter of neuroleptic malignant syndrome, and should be managed aggressively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=see_link\">",
"     \"Severe hyperthermia (heat stroke) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients who present with CNS depression, miosis, and an uncertain history, a trial administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    is warranted to exclude the possibility of opioid overdose [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4600/abstract/25\">",
"     25",
"    </a>",
"    ]. Naloxone does not reverse the CNS depression caused by antipsychotic medication overdosage. The use and dosing of naloxone are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=see_link&amp;anchor=H14#H14\">",
"     \"Opioid intoxication in adults\", section on 'Basic measures and antidotal therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/21/22874?source=see_link&amp;anchor=H27#H27\">",
"     \"Opioid intoxication in children and adolescents\", section on 'Naloxone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The benzodiazepine antidote",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/6/41062?source=see_link\">",
"     flumazenil",
"    </a>",
"    is",
"    <strong>",
"     NOT",
"    </strong>",
"    effective for treating antipsychotic medication overdose. Because of the risk of seizures, flumazenil should",
"    <strong>",
"     NOT",
"    </strong>",
"    be administered to the patient with an unknown overdose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=see_link&amp;anchor=H14#H14\">",
"     \"Benzodiazepine poisoning and withdrawal\", section on 'Antidote (flumazenil)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     GI decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antipsychotic medication overdose does not permanently injure any organ. If hypoxia and aspiration pneumonitis can be prevented, patients generally do well. No study has shown that gastrointestinal (GI) decontamination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/52/39750?source=see_link\">",
"     activated charcoal",
"    </a>",
"    (AC) improves the outcome or hastens the recovery from antipsychotic overdose. Therefore, GI decontamination is not mandatory. A single dose of AC (1",
"    <span class=\"nowrap\">",
"     g/kg,",
"    </span>",
"    up to 50 g) may be administered to patients with intact airway reflexes or whose airway is protected following endotracheal intubation. There is no role for cathartics or multiple dose AC unless coingestants are present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=see_link\">",
"     \"Gastrointestinal decontamination of poisoned adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Acute extrapyramidal syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute extrapyramidal syndromes (EPS), such as dystonic reactions and akathisia, are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    (25 to 50 mg IV in adults; 0.5 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in children).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/55/3958?source=see_link\">",
"     Benztropine",
"    </a>",
"    (1 to 2 mg IV in adults; 0.05",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in children over three years old with severe reaction) may be used initially, or if diphenhydramine therapy fails. Response is often dramatic and typically occurs within minutes of intravenous drug administration. Although the IV route is preferred, both diphenhydramine and benztropine may be given IM or orally. If initial treatment is successful, therapy is continued orally for two to three days to prevent recurrence.",
"   </p>",
"   <p>",
"    Alternative treatments for EPS include benzodiazepines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    1 to 2 mg IV in adults; 0.05",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV in children),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    (100 mg orally twice or three times daily in adults), or biperiden (2 mg orally in adults). At least two controlled studies have shown amantadine to be as effective as anticholinergic therapy, with fewer side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4600/abstract/16,26\">",
"     16,26",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     Propranolol",
"    </a>",
"    (20 to 40 mg initial dose) reduces involuntary movements in akathisia, but does not reduce anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4600/abstract/27\">",
"     27",
"    </a>",
"    ]. A randomized trial of 13 patients with acute akathisia from antipsychotic medications reported a benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/0/24584?source=see_link\">",
"     trazodone",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    orally in adults) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4600/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     QT interval prolongation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many typical antipsychotic medications prolong the QT interval, torsades de pointes (TdP) is uncommon. Management of QT prolongation consists of cardiac monitoring and correction of electrolyte disorders, particularly hypokalemia and hypomagnesemia. Intravenous potassium infusion was found to correct drug related QT prolongation in an observational study of 12 subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4600/abstract/29\">",
"     29",
"    </a>",
"    ]. However, prophylactic administration of potassium to patients without hypokalemia is not advised. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link\">",
"     \"Clinical manifestations and treatment of hypokalemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Should polymorphic ventricular tachycardia (VT) occur, it can be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    (1 to 2 grams IV), overdrive pacing,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/31/23029?source=see_link\">",
"     isoproterenol",
"    </a>",
"    infusion, or synchronized or unsynchronized cardioversion. Stopping any offending medication, including antipsychotic medications that prolong the QT interval, is paramount. Because up to 10 percent of patients who develop medication-related TdP harbor mutations associated with the long QT syndrome, these patients should be referred to a cardiologist. The management of polymorphic VT is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of the acute management of tachyarrhythmias\", section on 'Torsades de pointes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to avoid giving the patient with a prolonged QT interval medications that would further prolong repolarization. The United States Agency for Healthcare Research and Quality funds a database of such drugs, which can be found at",
"    <a class=\"external\" href=\"file://www.qtdrugs.org/\">",
"     www.qtdrugs.org",
"    </a>",
"    . In addition to antipsychotics and antiemetics, common medications on this list include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/43/22199?source=see_link\">",
"     pentamidine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4600/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies involving patients with the genetically determined congenital long-QT syndrome suggest that prolongation of the absolute (uncorrected) QT interval beyond 500 msec confers an increased risk of TdP. Unfortunately, data correlating the QT interval (absolute or corrected) with the risk of drug induced TdP are lacking, and some evidence is contradictory. A reasonable, conservative approach is to continue monitoring a patient with medication-induced QT prolongation until the QTc is below 500 msec and decreasing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Anticholinergic delirium",
"    </span>",
"    &nbsp;&mdash;&nbsp;All typical antipsychotic medications have anticholinergic (antimuscarinic) properties; overdoses of typical antipsychotic medications occasionally present with anticholinergic delirium. The management of anticholinergic delirium and related symptoms is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43319?source=see_link\">",
"     \"Anticholinergic poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Neuroleptic malignant syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroleptic malignant syndrome (NMS) is an uncommon but potentially lethal side effect of antipsychotic medications characterized by mental status change, rigidity, fever, and dysautonomia (eg, labile blood pressure). The management of NMS is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link&amp;anchor=H23#H23\">",
"     \"Neuroleptic malignant syndrome\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A related condition, neuroleptic induced catatonia, has been described. Neuroleptic induced catatonia resembles NMS, but without fever, and usually responds to benzodiazepines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link&amp;anchor=H15#H15\">",
"     \"Neuroleptic malignant syndrome\", section on 'Malignant catatonia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Extracorporeal removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of their lipophilicity, high protein binding, and large volume of distribution, hemodialysis is not useful in the management of antipsychotic medication overdose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Ongoing treatment and disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;After initial stabilization, care of the patient with typical antipsychotic medication overdose is primarily supportive. Because the elimination half-life of these agents ranges from 6 to 24 hours and the antimuscarinic effects of the drugs can cause prolonged GI absorption, recovery generally takes one to three days. Although occasionally patients wake up quickly enough to be discharged from the emergency department (ED), hospital admission is the rule. Peak clinical effects are usually manifest upon or shortly after arrival to the hospital. Depending upon the nursing and monitoring resources available on inpatient units, patients who remain stable after a period of observation in the ED may not require ICU admission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PEDIATRIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The manifestations and management of typical antipsychotic medication overdose are the same in children and adults.",
"   </p>",
"   <p>",
"    A child who accidentally ingests a dose of a typical antipsychotic medication that is less than the equivalent of the maximum therapeutic dose for a 24 hour period for that child's weight, has no sign of intoxication after a four to six hour period of observation, and has reliable caregivers may be observed at home rather than admitted to the hospital.",
"   </p>",
"   <p>",
"    Consultation with a poison control center is strongly recommended in all cases of pediatric overdose. (See",
"    <a class=\"local\" href=\"#H5184641\">",
"     'Additional resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5184641\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A summary table to facilitate emergent management is provided (",
"    <a class=\"graphic graphic_table graphicRef64216 \" href=\"UTD.htm?28/24/29068\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Great variability exists in the amount of typical antipsychotic medication needed to cause signs and symptoms of overdose. Many patients present obtunded and history is obtained from family, friends, first responders, and pharmacists. Acute extrapyramidal syndromes (EPS), such as akathisia and dystonic reactions, can occur with any dose. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Acute extrapyramidal syndromes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Typical antipsychotic poisoning does not cause any pathognomonic signs. The range of possible examination findings is described in the text. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who have overdosed on antipsychotic medication may be clinically indistinguishable from those who have overdosed on a wide variety of medications with sedative properties (eg, benzodiazepines, anticonvulsants, cyclic antidepressants, atypical antipsychotics), as well as patients with somnolence or delirium from medical causes (eg, hypoglycemia, CNS infection, head trauma). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with a pure antipsychotic medication overdose present with CNS depression and no more than minor vital sign perturbations. These cases are managed with supportive care. Some patients overdose on multiple substances and require airway protection. Hypotension is treated with IV boluses of isotonic fluid. QRS prolongation from acute antipsychotic intoxication is treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Airway, breathing, and circulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe complications from typical antipsychotic poisoning rarely occur. Seizures are treated with benzodiazepines. Severe hyperthermia, particularly if it develops in the setting of muscular rigidity, altered mental status, and autonomic instability, raises the specter of neuroleptic malignant syndrome, and should be managed aggressively. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'General treatment and antidotal therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=see_link\">",
"       \"Severe hyperthermia (heat stroke) in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although many typical antipsychotic medications prolong the QT interval, torsades de pointes is uncommon. Management of QT prolongation consists of cardiac monitoring and correction of electrolyte disorders, particularly hypokalemia and hypomagnesemia. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'QT interval prolongation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/1\">",
"      Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report. Clin Toxicol (Phila) 2011; 49:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/2\">",
"      Sekine Y, Rikihisa T, Ogata H, et al. Correlations between in vitro affinity of antipsychotics to various central neurotransmitter receptors and clinical incidence of their adverse drug reactions. Eur J Clin Pharmacol 1999; 55:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/3\">",
"      White, SR. Acute dystonic reaction and the neuroleptic malignant syndrome. J Pharm Practice 2005; 18:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/4\">",
"      Crumb WJ Jr, Ekins S, Sarazan RD, et al. Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis. Pharm Res 2006; 23:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/5\">",
"      Drolet B, Zhang S, Desch&ecirc;nes D, et al. Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. J Cardiovasc Electrophysiol 1999; 10:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/6\">",
"      Reilly JG, Ayis SA, Ferrier IN, et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/7\">",
"      Buckley NA, Whyte IM, Dawson AH. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J Toxicol Clin Toxicol 1995; 33:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/8\">",
"      Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs 2002; 62:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/9\">",
"      Salih IS, Thanacoody RH, McKay GA, Thomas SH. Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses. Clin Pharmacol Ther 2007; 82:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/10\">",
"      Di Salvo TG, O'Gara PT. Torsade de pointes caused by high-dose intravenous haloperidol in cardiac patients. Clin Cardiol 1995; 18:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/11\">",
"      Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/12\">",
"      Arita M, Nagamoto Y, Saikawa T. Intraventricular conduction disturbance due to delayed recovery from ventricular inactivation in chlorpromazine-treated dogs. Recent Adv Stud Cardiac Struct Metab 1976; 11:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/13\">",
"      Ogata N, Narahashi T. Block of sodium channels by psychotropic drugs in single guinea-pig cardiac myocytes. Br J Pharmacol 1989; 97:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/14\">",
"      Ogata N, Yoshii M, Narahashi T. Differential block of sodium and calcium channels by chlorpromazine in mouse neuroblastoma cells. J Physiol 1990; 420:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/15\">",
"      Enyeart JJ, Dirksen RT, Sharma VK, et al. Antipsychotic pimozide is a potent Ca2+ channel blocker in heart. Mol Pharmacol 1990; 37:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/16\">",
"      Van Putten T, Gelenberg AJ, Lavori PW, et al. Anticholinergic effects on memory: benztropine vs. amantadine. Psychopharmacol Bull 1987; 23:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/17\">",
"      Kubo S, Orihara Y, Kitamura O, et al. An autopsy case of neuroleptic malignant syndrome (NMS) and its immunohistochemical findings of muscle-associated proteins and mitochondria. Forensic Sci Int 2001; 115:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/18\">",
"      Martin DT, Swash M. Muscle pathology in the neuroleptic malignant syndrome. J Neurol 1987; 235:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/19\">",
"      Caroff SN, Rosenberg H, Fletcher JE, et al. Malignant hyperthermia susceptibility in neuroleptic malignant syndrome. Anesthesiology 1987; 67:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/20\">",
"      Isah AO, Rawlins MD, Bateman DN. Clinical pharmacology of prochlorperazine in healthy young males. Br J Clin Pharmacol 1991; 32:677.",
"     </a>",
"    </li>",
"    <li>",
"     Klasco, RK (Ed): DRUGDEX&reg; System, Vol. 136. Thomson Healthcare, Greenwood Village, Colorado (Edition expires 6/2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/22\">",
"      Drotts DL, Vinson DR. Prochlorperazine induces akathisia in emergency patients. Ann Emerg Med 1999; 34:469.",
"     </a>",
"    </li>",
"    <li>",
"     Canadian Movement Disorders Group. Acute Dystonic Reaction. www.cmdg.org/Movement_/drug/Acutedystonicreaction/acutedystonicreaction.htm (Accessed on October 15, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/24\">",
"      Meulendijks D, Mannesse CK, Jansen PA, et al. Antipsychotic-induced hyponatraemia: a systematic review of the published evidence. Drug Saf 2010; 33:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/25\">",
"      Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/26\">",
"      K&ouml;nig P, Chwatal K, Havelec L, et al. Amantadine versus biperiden: a double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders. Neuropsychobiology 1996; 33:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/27\">",
"      Adler L, Angrist B, Peselow E, et al. A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. Br J Psychiatry 1986; 149:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/28\">",
"      Stryjer R, Rosenzcwaig S, Bar F, et al. Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind, crossover study. Clin Neuropharmacol 2010; 33:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4600/abstract/29\">",
"      Choy AM, Lang CC, Chomsky DM, et al. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation 1997; 96:2149.",
"     </a>",
"    </li>",
"    <li>",
"     Arizona Center for Education and Research on Therapeutics. Drugs with Risk of Torsades de Pointes. www.qtdrugs.org/medical-pros/drug-lists/list-01.cfm?sort=Generic_name (Accessed on October 15, 2008).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 315 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-C008A65255-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_31_4600=[""].join("\n");
var outline_f4_31_4600=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY AND CELLULAR TOXICOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      KINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES OF OVERDOSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LABORATORY EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Airway, breathing, and circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      General treatment and antidotal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      GI decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Acute extrapyramidal syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      QT interval prolongation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Anticholinergic delirium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Extracorporeal removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Ongoing treatment and disposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PEDIATRIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5184641\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/315\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/315|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/19/41276\" title=\"table 1\">",
"      Antipsychotic medications available in US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/24/29068\" title=\"table 2\">",
"      First generation antipsychotic Rx poisoning - Rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/38/31339\" title=\"table 3\">",
"      Kinetics of common first generation antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/43/3773\" title=\"table 4\">",
"      Causes of delirium and confusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43319?source=related_link\">",
"      Anticholinergic poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11080?source=related_link\">",
"      Benzodiazepine poisoning and withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/58/16297?source=related_link\">",
"      Gastrointestinal decontamination of poisoned adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1129?source=related_link\">",
"      General approach to drug poisoning in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=related_link\">",
"      Opioid intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/21/22874?source=related_link\">",
"      Opioid intoxication in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6473?source=related_link\">",
"      Overview of the acute management of tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41863?source=related_link\">",
"      Phenytoin poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/55/1912?source=related_link\">",
"      Rapid sequence intubation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43320?source=related_link\">",
"      Second generation (atypical) antipsychotic medication poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=related_link\">",
"      Severe hyperthermia (heat stroke) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=related_link\">",
"      Stupor and coma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36231?source=related_link\">",
"      Tricyclic antidepressant poisoning",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_31_4601="Pentobarbital: Drug information";
var content_f4_31_4601=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pentobarbital: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/7/38003?source=see_link\">",
"    see \"Pentobarbital: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/24/17801?source=see_link\">",
"    see \"Pentobarbital: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F208174\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Nembutal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F208175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Nembutal&reg; Sodium",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F208200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anticonvulsant, Barbiturate;",
"     </li>",
"     <li>",
"      Barbiturate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F208178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Adjust dose based on patients age, weight, and condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypnotic/sedative:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 150-200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Initial: 100 mg; decrease dose for elderly or debilitated patients. If needed, may administer additional increments after at least 1 minute, up to a total dose of 200-500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Barbiturate coma in severe brain injury patients/elevated intracranial pressure (unlabeled use; Bratton, 2007):",
"     </b>",
"     I.V.: Loading dose: 10 mg/kg given over 30 minutes (or &le;25 mg/minute), followed by 5 mg/kg every hour for 3 doses; monitor blood pressure and respiratory rate. Maintenance infusion: Initial: 1 mg/kg/hour; may increase to 2-4 mg/kg/hour; maintain burst suppression on EEG.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Refractory status epilepticus:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Intubation required; adjust dose based on hemodynamics, seizure activity, and EEG. Various regimens available (Abou Khaled, 2008; Millikan, 2009; Mirski, 2008; Yaffe, 1993):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loading dose: 10-15 mg/kg (5-10 mg/kg in patients with pre-existing hypotension) administer slowly over 1 hour; initial maintenance infusion: 0.5-1 mg/kg/hour; adjust to maintain burst suppression pattern on EEG; maintenance infusion dose range: 0.5-10 mg/kg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     During active seizure activity when increasing maintenance infusion rate, some experts suggest administration of an additional 5 mg/kg bolus given the long half-life of pentobarbital.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F208190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/24/17801?source=see_link\">",
"      see \"Pentobarbital: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Adjust dose based on patients age, weight, and condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypnotic/sedative:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 2-6 mg/kg; maximum: 100 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: 1-6 mg/kg titrated in 1-2 mg/kg increments every 3-5 minutes to desired effect (Krauss, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Refractory status epilepticus:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Intubation required; adjust dose based on hemodynamics, seizure activity, and EEG. Various regimens available (Abend, 2008; Hanhan, 2001; Holmes, 1999; Kim, 2001):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loading dose: 5-15 mg/kg given slowly over 1 hour; maintenance infusion: 0.5-5 mg/kg/hour to maintain burst suppression; continue for 12-48 hours of no seizure activity; may taper infusion rate by 0.5 mg/kg/hour every 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F208179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended for use in the elderly; decrease dose if use becomes necessary.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F10583544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduce dosage in patients with renal dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F208180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduce dosage in patients with liver dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F208152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nembutal&reg;: 50 mg/mL (20 mL, 50 mL) [contains ethanol 10%, propylene glycol 40%]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F208136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F208202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F208156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pentobarbital may be administered by deep I.M. or slow I.V. injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Inject into a large muscle. No more than 5 mL (250 mg) should be injected at any one site because of possible tissue irritation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Do not exceed 50 mg/minute; I.V. push doses may be given undiluted. Parenteral solutions are highly alkaline; avoid extravasation; avoid intra-arterial injection.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F208208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, insulin (regular), linezolid, propofol.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, fenoldopam.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Aminophylline, ephedrine, hyaluronidase, hydromorphone, neostigmine, scopolamine, sodium bicarbonate, thiopental.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Butorphanol, chlorpromazine, cimetidine, dimenhydrinate, diphenhydramine, droperidol, fentanyl, glycopyrrolate, hydroxyzine, meperidine, midazolam, nalbuphine, pentazocine, prochlorperazine edisylate, promethazine, ranitidine.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Atropine, morphine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F208155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sedative/hypnotic; refractory status epilepticus",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F7716903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Barbiturate coma in patients with severe brain injury (eg, hemorrhagic stroke, traumatic brain injury) and increased intracranial pressure",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F208210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       PENTobarbital may be confused with PHENobarbital",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nembutal&reg; may be confused with Myambutol&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F208198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, hypotension, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal thinking, agitation, anxiety, ataxia, CNS excitation, confusion, depression, dizziness, drowsiness, fever, hallucinations, headache, hyperkinesia, insomnia, nervousness, nightmares, psychiatric disturbances, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, exfoliative dermatitis, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Megaloblastic anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Apnea (especially with rapid I.V. use), hypoventilation, laryngospasm, respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Gangrene with inadvertent intra-arterial injection, hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F208159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to barbiturates or any component of the formulation; porphyria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F208140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May cause hypotension particularly when administered intravenously; use with caution in hemodynamically unstable patients (hypotension or shock). High doses used to induce pentobarbital coma cause hypotension requiring vasopressor therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory depression: May cause respiratory depression particularly when administered intravenously; use with caution in patients with respiratory disease. Intubation is typically required prior to treatment for status epilepticus or traumatic brain injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with depression or suicidal tendencies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; reduce dose as appropriate. Do not use in patients with hepatic coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; reduce dose as appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Substance abuse: Use with caution in patients with a history of drug abuse; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in patients who are debilitated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use due to risk of overdose with low dosages, tolerance to sleep effects, and increased risk of physical dependence (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Alkaline solution: Solution for injection is highly alkaline and extravasation may cause local tissue damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Propylene glycol toxicity: Intravenous solution may contain propylene glycol (PG). One case report has described a patient who developed lactic acidosis possibly secondary to PG accumulation following a continuous infusion of pentobarbital (Miller, 2008). Consider monitoring for signs of PG toxicity (eg, lactic acidosis, acute renal failure, osmol gap) in patients who require a continuous infusion of pentobarbital.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute pain: Do not administer to patients in acute pain; may heighten/worsen sense of pain.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Anticonvulsants should not be discontinued abruptly because of the possibility of increasing seizure frequency; therapy should be withdrawn gradually to minimize the potential of increased seizure frequency, unless safety concerns require a more rapid withdrawal.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F208195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Induces",
"     </b>",
"     CYP2A6 (strong), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F208145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: Barbiturates may increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inducers may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor clinical response.  Reduce the oral aripiprazole dose to 10-15 mg/day if the inducer is discontinued. Avoid use of CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Barbiturates may decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Boceprevir.  Management: Avoid strong CYP3A4 inducers with boceprevir when possible, and closely monitor response to boceprevir if such a combination cannot be avoided. Carbamazepine, phenytoin, phenobarbital, rifampin, and St. John's wort are considered contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Barbiturates may increase the metabolism of Calcium Channel Blockers.  Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of Anticonvulsants (Barbiturate). Specifically, osteomalacia and rickets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloramphenicol: Barbiturates may increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Barbiturates may diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible.  Management: Use of a non-hormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Barbiturates may diminish the therapeutic effect of Contraceptives (Progestins). Contraceptive failure is possible.  Management: Use of alternative, nonhormonal contraceptives is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Barbiturates may decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Barbiturates may increase the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates.  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Barbiturates may increase the metabolism of Disopyramide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxycycline: Barbiturates may decrease the serum concentration of Doxycycline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide: Barbiturates may decrease the serum concentration of Etoposide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etoposide Phosphate: Barbiturates may decrease the serum concentration of Etoposide Phosphate. Barbiturates may increase the metabolism, via CYP isoenzymes, of etoposide phosphate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: Barbiturates may decrease the serum concentration of Felbamate. Felbamate may increase the serum concentration of Barbiturates.  Management: Monitor for elevated barbiturate concentrations/toxicity if felbamate is initiated/dose increased, or reduced concentrations/effects if felbamate is discontinued/dose decreased. Refer to phenobarbital dosing guidelines for patients receiving that agent.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Barbiturates may enhance the CNS depressant effect of Fosphenytoin. Barbiturates may decrease the serum concentration of Fosphenytoin. Fosphenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse drug reactions, consider increasing gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers.  Carefully monitor clinical response and development of adverse reactions.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: Barbiturates may decrease the serum concentration of Griseofulvin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of Barbiturates. Management: Consider a decrease in the barbiturate dose, as appropriate, when used together with hydroxyzine.  With concurrent use, monitor patients closely for excessive response to the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     to 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (given as a 4-hour infusion), as tolerated, should be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May diminish the therapeutic effect of Anticonvulsants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Barbiturates may decrease the serum concentration of LamoTRIgine.  Management: See lamotrigine prescribing information for specific age-dependent dosing guidelines regarding concurrent use with a barbiturate, as well as for adjusting lamotrigine dosing if concurrent barbiturate therapy is discontinued.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: May diminish the therapeutic effect of Anticonvulsants. Mefloquine may decrease the serum concentration of Anticonvulsants. Management: Mefloquine is contraindicated for malaria prophylaxis in persons with a history of convulsions.  Monitor anticonvulsant concentrations and treatment response closely with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Barbiturates may enhance the CNS depressant effect of Meperidine. Barbiturates may increase serum concentrations of the active metabolite(s) of Meperidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Barbiturates may enhance the CNS depressant effect of Methadone. Barbiturates may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mifepristone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pazopanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Avoid use of perampanel with strong CYP3A inducers other than enzyme-inducing antiepileptic drugs (EIAEDs).  Increase perampanel starting dose to 4 mg/day when used with EIAEDs such as phenytoin, carbamazepine, or oxcarbazepine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May enhance the CNS depressant effect of Barbiturates. Barbiturates may decrease the serum concentration of Phenytoin. Phenytoin may increase the serum concentration of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May enhance the adverse/toxic effect of Barbiturates. Primidone is converted to phenobarbital, and thus becomes additive with existing barbiturate therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: Barbiturates may decrease the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pyridoxine: May increase the metabolism of Barbiturates. Apparent in high pyridoxine doses (eg, 200 mg/day)",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Barbiturates may enhance the hepatotoxic effect of QuiNIDine. Barbiturates may decrease the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Barbiturates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining strong CYP3A4 inducers with roflumilast.  The Canadian product monograph makes no such recommendation but notes that such agents may reduce roflumilast therapeutic effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inducers (Strong) may decrease the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inducers may decrease the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teniposide: Barbiturates may decrease the serum concentration of Teniposide.  Management: Consider alternatives to combined treatment with barbiturates and teniposide due to the potential for decreased teniposide concentrations.  If the combination cannot be avoided, monitor teniposide response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Barbiturates may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Barbiturates may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Barbiturates may increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May decrease the metabolism of Barbiturates. Barbiturates may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Barbiturates may increase the metabolism of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F208170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F208147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10580824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Barbiturates can be detected in the placenta, fetal liver and fetal brain. Fetal and maternal blood concentrations may be similar following parenteral administration. An increased incidence of fetal abnormalities may occur following maternal use. When used during the third trimester of pregnancy, withdrawal symptoms may occur in the neonate including seizures and hyperirritability; symptoms may be delayed up to 14 days. Use during labor does not impair uterine activity; however, respiratory depression may occur in the newborn; resuscitation equipment should be available, especially for premature infants.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F208183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10580825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of barbiturates are found in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Nembutal Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (20 mL): $929.18",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F208149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory status (for conscious sedation, includes pulse oximetry), cardiovascular status, CNS status; cardiac monitor and blood pressure monitor required; temperature with high doses (eg, barbiturate coma)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Elevated ICP: Monitor ICP, CPP, EEG",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F208153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sedation: 1-5 mcg/mL (SI: 4-22 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Coma or intracranial pressure therapy: Target: 30-40 mcg/mL (SI: 132-176 micromole/L) (Bratton, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Potentially toxic: &gt;10 mcg/mL (SI: &gt;44 micromole/L); dependent on reason for use and patient condition",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dormital (UY);",
"     </li>",
"     <li>",
"      Entobar (KP);",
"     </li>",
"     <li>",
"      Mebumal (DK);",
"     </li>",
"     <li>",
"      Medinox Mono (DE);",
"     </li>",
"     <li>",
"      Nembutal (AT);",
"     </li>",
"     <li>",
"      Pentone (AU);",
"     </li>",
"     <li>",
"      Praecicalm (DE);",
"     </li>",
"     <li>",
"      Prodormol (IL);",
"     </li>",
"     <li>",
"      Sombutol (FI);",
"     </li>",
"     <li>",
"      Sopental (ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F208139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Barbiturate with sedative, hypnotic, and anticonvulsant properties. Barbiturates depress the sensory cortex, decrease motor activity, alter cerebellar function, and produce drowsiness, sedation, and hypnosis. In high doses, barbiturates exhibit anticonvulsant activity; barbiturates produce dose-dependent respiratory depression; reduce brain metabolism and cerebral blood flow in order to decrease intracranial pressure",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F208158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.M.: 10-15 minutes (Krauss, 2006); I.V.: Almost immediate, within 3-5 minutes (Krauss, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: I.V.: Variable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Children: 0.8 L/kg (Schaible, 1982); Adults: 1 L/kg (Ehrnebo, 1974)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 45% to 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via hydroxylation and glucuronidation (Wermeling, 1985)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: Children: 26 &plusmn; 16 hours (Schaible, 1982); Adults: Healthy: 22 hours (average; Ehrnebo, 1974); (range: 15-50 hours; dose dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abend NS and Dlugos DJ, \"Treatment of Refractory Status Epilepticus: Literature Review and a Proposed Protocol,\"",
"      <i>",
"       Pediatr Neurol",
"      </i>",
"      , 2008, 38(6):377-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/31/4601/abstract-text/18486818/pubmed\" id=\"18486818\" target=\"_blank\">",
"        18486818",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Abou Khaled KJ, Hirsch LJ, &ldquo;Updates in the Management of Seizures and Status Epilepticus in Critically Ill Patients,&rdquo;",
"      <i>",
"       Neurol Clin",
"      </i>",
"      , 2008, 26(2):385-408, viii.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/31/4601/abstract-text/18514819/pubmed\" id=\"18514819\" target=\"_blank\">",
"        18514819",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/31/4601/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, &ldquo;Guidelines for the Management of Severe Traumatic Brain Injury,&rdquo;",
"      <i>",
"       J Neurotrauma",
"      </i>",
"      , 2007, 24(Suppl 1):1-106.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/31/4601/abstract-text/17511534/pubmed\" id=\"17511534\" target=\"_blank\">",
"        17511534",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brain Trauma Foundation, American Association of Neurological Surgeons, Joint Section on Neurotrauma and Critical Care, &ldquo;Use of Barbiturates in the Control of Intracranial Hypertension,&rdquo;",
"      <i>",
"       J Neurotrauma",
"      </i>",
"      , 2000, 17(6-7):527-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/31/4601/abstract-text/10937896/pubmed\" id=\"10937896\" target=\"_blank\">",
"        10937896",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bratton SL, Chestnut RM, Ghajar J, et al, &ldquo;Guidelines for the Management of Severe Traumatic Brain Injury. XI. Anesthetics, Analgesics, and Sedatives,&rdquo;",
"      <i>",
"       J Neurotrauma",
"      </i>",
"      , 2007, (24 Suppl 1):71-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/31/4601/abstract-text/17511550/pubmed\" id=\"17511550\" target=\"_blank\">",
"        17511550",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ehrnebo M, &ldquo;Pharmacokinetics and Distribution Properties Of Pentobarbital in Humans Following Oral and Intravenous Administration,&rdquo;",
"      <i>",
"       J Pharm Sci",
"      </i>",
"      , 1974, 63(7):1114-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/31/4601/abstract-text/4853598/pubmed\" id=\"4853598\" target=\"_blank\">",
"        4853598",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eisenberg HM, Frankowski RF, Contant CF, et al, &ldquo;High-Dose Barbiturate Control of Elevated Intracranial Pressure in Patients With Severe Head Injury,&rdquo;",
"      <i>",
"       J Neurosurg",
"      </i>",
"      , 1988, 69(1):15-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/31/4601/abstract-text/3288723/pubmed\" id=\"3288723\" target=\"_blank\">",
"        3288723",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fischer JH and Raineri DL, &ldquo;Pentobarbital Anesthesia for Status Epilepticus,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1987, 6(8):601-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/31/4601/abstract-text/3691007/pubmed\" id=\"3691007\" target=\"_blank\">",
"        3691007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hanhan UA, Fiallos MR, and Orlowski JP, &ldquo;Status Epilepticus,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 2001, 48(3):683-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/31/4601/abstract-text/11411300/pubmed\" id=\"11411300\" target=\"_blank\">",
"        11411300",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Holmes GL and Riviello JJ Jr, \"Midazolam and Pentobarbital for Refractory Status Epilepticus,\"",
"      <i>",
"       Pediatr Neurol",
"      </i>",
"      , 1999, 20(4):259-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/31/4601/abstract-text/10328273/pubmed\" id=\"10328273\" target=\"_blank\">",
"        10328273",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hubbard AM, Markowitz RI, Kimmel B, et al, &ldquo;Sedation for Pediatric Patients Undergoing CT and MRI,&rdquo;",
"      <i>",
"       J Comput Assist Tomogr",
"      </i>",
"      , 1992, 16(1):3-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/31/4601/abstract-text/1729302/pubmed\" id=\"1729302\" target=\"_blank\">",
"        1729302",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kim SJ, Lee DY, and Kim JS, \"Neurologic Outcomes of Pediatric Epileptic Patients With Pentobarbital Coma,\"",
"      <i>",
"       Pediatr Neurol",
"      </i>",
"      , 2001, 25(3):217-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/31/4601/abstract-text/11587876/pubmed\" id=\"11587876\" target=\"_blank\">",
"        11587876",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kochanek PM, Carney N, Adelson PD, et al, &ldquo;Guidelines for the Acute Medical Management of Severe Traumatic Brain Injury in Infants, Children, and Adolescents -- Second Edition,&rdquo;",
"      <i>",
"       Pediatr Crit Care Med",
"      </i>",
"      , 2012, 13(Suppl 1):1-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/31/4601/abstract-text/22217782/pubmed\" id=\"22217782\" target=\"_blank\">",
"        22217782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Krauss B and Green SM, &ldquo;Procedural Sedation and Analgesia in Children,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      ,  2006, 367(9512):766-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/31/4601/abstract-text/16517277/pubmed\" id=\"16517277\" target=\"_blank\">",
"        16517277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Manno EM, &ldquo;New Management Strategies in the Treatment of Status Epilepticus,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 2003, 78(4):508-18.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/31/4601/abstract-text/12683704/pubmed\" id=\"12683704\" target=\"_blank\">",
"        12683704",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Meierkord H, Boon P, Engelsen B, et al, &ldquo;EFNS Guideline on the Management of Status Epilepticus in Adults,&rdquo;",
"      <i>",
"       Eur J Neurol",
"      </i>",
"      , 2010,17(3):348-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/31/4601/abstract-text/20050893/pubmed\" id=\"20050893\" target=\"_blank\">",
"        20050893",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Miller MA, Forni A, and Yogaratnam D, &ldquo;Propylene Glycol-Induced Lactic Acidosis in a Patient Receiving Continuous Infusion Pentobarbital,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2008,  42(10):1502-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/31/4601/abstract-text/18698010/pubmed\" id=\"18698010\" target=\"_blank\">",
"        18698010",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Millikan D, Rice B, and Silbergleit R, &ldquo;Emergency Treatment of Status Epilepticus: Current Thinking,&rdquo;",
"      <i>",
"       Emerg Med Clin North Am",
"      </i>",
"      , 2009, 27(1):101-13, ix.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/31/4601/abstract-text/19218022/pubmed\" id=\"19218022\" target=\"_blank\">",
"        19218022",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mirski MA and Varelas PN, &ldquo;Seizures and Status Epilepticus in the Critically Ill,&rdquo;",
"      <i>",
"       Crit Care Clin",
"      </i>",
"      , 2008, 24(1):115-47",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/31/4601/abstract-text/18241782/pubmed\" id=\"18241782\" target=\"_blank\">",
"        18241782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pereira JK, Burrows PE, Richards HM, et al, &ldquo;Comparison of Sedation Regimens for Pediatric Outpatient CT,&rdquo;",
"      <i>",
"       Pediatr Radiol",
"      </i>",
"      , 1993, 23(5):341-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/31/4601/abstract-text/8233681/pubmed\" id=\"8233681\" target=\"_blank\">",
"        8233681",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schaible DH, Cupit GC, Swedlow DB, et al, &ldquo;High-Dose Pentobarbital Pharmacokinetics in Hypothermic Brain-Injured Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1982, 100(4):655-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/31/4601/abstract-text/7062221/pubmed\" id=\"7062221\" target=\"_blank\">",
"        7062221",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wermeling D, Record K, Bell R, et al, &ldquo;Hemodialysis Clearance of Pentobarbital During Continuous Infusion,&rdquo;",
"      <i>",
"       Ther Drug Monit",
"      </i>",
"      , 1985, 7(4):485-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/31/4601/abstract-text/4082247/pubmed\" id=\"4082247\" target=\"_blank\">",
"        4082247",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yaffe K and Lowenstein DH, &ldquo;Prognostic Factors of Pentobarbital Therapy for Refractory Generalized Status Epilepticus,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1993, 43(5):895-900.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/31/4601/abstract-text/8492944/pubmed\" id=\"8492944\" target=\"_blank\">",
"        8492944",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9754 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-F770B2E4D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_31_4601=[""].join("\n");
var outline_f4_31_4601=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208174\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208175\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208200\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208178\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208190\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208179\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10583544\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208180\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208152\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208136\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208202\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208156\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208208\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208155\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7716903\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208210\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208198\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208159\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208140\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208195\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208145\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208170\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208147\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10580824\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208183\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10580825\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570484\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208149\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208153\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038764\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208139\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F208158\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9754\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9754|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/7/38003?source=related_link\">",
"      Pentobarbital: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/24/17801?source=related_link\">",
"      Pentobarbital: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_31_4602="Epidemiology, transmission, and prevention of hepatitis B virus infection";
var content_f4_31_4602=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, transmission, and prevention of hepatitis B virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/31/4602/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/31/4602/contributors\">",
"     Eng-Kiong Teo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/31/4602/contributors\">",
"     Anna SF Lok, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/31/4602/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/31/4602/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/31/4602/contributors\">",
"     Rafael Esteban, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/31/4602/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/31/4602/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/31/4602/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis B virus (HBV) infection is a global public health problem. It is estimated that there are more than 350 million HBV carriers in the world, of whom roughly one million die annually from HBV-related liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/1\">",
"     1",
"    </a>",
"    ]. The implementation of effective vaccination programs in many countries has resulted in a significant decrease in the incidence of acute hepatitis B. Nevertheless, hepatitis B remains an important cause of morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The spectrum of clinical manifestations of HBV infection varies in both acute and chronic disease. During the acute phase, manifestations range from subclinical or anicteric hepatitis to icteric hepatitis and, in some cases, fulminant hepatitis. During the chronic phase, manifestations range from an asymptomatic carrier state to chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Extrahepatic manifestations also can occur with both acute and chronic infection.",
"   </p>",
"   <p>",
"    This topic review will discuss the epidemiology, modes of transmission, and prevention of HBV infection. The clinical manifestations and natural history of HBV infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of HBV carriers varies from 0.1 percent to 2 percent in low prevalence areas (United States and Canada, Western Europe, Australia and New Zealand), to 3 to 5 percent in intermediate prevalence areas (Mediterranean countries, Japan, Central Asia, Middle East, and Latin and South America), to 10 to 20 percent in high prevalence areas (southeast Asia, China, sub-Saharan Africa) (",
"    <a class=\"graphic graphic_table graphicRef51820 \" href=\"UTD.htm?21/30/21995\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62806 \" href=\"UTD.htm?6/43/6838\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. A systematic review focusing on data in the United States estimated that there are 2.2 million individuals with chronic HBV, two-thirds of whom were foreign born [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The wide range in HBV carrier rate in different parts of the world is largely related to differences in the age at infection, which is inversely related to the risk of chronicity. The rate of progression from acute to chronic HBV infection is approximately 90 percent for perinatally acquired infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/4\">",
"     4",
"    </a>",
"    ], 20 to 50 percent for infections between the age of 1 and 5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/5,6\">",
"     5,6",
"    </a>",
"    ], and less than 5 percent for adult acquired infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, the incidence of acute hepatitis B has decreased by 81 percent from 1990 to 2006, with the greatest decline among children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/6\">",
"     6",
"    </a>",
"    ]. The incidence in 2007 was estimated to be 1.5 per 100,000 persons. There were 4519 acute, symptomatic cases reported but an estimated 43,000 new infections overall, with most infections occurring in men ages 25 to 44 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/7\">",
"     7",
"    </a>",
"    ]. The most common risk factors were sexual exposure (sexual contact with a person known to have hepatitis B, multiple sex partners, and men having sex with men) and injection drug use. These data indicate that vaccination programs targeted at high risk adults are needed to further reduce transmission of HBV in the United States. Hepatitis B was listed as the cause of 724 deaths and as a contributing cause of death in 1815 patients in 2007, based upon data from the National Center for Health Statistics [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The data from NHANES 1988 to 1994 were compared with NHANES 1999 to 2006 to investigate the effect of the vaccination effort [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/9\">",
"     9",
"    </a>",
"    ]. Overall, the prevalence of past and present hepatitis B infection increased with age, from 0.6 percent for children between the ages of 6 and 11 years to 7.3 percent for those above 60 years old. Conversely, vaccine-induced immunity was significantly higher among individuals between 6 and 11 years old (54 compared with 5 percent among those more than 60 years old). The prevalence of HBV infection decreased from 1.9 to 0.6 percent among children 6 to 19 years old and 5.9 to 4.6 percent among those 20 to 49 years old, but it remained unchanged among those above 50 years old. Foreign-born participants of the study showed a significant decrease in prevalence of chronic HBV infection from 1.75 to 0.89 percent. Although this reduction in prevalence was significant, it was still 15-fold higher than US-born participants. The reduction was most evident among foreign-born children 6 to 19 years old with prevalence decreasing from 12.8 to 2.0 percent. Among the US-born children surveyed from 1999 to 2006, there was no longer any difference in the prevalence of chronic HBV infection among the different races and ethnic groups, with prevalence ranging from 0.1 to 0.6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/9\">",
"     9",
"    </a>",
"    ]. These results showed that the vaccination program in the United States has been successful in reducing the prevalence of HBV infection, especially among the higher risk populations.",
"   </p>",
"   <p>",
"    In a separate analysis examining nearly 40,000 participants in the National Health and Nutrition Examination Survey in the United States (1999 to 2008), 0.127 percent of those older than six had chronic HBV infection (approximately 704,000 persons), while 4.6 percent (approximately 12 million persons) had evidence of prior exposure to HBV [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/10\">",
"     10",
"    </a>",
"    ]. Infection and past exposure were rare in those ages 6 to 19.",
"   </p>",
"   <p>",
"    Data on prevalence of HBV infection from NHANES may be underestimates since the study did not include certain groups at increased risk of HBV (eg, prisoners or a sufficient sample of persons of Asian or Pacific Islander descent). These populations are known to have a significantly higher prevalence of chronic hepatitis B. In a survey conducted among Asian and Pacific Islander population living in New York City, 15 percent were positive for HBsAg [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the decrease in incidence of acute HBV infection, an analysis of hospitalization records found that the rate of HBV-related hospitalizations, cancers, and deaths in the United States have more than doubled during the past decade [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/12\">",
"     12",
"    </a>",
"    ]. This may be due to the delay in implementation of universal vaccination (which was instituted in 1991), the influx of immigrants from endemic areas, improved diagnosis, and better documentation of infection.",
"   </p>",
"   <p>",
"    Several surveys have found that the prevalence of chronic HBV infection among persons born in HBV endemic countries is similar to that in the country of origin. Based on the United States census, it was estimated that during 1994 to 2003, 40,000 immigrants with chronic HBV infection were admitted annually to the United States for permanent residence [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/6\">",
"     6",
"    </a>",
"    ]. In one study (based on a review of published epidemiologic data), the disease burden from chronic HBV related to foreign born individuals was estimated to be as high as 3 million [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar trends have been observed in Canada, Australia, and many western European countries [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Updated recommendations for the United States Centers for Disease Control and Prevention (in 2008) recommend testing of individuals born in areas where the prevalence of HBsAg is &ge;2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/16\">",
"     16",
"    </a>",
"    ]. This includes Africa, East Asia including China, Korea, Indonesia, and the Philippines, the Middle East except Israel, south and Western Pacific islands, the interior Amazon River basin, and certain parts of the Caribbean (Haiti and the Dominican Republic). Other indications for testing for chronic hepatitis B include individuals with parents from high endemic countries who were not vaccinated at birth; intravenous drug users; men who have sex with men; individuals on immunosuppressive therapy for cancer, organ transplant, rheumatological or gastroenterological conditions; patients with elevated alanine or aspartate aminotransferases of unknown etiology; donors of blood, plasma, semen, tissues and organs; patients on hemodialysis, all pregnant women; infants born to HBsAg+ mothers; household members, needle-sharing or sexual contacts of patients with chronic hepatitis B; persons who are sources of blood or body fluid exposure to others and individuals who tested positive for HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MODES OF TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predominant mode of transmission of HBV varies in different geographical areas. Perinatal infection is the predominant mode of transmission in high prevalence areas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/2,17\">",
"     2,17",
"    </a>",
"    ]. In comparison, horizontal transmission, particularly in early childhood, accounts for most cases of chronic HBV infection in intermediate prevalence areas, while unprotected sexual intercourse and intravenous drug use in adults are the major routes of spread in low prevalence areas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Perinatal transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infection rate among infants born to HBeAg-positive mothers is as high as 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/4\">",
"     4",
"    </a>",
"    ]. Maternal-infant transmission may occur in utero, at the time of birth, or after birth. The high protective efficacy (95 percent) of neonatal vaccination suggests that most infections occur predominantly at or before birth. There is no evidence that cesarean section prevents maternal-infant transmission. Thus, Cesarean section should",
"    <strong>",
"     not",
"    </strong>",
"    be routinely recommended for carrier mothers.",
"   </p>",
"   <p>",
"    Transplacental passage of HBV is rare. The risk of transmission during amniocentesis is also low, particularly in mothers who are HBeAg negative and when the procedure is done using a 22-gauge needle under continuous guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=see_link\">",
"     \"Diagnostic amniocentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The high frequency of perinatal transmission in endemic areas is probably related to the high prevalence (40 to 50 percent) of HBeAg in women of reproductive age. These women remain infectious because of the slow rate of HBeAg seroconversion during the first two decades of life. Studies in Chinese children prior to introduction of universal vaccination of newborns have found HBeAg in as many as 90 percent below the age of 5, and up to 80 percent below the age of 20 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The cumulative rate of spontaneous HBeAg clearance is estimated to be only 15 percent after 20 years of infection, leaving many women of childbearing age still highly infectious [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In Taiwan, where universal vaccination of newborns has been implemented, the prevalence of HBsAg among teenagers born after implementation of universal vaccination at birth has decreased to 0.6 to 2.1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A survey in an urban South-East Asian country estimated the overall risk of perinatal transmission in all HBsAg positive mothers to be 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/24\">",
"     24",
"    </a>",
"    ]. However, the risk of maternal-infant transmission is related to the HBV replicative status of the mother. It is 85 to 90 percent in infants born to HBeAg positive mothers and 32 percent in infants born to HBeAg negative mothers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/25\">",
"     25",
"    </a>",
"    ]. Children born of HBeAg positive mothers remain at risk for HBV infection even if they receive vaccination and immunoprophylaxis (approximately 9 percent in one large cohort study) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Maternal serum HBV DNA levels also correlate with the risk of transmission. Vertical transmission of hepatitis B occurs in 9 to 39 percent of infants of highly viremic mothers (&ge;8 log",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    despite postnatal vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 773 HBsAg positive mothers in Taiwan, the odds ratio for having an infected infant increased from 1 to 147 as the maternal serum HBV DNA levels increased from 5",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      to &gt;1400",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study conducted in China involving 112 newborns of mothers with chronic HBV infection, the rate of infection increased from 0 percent in mothers with serum HBV DNA &lt;5 log10",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      to 50 percent in those with HBV DNA between 9 and 10 log10",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study conducted in Australia on 138 babies born to HBV DNA positive mothers showed a similar trend [",
"      <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/32\">",
"       32",
"      </a>",
"      ]. HBV transmission was detected in four babies despite the use of HBIG and HBV vaccination in three and the vaccine alone in one. All four babies were born to mothers with high HBV DNA levels (&gt;10(8)",
"      <span class=\"nowrap\">",
"       copies/mL).",
"      </span>",
"      The authors concluded that vertical transmission of HBV can occur in highly viremic mothers despite active and passive immunization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Testing for HBsAg should be performed on all women at the first prenatal visit (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link\">",
"     \"Initial prenatal assessment and patient education\"",
"    </a>",
"    ) and repeated late in pregnancy in those at high risk for HBV infection. The current recommendation is to provide passive-active immunization to newborns of carrier mothers.",
"   </p>",
"   <p>",
"    A growing number of trials have investigated the role of adding antiviral therapy to standard passive-active immunization. Several studies have examined",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    prophylaxis given late in pregnancy. A meta-analysis of 10 studies concluded that the administration of lamivudine to the mother in late pregnancy in addition to hepatitis B vaccination and hepatitis B immunoglobulin prophylaxis for the infant significantly reduced mother-to-child transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/33\">",
"     33",
"    </a>",
"    ]. The preferred endpoint for demonstration of maternal-infant transmission of HBV is the presence of HBsAg 9 to 12 months after delivery. Among five studies that included this endpoint, only one showed a significant benefit from lamivudine prophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/61/3033?source=see_link\">",
"     \"Hepatitis B and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study enrolled mothers with a gestational age of 20 to 32 weeks and HBV DNA &gt;10(7)",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    (~2 x 10(6) int.",
"    <span class=\"nowrap\">",
"     unit/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/34\">",
"     34",
"    </a>",
"    ]. Eligible mothers were offered",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    (600",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    and those who refused treatment were included in the control group. All infants received HBIG and HBV vaccine. The baseline characteristics of the mothers in the two groups were comparable. Mean HBV DNA decreased from 8.1 log",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    at baseline to 2.4 log",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    at delivery in the treatment group. At delivery, 33 percent of the mothers in the treatment group had undetectable HBV DNA, and none of these mothers had HBV DNA &gt;6 log",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"    By contrast, 100 percent of the mothers in the control group had HBV DNA &gt;6 log",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    and 39 percent had HBV DNA &gt;8 log",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"    None of the 132 infants in the telbivudine group had positive HBsAg or detectable HBV DNA at seven months, whereas a significantly higher proportion of infants in the control group (7 of 88 infants, 8 percent) were seropositive for HBsAg and HBV DNA. The mothers of all seven infants who were infected had high HBV DNA prior to delivery. Eighteen of 88 mothers who discontinued telbivudine one month post partum had an increase in ALT, but only one mother had ALT &gt;5 times the upper limit of normal four weeks later. No adverse event was noted in the infants, and no significant difference was noted with respect to weight, height, or Apgar score between the two groups. These data suggest that telbivudine is safe for use in pregnancy, and antiviral therapy can reduce the risk of maternal infant transmission of HBV infection; however, it must be emphasized that the number of infants exposed to telbivudine was small, and the study was not randomized.",
"   </p>",
"   <p>",
"    More data are needed to clarify the HBV DNA cutoff for recommending antiviral therapy to pregnant HBV carriers, and the optimal timing and choice of agents for prophylaxis. At present, we tend to offer antiviral prophylaxis in women who have a high viral load (more than 8 log(10) int.",
"    <span class=\"nowrap\">",
"     unit/mL).",
"    </span>",
"    Treatment should be started preferably six to eight weeks before delivery to allow enough time for HBV DNA levels to decline. Of the available oral agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    are pregnancy class B drugs, while others are class C drugs. Human data are available through the anti-retroviral registry. Data on roughly 1000 newborns of mothers who received tenofovir during pregnancy and roughly 3000 newborns of mothers who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    during pregnancy (some of whom received treatment during the first trimester) did not show any difference in rates of birth defects among live births compared with the general population. However, these data were based on self-reporting. In vivo data on other antiviral agents are limited.",
"   </p>",
"   <p>",
"    Based upon these data,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    are preferred if antiviral therapy is contemplated in pregnant women, but",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    can also be considered. The choice depends on the intended duration of therapy. Tenofovir is a better choice in women who will receive long-term treatment because of the low risk of resistance. Breast feeding is another consideration since",
"    <span class=\"nowrap\">",
"     nucleos/tide",
"    </span>",
"    analogs can be secreted in breast milk. Because tenofovir is administered as a prodrug, it may be preferred in nursing mothers. When antiviral therapy should be stopped has not been determined, many experts would stop treatment 4 to12 weeks after delivery if the sole purpose of antiviral therapy is to decrease the risk of maternal-infant transmission. Mothers contemplating breast feeding may stop treatment after delivery. Close monitoring is necessary after treatment is stopped since the risk of a flare is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breastfeeding does not appear to increase the risk of transmission. Although HBV DNA has been detected in the colostrum of HBsAg positive mothers, a study on 147 infants born to carrier mothers revealed no evidence for a relationship between breastfeeding and the subsequent development of chronic HBV infection in the babies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/35\">",
"     35",
"    </a>",
"    ]. In another study involving 369 neonates born to mothers with chronic HBV infection, of whom all received and completed the HBV immunoprophylaxis program, none of the 101 breastfed infants and nine formula-fed infants was positive for HBsAg.",
"   </p>",
"   <p>",
"    This study illustrates that, with appropriate immunoprophylaxis, breastfeeding of infants of HBV carriers poses no additional risk for the transmission of HBV [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/36\">",
"     36",
"    </a>",
"    ]. Infants who received HBIG and the first dose of vaccine at birth may be breastfed as long as they complete the course of vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/28\">",
"     28",
"    </a>",
"    ], but carrier mothers should not participate in donating breast milk. Mothers intending to breastfeed their babies should not delay until the babies are fully immunized. Mothers with chronic hepatitis B who are breastfeeding should also exercise care to prevent bleeding from cracked nipples.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H112596570\">",
"    <span class=\"h2\">",
"     Paternal transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;From genotypic and phylogenetic analysis, transmission of HBV from father to infants is possible. A study conducted in Taiwan showed that the HBV infection rate was 85 to 87 percent among neonates born to HBsAg-positive mothers regardless of the paternal HBsAg status. The infection rate was 65 percent among neonates born to HBsAg-negative mothers with HBsAg-positive fathers [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/37\">",
"     37",
"    </a>",
"    ]. Most of these transmissions were believed to be from exposure of the unprotected infants to infected blood and body fluids of the fathers through close contact. Some studies have detected HBV in sperm, but there is no clinical evidence to support that \"infected\" sperm results in transmission of HBV infection to the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/38-41\">",
"     38-41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Horizontal transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children may acquire HBV infection through horizontal transmission via minor breaks in the skin or mucous membranes or close bodily contacts with other children. In addition, HBV can survive outside the human body for a prolonged period; as a result, transmission via contaminated household articles such as toothbrushes, razors, and even toys may be possible. Although HBV DNA has been detected in various bodily secretions of hepatitis B carriers, there is no firm evidence of HBV transmission via body fluids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of transfusion-related hepatitis B decreased significantly after the exclusion of paid blood donors and the introduction of hepatitis B surface antigen (HBsAg) screening of donors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/24\">",
"     24",
"    </a>",
"    ]. In a retrospective review of records of posttransfusion hepatitis B from 1991 to 1997 in the United Kingdom, the risk of acquiring posttransfusion hepatitis B was 0.6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, both HBsAg and anti-HBc (hepatitis B core antibody) are used for donor screening. Anti-HBc was initially used as a surrogate marker for non-A, non-B hepatitis virus but has been retained after implementation of hepatitis C testing to detect donors who are in the window phase during recovery from acute hepatitis B or who have low level chronic HBV infection (",
"    <a class=\"graphic graphic_figure graphicRef69344 \" href=\"UTD.htm?41/25/42398\">",
"     figure 2",
"    </a>",
"    ). The window phase remains an important issue since an anonymous survey of almost 35,000 blood donors in the United States found that 0.4 percent admitted to a high-risk behavior within the three months before blood donation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The practical value of anti-HBc screening is not clear because of the low incidence of transfusion-associated HBV infection in low prevalence areas and the need to exclude as many as 22 percent of the donor population in high prevalence areas [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/22,43\">",
"     22,43",
"    </a>",
"    ]. In the United States, the risk of posttransfusion hepatitis B is estimated to be one to four per million blood component transfused [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/44\">",
"     44",
"    </a>",
"    ]. In China where HBV is endemic, the risk of posttransfusion HBV infection is higher: 1 in 17,501 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/45\">",
"     45",
"    </a>",
"    ]. Patients requiring multiple transfusions, such as those with hemophilia and thalassemia, are at increased risk of contracting HBV infection.",
"   </p>",
"   <p>",
"    To further reduce the risk of transfusion associated HBV infection, nucleic acid testing (NAT) is being considered in screening blood donors for HBV. A study conducted in China reported a yield of 9.5 per million donations for mini pool NAT, with the yield increasing to 28.3 per million donations for individual donor NAT [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/45\">",
"     45",
"    </a>",
"    ]. This is in contrast to a low prevalence region like Germany where mini pool NAT only decreased the rate of serologically undetected HBV infection from 1 in 230,000 to 1 in 620,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The implementation of NAT in countries of high prevalence is hampered by the cost involved while it is considered not cost effective in countries with low prevalence. Nevertheless, some countries including Singapore, Spain, Germany, and the United States have started using NAT for the screening of HBV infection. Blood samples are tested in pools and then individual donation samples are tested if contained in a reactive pool [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sexual transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual transmission remains the major mode of spread of HBV in developed countries [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is estimated that heterosexual transmission accounts for approximately 39 percent of new HBV infection among adults in the United States and transmission among men having sex with men (MSM) accounts for approximately 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sexual transmission of hepatitis B can be prevented by vaccination of spouses and steady sex partners in individuals with monogamous partners, and safe sex practice including use of condoms in subjects with multiple partners.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Percutaneous inoculation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous transmission usually happens among intravenous drug users who share syringes and needles. In the United States, IDU accounts for 16 percent of new hepatitis B infections [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/6\">",
"     6",
"    </a>",
"    ]. One study estimated that there were 6.4 million intravenous drug users who were anti-HBc positive, while there were 1.2 million who were HBsAg positive [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/49\">",
"     49",
"    </a>",
"    ]. The risk of HBV transmission increases with the number of years of drug use, frequency of injection, and sharing of drug preparation equipment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Household contacts can also transmit hepatitis B through the sharing of razors or toothbrushes. Certain practices like acupuncture, tattooing, and body piercing have also been associated with transmission of hepatitis B. Public health education and the use of disposable needles or equipment are important in preventing this mode of transmission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Nosocomial infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;HBV is the most commonly transmitted blood-borne virus in the healthcare setting [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/27,53\">",
"     27,53",
"    </a>",
"    ]. Transmission generally occurs from patient to patient or from patient to health care personnel via contaminated instruments or an accidental needle stick. Nosocomial transmission can be prevented by screening blood and blood products, using disposable needles and equipment, properly sterilizing surgical instruments, enforcing infection control measures, and vaccinating healthcare workers.",
"   </p>",
"   <p>",
"    Healthcare workers, particularly surgeons, pathologists, and clinicians working in hemodialysis and oncology units, have the highest risks of HBV infection. However, with the implementation of routine hepatitis B vaccination of health care workers and the use of standard precautions to prevent exposure to blood-borne pathogens, HBV infection in this population has become a rare occurrence. The incidence of HBV infection among health care workers has been lower than that of the general population since the mid-90s [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. This is in contrast to the high prevalence of HBV serological markers in surveillance studies performed in the 1970s and 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1993, the Viral Hepatitis Prevention Board formulated a seven-point consensus to contain hepatitis B as an occupational hazard (",
"    <a class=\"graphic graphic_table graphicRef64865 \" href=\"UTD.htm?30/23/31099\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/58\">",
"     58",
"    </a>",
"    ]. In addition to vaccination of healthcare workers, a number of infection control measures were recommended, and enforcement of these measures is monitored by the United States Occupational Safety and Health Administration (OSHA). The current OSHA's Bloodborne Pathogen Standard requires that employers offer hepatitis B vaccination to employees who are reasonably anticipated to have exposure to blood or other potentially infectious material. The offer must be made within 10 days of employment and at no cost to the employee. OSHA regulations can be viewed online at",
"    <a class=\"external\" href=\"file://www.osha.gov/law-regs.html\">",
"     file://www.osha.gov/law-regs.html",
"    </a>",
"    . In addition, since 2007, OSHA expects employers to put in more effort in the documentation of their employees' hepatitis B immune status. The vaccination records will be important in postexposure treatment and counseling.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93960993\">",
"    <span class=\"h3\">",
"     Infected healthcare workers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the publicity about hepatitis B transmission from healthcare workers to patients, transmission from infected health care workers to patients is relatively infrequent compared to transmission from patients to health care workers. Transmission usually results from unsafe injection practices, which often could have been avoided with standard precautions and appropriate aseptic techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, several reports have demonstrated that transmission can occur even when such policies are followed. One outbreak was traced to a cardiothoracic surgeon, despite adequate infection control during the operations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/60\">",
"     60",
"    </a>",
"    ]. Transmission was traced to tears in gloves and cuts on the surgeon's fingers during prolonged suturing. There were other instances in which small outbreaks of acute hepatitis B were detected in health care settings secondary to use of fingerstick devices for glucose monitoring, subdermal electrodes for EEG, and unsafe practices while using multiple-dose vials of medications [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/61\">",
"     61",
"    </a>",
"    ]. A review of cases of viral hepatitis in the United States from 1998 to 2008 in health care settings outside hospitals revealed 18 outbreaks with 173 persons with incident HBV infection. These outbreaks occurred mainly in outpatient clinics or ambulatory hemodialysis centers due to lapses in infection control measures like syringe reuse, contamination of injectable medications or flush solutions, and the reuse of fingerstick devices meant only for single use [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/27\">",
"     27",
"    </a>",
"    ]. In another series from 1996 to 2002, there were reports of 12 infected health care workers infecting a total of 91 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/62\">",
"     62",
"    </a>",
"    ]. The number of infected patients was likely to be an under-estimate as many infected patients may be asymptomatic, and only a fraction of the exposed patients were recalled for testing. Enforcement of the use of safer devices (eg, blunt suture needles), safer practice, and the use of personal protective equipment may be more effective than practice restrictions in the prevention of nosocomial hepatitis B infection.",
"   </p>",
"   <p>",
"    The risk of HBV transmission from infected healthcare workers has generally been considered to be greatest among HBV carriers who are HBeAg positive [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/63\">",
"     63",
"    </a>",
"    ]. However, transmission from HBeAg negative carriers with high HBV DNA levels has been reported. Based upon data from studies on vertical transmission, one group estimated that transmission from a needlestick was unlikely when serum HBV DNA is below 10(7) genome",
"    <span class=\"nowrap\">",
"     equivalents/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/64\">",
"     64",
"    </a>",
"    ]. Among healthcare workers who actually transmitted HBV, serum HBV DNA levels ranged between 5 X10(9) and 6.35 X 10(4) genome",
"    <span class=\"nowrap\">",
"     equivalents/mL,",
"    </span>",
"    suggesting that it may be reasonable to treat healthcare workers who have high HBV DNA levels to reduce the risk of nosocomial infection. Such an approach should consider other factors related to the need for treatment (such as likelihood of response and liver histology) and the risk of injuries based upon the healthcare workers' activities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173689405\">",
"    <span class=\"h4\">",
"     Guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines have been issued by a number of organizations. In July 2012, the United States Centers for Disease Control and Prevention (CDC) updated their recommendations for the management of hepatitis B virus-infected health care providers and students [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/65\">",
"     65",
"    </a>",
"    ]. Compared to the previous recommendations (from 1991), the new recommendations were based upon a number of advances in the understanding of the treatment and prevention of HBV infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The adoption of many interventions including Standard Precautions has almost eliminated the very low risk of HBV transmission from health care provider to patients, even in exposure-prone procedures. In addition, there are many work practices and engineering controls to further reduce the risk of health care provider to patient transmission of HBV infection.",
"     </li>",
"     <li>",
"      Documentations that the transmission of HBV infection from health care provider to patients is rare.",
"     </li>",
"     <li>",
"      An understanding that the transmission of HBV infection from health care provider to patients appears to occur only when the HBV DNA level of the health care provider is more than 8000 int.",
"      <span class=\"nowrap\">",
"       unit/mL",
"      </span>",
"      and the recognition of the effectiveness of anti-HBV medications in reducing the HBV viral load.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a result, the updated recommendations include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals with chronic HBV infection should not be excluded from the practice or study to be a health care provider. Strict adherence to Standard Precautions should be implemented in these settings.",
"     </li>",
"     <li>",
"      The CDC discourages non-evidence based practices imposed on chronically HBV-infected health-care providers and students such as the need to:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Demonstrate HBV loads of lower than detectable limits on a regular basis more frequently than at six-month intervals.",
"     </li>",
"     <li>",
"      Notify patients of the HBV-infection status of their care giver.",
"     </li>",
"     <li>",
"      Initiate antiviral therapy solely to lower HBV load for suitability to practice.",
"     </li>",
"     <li>",
"      Force the health care provider to change practice, exclude from exposure-prone procedures, or any other restriction that prohibits the health care provider from practice. Similarly, individuals with chronic HBV infection should not be prevented from pursuing this course of study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All health care providers and students should receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      according to current CDC recommendations. Post-vaccination (three-dose series) assessment for development of hepatitis B surface antibody and, if necessary, revaccination must be accomplished. Nonresponders after revaccination should be tested for HBsAg and anti-HBc to determine their infection status.",
"     </li>",
"     <li>",
"      Prevaccination testing for HBsAg and anti-HBc is not indicated unless the health care providers and students at increased risk for HBV infection, such as those born to mothers in or from endemic countries and sexually active men who have sex with men.",
"     </li>",
"     <li>",
"      Health care providers involved in exposure-prone procedures should be tested for HBV infection before vaccination. Patients exposed to the blood of an HBV-infected health care provider should receive postexposure prophylaxis and testing using the same approaches as would have occurred had the healthcare provider been exposed to an infected patient's blood.",
"     </li>",
"     <li>",
"      Healthcare providers and students who do not perform exposure-prone procedures should not have restrictions of their activities or study. They should continue to receive medical care but do not need to achieve low or undetectable levels of circulating HBV DNA, HBeAg negativity, or be reviewed by an expert review panel regarding the procedures they are allowed to perform.",
"     </li>",
"     <li>",
"      Health care providers who perform exposure-prone procedures should be guided by an expert review panel regarding the procedures that they can perform. At the same time, confidentiality of the health care provider's or student's HBV serologic status should be maintained.",
"     </li>",
"     <li>",
"      HBV-infected providers can perform exposure-prone procedures if the HBV viral load is low or undetectable. Such documentation need not be performed more frequently than every six months unless interventions were instituted to health care providers with higher levels of HBV DNA.",
"     </li>",
"     <li>",
"      An HBV DNA level of 1000 int.",
"      <span class=\"nowrap\">",
"       unit/mL",
"      </span>",
"      (5000",
"      <span class=\"nowrap\">",
"       GE/mL)",
"      </span>",
"      or its equivalent is an appropriate threshold to adopt. An assay that can detect as low as 10 to 30 int.",
"      <span class=\"nowrap\">",
"       unit/mL",
"      </span>",
"      can be used, especially if the individual institutional expert review panel wishes to adopt a lower threshold.",
"     </li>",
"     <li>",
"      In the event that a health care provider performing exposure-prone procedures presents with an HBV DNA level exceeding 1000 int.",
"      <span class=\"nowrap\">",
"       unit/mL,",
"      </span>",
"      the HBV-infected provider is required to abstain from performing exposure-prone procedures, while retesting or other appropriate interventions are instituted to achieve a lower-than-threshold HBV DNA level.",
"     </li>",
"     <li>",
"      Health care institutions as well as medical and dental schools should have clear, written policies and procedures for the identification and management of HBV-infected health care providers, students, and school applicants. These policies should include the ability to identify and convene an expert review panel for the management of HBV-infected providers performing exposure-prone procedures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In 2010, the Society for Healthcare epidemiology of America (SHEA) provided updated recommendations on infected healthcare workers, the key points of which are summarized below [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/66\">",
"     66",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All providers should follow Standard Precautions.",
"     </li>",
"     <li>",
"      HBV-infected healthcare providers should not be prohibited from participating in patient-care activities solely because of HBV status. However, the guidelines define categories of procedures with variable risk of transmitting infection.",
"     </li>",
"     <li>",
"      The guidelines recommend that providers who are HBeAg positive or who have a circulating viral load greater than 10(4)",
"      <span class=\"nowrap\">",
"       GE/mL",
"      </span>",
"      (roughly 2000 int.",
"      <span class=\"nowrap\">",
"       unit/mL)",
"      </span>",
"      routinely use double gloves for all invasive procedures and that they not perform exposure-prone procedures. The guidelines suggest a number of parameters under which providers with a lower viral load be permitted to perform exposure-prone procedures. They also recognize that providers with a higher viral load may undergo antiviral therapy and resume performance of exposure-prone procedures after HBV DNA is suppressed, provided that viral load is monitored.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Guidelines have also been established in many developed countries to define the parameters in which healthcare providers with hepatitis B can operate. In the United Kingdom, the Department of Health policy restricts health care workers who are HBeAg negative but with HBV DNA exceeding 1000 genomes equivalents per mL from performing exposure-prone procedures. For health care workers whose HBV DNA does not exceed 1000 genomes equivalents per mL, they are required to be retested annually. There are no restrictions to their work practices but they should receive appropriate occupational health advice [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In New South Wales in Australia, the policy states that health care workers who are HBeAg positive or HBV DNA positive should be excluded from exposure prone procedures. There is however, no mention on the type of test for HBV DNA or the actual HBV DNA level that is acceptable to the health authorities [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Organ transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organ donors are routinely screened for HBsAg. Transmission of HBV infection has been reported after transplantation of extrahepatic organs, such as kidneys and even cornea, from HBsAg positive donors. The role of anti-HBc in organ donor screening is less certain because of the possibility of false positive results, the potential loss of up to 5 percent of donors even in low endemic areas, and the uncertainty about the infectivity of organs, especially extrahepatic organs, from donors who have isolated anti-HBc [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/69-72\">",
"     69-72",
"    </a>",
"    ]. The risk of using livers from such donors is significantly higher as illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database identified 23 liver transplants from isolated anti-HBc positive donors [",
"      <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/72\">",
"       72",
"      </a>",
"      ]. Eighteen developed HBV infection compared with only 3 of 651 from anti-HBc negative donors.",
"     </li>",
"     <li>",
"      In a smaller series, the transplantation of organs from isolated anti-HBc positive donors resulted in the conversion of HBsAg negative recipients to HBsAg positivity in three of six liver transplants versus none of seven heart transplants and 1 of 42 renal transplants [",
"      <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increased risk of posttransplant hepatitis B is seen primarily among seronegative liver recipients. In a study involving 210 anti-HBc positive donors, there were no cases of posttransplant hepatitis B among 251 kidney and 25 heart recipients. There was also no posttransplant hepatitis B in liver recipients with anti-HBs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anti-HBc. However, among seronegative liver recipients, posttransplant hepatitis B was seen in 43 percent of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/73\">",
"     73",
"    </a>",
"    ]. These data underscore the importance of serological testing and HBV vaccination among potential transplant recipients.",
"   </p>",
"   <p>",
"    Whether testing donors for HBV DNA can reduce the risk of HBV in recipients is still being determined. In a report from France that included 11,115 consecutive organ, tissue, and cell donors, HBV DNA was detected in 0.07 percent of individuals who had no serologic markers for chronic HBV [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/74\">",
"     74",
"    </a>",
"    ]. The authors noted that the cost-effectiveness of such a program requires further clarification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     POSTEXPOSURE PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postexposure prophylaxis is recommended for all nonvaccinated individuals who are exposed to blood or infectious secretions. The first dose of vaccine should be given as early as possible and within 12 hours of exposure. If the source is known to be HBsAg positive, one dose of HBIG should be administered at the same time in another site. The other two doses of vaccine should be administered according to the usual schedule. In individuals who have been vaccinated and have a documented response, no postexposure prophylaxis is required. Individuals who have no postvaccination testing will require a second course of vaccination unless anti-HBs is detectable at the time of exposure. Individuals who are documented to be nonresponders will require two doses of HBIG given one month apart. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23416?source=see_link\">",
"     \"Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Centers for Disease Control and Prevention has also issued recommendations for individuals who are wounded during bombings and similar mass-casualty events [",
"    <a class=\"abstract\" href=\"UTD.htm?4/31/4602/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persons for whom neither a reliable history of completed vaccination against HBV or a known contraindication to vaccination should receive the first dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      as soon as possible (preferably within 24 hours) and not later than seven days after the event.",
"     </li>",
"     <li>",
"      Persons who receive or are identified as candidates for a dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      while undergoing evaluation or treatment in a mass casualty event should be discharged with referrals for follow-up and written information on predischarge treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109607998\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of hepatitis B virus (HBV) carriers varies from 0.1 to 2 percent in low prevalence areas (United States, Canada, Western Europe, Australia, and New Zealand), to 3 to 5 percent in intermediate prevalence areas (Mediterranean countries, Japan, Central Asia, Middle East, and Latin and South America), to 10 to 20 percent in high prevalence areas (southeast Asia, China, sub-Saharan Africa) (",
"      <a class=\"graphic graphic_table graphicRef51820 \" href=\"UTD.htm?21/30/21995\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef62806 \" href=\"UTD.htm?6/43/6838\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The predominant mode of transmission of HBV varies in different geographical areas. Perinatal infection is the predominant mode of transmission in high prevalence areas. In comparison, horizontal transmission, particularly in early childhood, accounts for most cases of chronic HBV infection in intermediate prevalence areas, while unprotected sexual intercourse and intravenous drug use in adults are the major routes of spread in low prevalence areas. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Modes of transmission'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/1\">",
"      Maynard JE. Hepatitis B: global importance and need for control. Vaccine 1990; 8 Suppl:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/2\">",
"      Alter MJ, Hadler SC, Margolis HS, et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA 1990; 263:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/3\">",
"      Kowdley KV, Wang CC, Welch S, et al. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology 2012; 56:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/4\">",
"      Stevens CE, Beasley RP, Tsui J, Lee WC. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975; 292:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/5\">",
"      Tassopoulos NC, Papaevangelou GJ, Sjogren MH, et al. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 1987; 92:1844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/6\">",
"      Wasley A, Grytdal S, Gallagher K, Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis--United States, 2006. MMWR Surveill Summ 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     FAQs for Health Professionals: Hepatitis B. www.cdc.gov/hepatitis/HBV/HBVfaq.htm#overview (Accessed on September 10, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/8\">",
"      Ly KN, Xing J, Klevens RM, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/9\">",
"      Wasley A, Kruszon-Moran D, Kuhnert W, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis 2010; 202:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/10\">",
"      Ioannou GN. Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey. Ann Intern Med 2011; 154:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Screening for chronic hepatitis B among Asian/Pacific Islander populations--New York City, 2005. MMWR Morb Mortal Wkly Rep 2006; 55:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/12\">",
"      Kim WR, Ishitani MB, Dickson ER, et al. Rising burden of hepatitis B in the United States: Should the other virus be forgotten? (abstract). Hepatology 2002; 36:222A.",
"     </a>",
"    </li>",
"    <li>",
"     Canadian Immunization Guide, 7th edition, Public Health Agency of Canada, Ottowa, Ontario 2006.",
"    </li>",
"    <li>",
"     Australian Government Department of Health and Ageing. Notification Rates of Hepatitis B (incident), received from State and Territory health authorities from 1991 to 2006 and year-to-date notifications for 2007 file://www9.health.gov.au/cda/Source/Rpt_4.cfm (Accessed on June 21, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/15\">",
"      Mossong J, Putz L, Patiny S, Schneider F. Seroepidemiology of hepatitis A and hepatitis B virus in Luxembourg. Epidemiol Infect 2006; 134:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/16\">",
"      Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/17\">",
"      Beasley RP, Hwang LY, Lin CC, et al. Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis 1982; 146:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/18\">",
"      Towers CV, Asrat T, Rumney P. The presence of hepatitis B surface antigen and deoxyribonucleic acid in amniotic fluid and cord blood. Am J Obstet Gynecol 2001; 184:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/19\">",
"      Lok AS, Lai CL, Wu PC, et al. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987; 92:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/20\">",
"      Lok AS, Lai CL. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 1988; 8:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/21\">",
"      Liaw YF, Chu CM, Lin DY, et al. Age-specific prevalence and significance of hepatitis B e antigen and antibody in chronic hepatitis B virus infection in Taiwan: a comparison among asymptomatic carriers, chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. J Med Virol 1984; 13:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/22\">",
"      Dodd RY. The risk of transfusion-transmitted infection. N Engl J Med 1992; 327:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/23\">",
"      Ni YH, Huang LM, Chang MH, et al. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology 2007; 132:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/24\">",
"      Goh KT. Prevention and control of hepatitis B virus infection in Singapore. Ann Acad Med Singapore 1997; 26:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/25\">",
"      Stevens CE, Toy PT, Tong MJ, et al. Perinatal hepatitis B virus transmission in the United States. Prevention by passive-active immunization. JAMA 1985; 253:1740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/26\">",
"      Chen HL, Lin LH, Hu FC, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology 2012; 142:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/27\">",
"      Thompson ND, Perz JF, Moorman AC, Holmberg SD. Nonhospital health care-associated hepatitis B and C virus transmission: United States, 1998-2008. Ann Intern Med 2009; 150:33.",
"     </a>",
"    </li>",
"    <li>",
"     Guidelines for Perinatal Care. In: American Academy of Pediatrics and American College of Obstetricians and Gynecologists, 4th ed, Washington, DC 1997. p.286.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/29\">",
"      Soldan K, Ramsay M, Collins M. Acute hepatitis B infection associated with blood transfusion in England and Wales, 1991-7: review of database. BMJ 1999; 318:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/30\">",
"      Burk RD, Hwang LY, Ho GY, et al. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 1994; 170:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/31\">",
"      Li XM, Shi MF, Yang YB, et al. Effect of hepatitis B immunoglobulin on interruption of HBV intrauterine infection. World J Gastroenterol 2004; 10:3215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/32\">",
"      Wiseman E, Fraser MA, Holden S, et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009; 190:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/33\">",
"      Shi Z, Yang Y, Ma L, et al. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol 2010; 116:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/34\">",
"      Han GR, Cao MK, Zhao W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011; 55:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/35\">",
"      Beasley RP, Stevens CE, Shiao IS, Meng HC. Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B. Lancet 1975; 2:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/36\">",
"      Hill JB, Sheffield JS, Kim MJ, et al. Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers. Obstet Gynecol 2002; 99:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/37\">",
"      Lin CL, Kao JH, Chen BF, et al. Application of hepatitis B virus genotyping and phylogenetic analysis in intrafamilial transmission of hepatitis B virus. Clin Infect Dis 2005; 41:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/38\">",
"      Ahmed MM, Huang TH, Xie QD. A sensitive and rapid assay for investigating vertical transmission of hepatitis B virus via male germ line using EGFP Vector as reporter. J Biomed Biotechnol 2008; 2008:495436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/39\">",
"      Ahmed MM, Huang TH, Xie QD. An improved experimental model for studying vertical transmission of hepatitis B virus via human spermatozoa. J Virol Methods 2008; 151:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/40\">",
"      Huang JM, Huang TH, Qiu HY, et al. Effects of hepatitis B virus infection on human sperm chromosomes. World J Gastroenterol 2003; 9:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/41\">",
"      Hadchouel M, Scotto J, Huret JL, et al. Presence of HBV DNA in spermatozoa: a possible vertical transmission of HBV via the germ line. J Med Virol 1985; 16:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/42\">",
"      Williams AE, Thomson RA, Schreiber GB, et al. Estimates of infectious disease risk factors in US blood donors. Retrovirus Epidemiology Donor Study. JAMA 1997; 277:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/43\">",
"      Chung HT, Lee JS, Lok AS. Prevention of posttransfusion hepatitis B and C by screening for antibody to hepatitis C virus and antibody to HBcAg. Hepatology 1993; 18:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/44\">",
"      Dodd RY. Current viral risks of blood and blood products. Ann Med 2000; 32:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/45\">",
"      Shang G, Seed CR, Wang F, et al. Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004. Transfusion 2007; 47:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/46\">",
"      Offergeld R, Faensen D, Ritter S, Hamouda O. Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: risk of virus transmission and the impact of nucleic acid amplification testing. Euro Surveill 2005; 10:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/47\">",
"      Alvarez do Barrio M, Gonz&aacute;lez D&iacute;ez R, Hern&aacute;ndez S&aacute;nchez JM, Oyonarte G&oacute;mez S. Residual risk of transfusion-transmitted viral infections in Spain, 1997-2002, and impact of nucleic acid testing. Euro Surveill 2005; 10:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/48\">",
"      Roth WK, Weber M, Petersen D, et al. NAT for HBV and anti-HBc testing increase blood safety. Transfusion 2002; 42:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/49\">",
"      Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/50\">",
"      Hagan H, McGough JP, Thiede H, et al. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol 1999; 149:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/51\">",
"      Des Jarlais DC, Diaz T, Perlis T, et al. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol 2003; 157:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/52\">",
"      Bialek SR, Bower WA, Mottram K, et al. Risk factors for hepatitis B in an outbreak of hepatitis B and D among injection drug users. J Urban Health 2005; 82:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/53\">",
"      Gerberding JL. The infected health care provider. N Engl J Med 1996; 334:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/54\">",
"      Occupational exposure to bloodborne pathogens--OSHA. Final rule. Fed Regist 1991; 56:64004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/55\">",
"      Centers for Disease Control (CDC). Guidelines for prevention of transmission of human immunodeficiency virus and hepatitis B virus to health-care and public-safety workers. MMWR Morb Mortal Wkly Rep 1989; 38 Suppl 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/56\">",
"      Mahoney FJ, Stewart K, Hu H, et al. Progress toward the elimination of hepatitis B virus transmission among health care workers in the United States. Arch Intern Med 1997; 157:2601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/57\">",
"      Dienstag JL, Ryan DM. Occupational exposure to hepatitis B virus in hospital personnel: infection or immunization? Am J Epidemiol 1982; 115:26.",
"     </a>",
"    </li>",
"    <li>",
"     Eliminating Hepatitis B as an occupational hazard. In: London medical imprint, Hallower J, Kane M, McCloy E (Eds), 1993. p.114.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/59\">",
"      Williams IT, Perz JF, Bell BP. Viral hepatitis transmission in ambulatory health care settings. Clin Infect Dis 2004; 38:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/60\">",
"      Harpaz R, Von Seidlein L, Averhoff FM, et al. Transmission of hepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control. N Engl J Med 1996; 334:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/61\">",
"      Centers for Disease Control and Prevention (CDC). Nosocomial hepatitis B virus infection associated with reusable fingerstick blood sampling devices--Ohio and New York City, 1996. MMWR Morb Mortal Wkly Rep 1997; 46:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/62\">",
"      Perry JL, Pearson RD, Jagger J. Infected health care workers and patient safety: a double standard. Am J Infect Control 2006; 34:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/63\">",
"      Enfield KB, Sharapov U, Hall KK, et al. Transmission of hepatitis B virus from an orthopedic surgeon with a high viral load. Clin Infect Dis 2013; 56:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/64\">",
"      Buster EH, van der Eijk AA, Schalm SW. Doctor to patient transmission of hepatitis B virus: implications of HBV DNA levels and potential new solutions. Antiviral Res 2003; 60:79.",
"     </a>",
"    </li>",
"    <li>",
"     Updated CDC Recommendations for the Management of Hepatitis B Virus&ndash;Infected Health-Care Providers and Students. US Government Printing Office; US Department of Health and Human Services, Centers for Disease Control and Prevention, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/66\">",
"      Henderson DK, Dembry L, Fishman NO, et al. SHEA guideline for management of healthcare workers who are infected with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus. Infect Control Hosp Epidemiol 2010; 31:203.",
"     </a>",
"    </li>",
"    <li>",
"     Hepatitis B Infected Health Care Workers. NHS Executive Health Service Circular HSC 2000/020 file://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4012257.pdf (Accessed on June 26, 2007).",
"    </li>",
"    <li>",
"     HIV, Hepatitis B or Hepatitis C - Health Care Workers Infected. New South Wales Health Policy Directive file://www.health.nsw.gov.au/policies/PD/2005/pdf/PD2005_162.pdf (Accessed on June 26, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/69\">",
"      Lok AS, Lai CL, Wu PC. Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: implications in hepatitis B vaccination programs. Hepatology 1988; 8:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/70\">",
"      Turner DP, Zuckerman M, Alexander GJ, et al. Risk of inappropriate exclusion of organ donors by introduction of hepatitis B core antibody testing. Transplantation 1997; 63:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/71\">",
"      Dickson RC, Everhart JE, Lake JR, et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997; 113:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/72\">",
"      Wachs ME, Amend WJ, Ascher NL, et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995; 59:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/73\">",
"      De Feo TM, Poli F, Mozzi F, et al. Risk of transmission of hepatitis B virus from anti-HBC positive cadaveric organ donors: a collaborative study. Transplant Proc 2005; 37:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/74\">",
"      Challine D, Chevaliez S, Pawlotsky JM. Efficacy of serologic marker screening in identifying hepatitis B virus infection in organ, tissue, and cell donors. Gastroenterology 2008; 135:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/31/4602/abstract/75\">",
"      Chapman LE, Sullivent EE, Grohskopf LA. Recommendations for postexposure interventions to prevent infection with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus, and tetanus in persons wounded during bombings and other mass-casualty events--United States, 2008. MMWR Morb Mortal Wkly Rep 2008; 57:RR-6.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3630 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.55.141.10-EC79731216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_31_4602=[""].join("\n");
var outline_f4_31_4602=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H109607998\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MODES OF TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Perinatal transmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H112596570\">",
"      Paternal transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Horizontal transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sexual transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Percutaneous inoculation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Nosocomial infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H93960993\">",
"      - Infected healthcare workers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H173689405\">",
"      Guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      POSTEXPOSURE PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109607998\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3630\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3630|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/43/6838\" title=\"figure 1\">",
"      HBV risk map",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/25/42398\" title=\"figure 2\">",
"      Serology acute and chronic HBV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3630|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/30/21995\" title=\"table 1\">",
"      Epidemiology of HBV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/23/31099\" title=\"table 2\">",
"      Viral hepatitis prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=related_link\">",
"      Clinical manifestations and natural history of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/11/16570?source=related_link\">",
"      Diagnostic amniocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/61/3033?source=related_link\">",
"      Hepatitis B and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23416?source=related_link\">",
"      Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_31_4603="Criteria for preeclampsia";
var content_f4_31_4603=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for the diagnosis of preeclampsia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Systolic blood pressure &ge;140 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         or",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diastolic blood pressure &ge;90 mmHg*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         and",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proteinuria &ge;0.3 grams in a 24-hour urine specimen",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The elevation in blood pressure should be sustained, which is generally regarded as two measurements at least six hours, but no more than seven days, apart.",
"    <div class=\"footnotes\">",
"     * Diastolic blood pressure is determined based upon the fifth Korotkoff sound (disappearance) with patient sitting.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     A random urine protein determination of 30 mg/dL or 1+ on dipstick is suggestive, but not diagnostic, of the presence of this criterion.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_31_4603=[""].join("\n");
var outline_f4_31_4603=null;
var title_f4_31_4604="TMP-SMX desens 9 day po";
var content_f4_31_4604=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F51870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F51870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Oral ambulatory incremental regimen for patients sensitive to TMP-SMX (three doses given each day)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Day",
"      </td>",
"      <td class=\"subtitle1\">",
"       SMX concentration (mg/ml)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Volume/Dose (cc)",
"      </td>",
"      <td class=\"subtitle1\">",
"       SMX Dose/Day (mg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       0.00002",
"      </td>",
"      <td>",
"       1, then 3, then 7",
"      </td>",
"      <td>",
"       0.00022",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       0.0002",
"      </td>",
"      <td>",
"       1, then 3, then 7",
"      </td>",
"      <td>",
"       0.0022",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       0.002",
"      </td>",
"      <td>",
"       1, then 3, then 7",
"      </td>",
"      <td>",
"       0.022",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       0.02",
"      </td>",
"      <td>",
"       1, then 3, then 7",
"      </td>",
"      <td>",
"       0.22",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       0.2",
"      </td>",
"      <td>",
"       1, then 3, then 7",
"      </td>",
"      <td>",
"       2.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       1, then 3, then 7",
"      </td>",
"      <td>",
"       22",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7",
"      </td>",
"      <td>",
"       20",
"      </td>",
"      <td>",
"       1, then 3, then 7",
"      </td>",
"      <td>",
"       220",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       40",
"      </td>",
"      <td>",
"       5, then 10, then 20",
"      </td>",
"      <td>",
"       1400",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       9 and thereafter",
"      </td>",
"      <td colspan=\"3\">",
"       one TMP-SMX DS tab (160 mg TMP-SMX 800 mg)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Rich, JD, Sullivan, T, Greineder, D, Kazanjian, PH. Trimethoprim/suflamethoxazole incremental dose regimen in human immunodeficiency virus-infected persons. Ann Allergy Asthma Immunol 1997; 79:409. Copyright &copy;1997 American College of Allergy, Asthma, and Immunology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_31_4604=[""].join("\n");
var outline_f4_31_4604=null;
var title_f4_31_4605="Lumbosacral myotomes";
var content_f4_31_4605=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F64209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F64209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lumbosacral myotomes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        L1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Femoral nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Iliopsoas (hip flexion)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        L2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Femoral nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Iliopsoas (hip flexion)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Quadriceps (knee extension)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Obturator nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hip adductors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        L3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Femoral nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Iliopsoas (hip flexion)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Quadriceps (knee extension)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Obturator nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hip adductors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        L4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Femoral nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Iliopsoas (hip flexion)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Quadriceps (knee extension)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Obturator nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hip adductors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        L5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Peroneal Nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ankle dorsiflexion (tibialis anterior)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ankle eversion (peroneus muscles)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Tibial nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ankle inversion (tibialis posterior)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Superior gluteal nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hip abduction (gluteus medius)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Leg internal rotation (tensor fascia latae)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        S1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Inferior gluteal nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hip extension (gluteus maximus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Sciatic nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Knee flexion (hamstrings)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Tibial nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ankle plantar flexion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        S2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Inferior gluteal nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hip extension (Gluteus maximus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Sciatic nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Knee flexion (hamstrings)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Tibial nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ankle plantar flexion",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_31_4605=[""].join("\n");
var outline_f4_31_4605=null;
var title_f4_31_4606="Radial bone density IHH";
var content_f4_31_4606=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F69980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F69980&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Reduced bone density in men with idiopathic hypogonadotropic hypogonadism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 311px; height: 414px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A: Radial (cortical) bone density as function of age in 16 men with idiopathic hypogonadotropic hypogonadism who had fused epiphyses. The lines indicate the mean (&plusmn;SD) radial bone density in normal men. Panel B: Radial bone density as function of age in seven men with idiopathic hypogonadotropic hypogonadism who had open epiphyses. Radial bone density was at least 2 SD below normal in 16 of the 23 men; in addition, eight had spinal bone densities below the fracture threshold (not shown).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified and reproduced with permission from: Finkelstein JS, Klibanski A, Neer RM, et al. Osteoporosis in men with idiopathic hypogonadotropic hypogonadism.&nbsp;Ann Intern Med 1987; 106:354.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_31_4606=[""].join("\n");
var outline_f4_31_4606=null;
var title_f4_31_4607="Fibrosis duration infection";
var content_f4_31_4607=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Association between stage of hepatic fibrosis and age at biopsy or duration of infection by alcohol consumption in patients with hepatitis C virus infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 629px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349:825. Copyright &copy;1997 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_31_4607=[""].join("\n");
var outline_f4_31_4607=null;
